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ABSTRACT 
 
Type I interferon is a cytokine induced upon virus infection that generates an 
antiviral state in neighbouring cells. Historically, research into avian interferon 
has lagged behind that into the mammalian system and hence reagents and 
assays are poorly developed. The avipoxvirus Fowlpox virus is naturally host 
restricted to avian cells. Modified Vaccinia virus Ankara (MVA) is an 
attenuated Vaccinia virus derived by serial passage in chicken embryonic 
fibroblasts (CEF), so that it too is now host restricted. 
In CEF pretreated with chicken interferon (ChIFN), plaque formation by 
Fowlpox virus (FP9 strain) was approximately 500-times less inhibited than 
MVA. A lack of bioinformatic clues within the FP9 genome sequence justified 
a broad-scale screen to identify any molecular determinants that contributed to 
this interferon resistance. 
The 266 kbp FP9 genome was divided into 61 overlapping fragments, each 
approximately 8 kbp long, to include each unique open reading frame (ORF) 
intact in at least one fragment. Splice-overlap-extension PCR protocols were 
optimised to assemble each genomic fragment with a guanine phosphoribosyl 
transferase (GPT) gene under the control of a poxvirus promoter, between two 
MVA flanks. These linear constructs were transfected into cells co-infected 
with MVA, for homologous recombination to insert the FP9 fragment and 
GPT cassette into the MVA genome. GPT-positive virus was enriched by 
culture with mycophenolic acid. 
In total, 65 recombinant viruses were recovered, representing 85% of the FP9 
ORFs. Fourteen fragments were independently duplicated to control for 
mutations that may have been introduced during PCR. Recombinant viruses 
were screened for an increased ability to plaque in ChIFN-treated cells 
identifying 2 FP9 fragments, Fowlpox Interferon Resistance locus (FIR) 1 and 
FIR2. Further recombinant MVA viruses each containing a single gene from 
FIR1 were constructed and assessed for interferon resistance using the same 
techniques, identifying FP9.014 as contributing to FP9 ChIFN resistance. 
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CHAPTER 1 
Introduction 
 
In this Chapter, interferon as an aspect of antiviral innate immunity will be 
discussed, with special reference to avian type I interferon. The poxviruses used 
in this study will then be introduced, followed by consideration of some aspects 
of the project design.  
 
1.1) Antiviral innate immunity 
Eukaryotic animal hosts have a number of defences against virus infection. 
Those that are not induced against specific microorganisms and are independent 
of prior contact are collectively referred to as innate immunity. These are often 
the first arms of host defence that are activated against an invading pathogen. In 
the late 19th century Ilya Mechnikov was the first to describe phagocytosis as an 
aspect of immunity. Phagocytosis is the expansion of the cellular plasma 
membrane to engulf and degrade extracellular particulate material, which may 
include whole microorganisms. Understanding of innate immunity subsequently 
grew to also include external barriers against infection (such as the skin, and 
lysozyme secreted by mucous membranes), death of the infected cell by various 
means, and making cells less suitable for subversion by the pathogen.  
Some antimicrobial peptides have direct antiviral properties against enveloped 
viruses including influenza virus and herpes simplex virus 1. These include 
surfactant protein D, produced by lung epithelial cells (Hartshorn et al., 1994), 
defensins, produced by neutrophils (Daher et al., 1986) and microbial cationic 
proteins, produced by macrophages (Lehrer et al., 1985). 
Cell death can deprive an infecting virus of a viable host. Apoptosis is a form of 
programmed cell suicide triggered by a range of stimuli, including damage to 
deoxyribonucleic acid (DNA) or mitochondria and stimulation of cell surface 
receptors. Characteristics include DNA condensation and laddering, organelle 
fragmentation and a lack of inflammation (Kerr, 1971; Kerr et al., 1972).  
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Some leukocytes are constituents of the innate immune system. Macrophages 
and polymorphic neutrophils are specialised phagocytes. Natural killer (NK) 
cells can recognise receptors on the surface of virally infected cells and induce 
apoptosis by releasing granzymes and perforins (recently reviewed by Cullen & 
Martin  (2008), Smyth et al. (2005) and Cerwenka & Lanier (2001)). 
Autophagy is an evolutionarily conserved cellular process where portions of the 
cytoplasm are degraded (Kirkegaard et al., 2004). This is used for ‘recycling’ 
organelle and cytoplasm components as well as removal of intracellular 
pathogens. During autophagy, an isolation membrane wraps around portions of 
the cytoplasm to form a double-membrane organelle, that fuses with late 
endosomes to degrade the contents (Levine & Deretic, 2007).  
Ribonucleic acid (RNA) interference (RNAi) is an innate immune response to 
viral infection in plants and invertebrates, where double-stranded (ds) RNA 
induces post-transcriptional silencing of genes encoding homologous mRNA 
(Fire et al., 1998). Although the RNAi system is evolutionarily conserved, and 
artificial induction confers antiviral protection, it has been argued that RNAi is 
less relevant in vertebrate antiviral immunity, where it has been superseded by 
the interferon (IFN) system (Cullen, 2006). 
 
1.2) Interferon 
IFN is a protein with cytokine activity that is produced and secreted by most 
cells in vertebrate organisms, which when bound to its cell surface receptor 
stimulates cells to enter an antiviral state. 
First identified by Isaacs and Lindenmann (1957; Isaacs et al., 1957), IFN was 
named for its property of virus “interference”. It was discovered when 
chorioallantoic membranes (CAM) that were stimulated by inactivated influenza 
virus were observed to produce a soluble factor that could inhibit subsequent 
viral growth when applied to fresh CAM prior to infection with viable influenza 
virus.  
IFN is noted for its species specificity. IFN produced by calf kidney cells or by 
chicken CAM is effective on homologous but not heterologous cells (Tyrell, 
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1959); a similar situation was found with chicken and mouse IFN (Baron et al., 
1964). However, mouse IFN retains 1:30 to 1:20 of its homologous activity on 
the more closely related rat or hamster cells (Buckler & Baron, 1966). Moehring 
and Stineberg (1970) found that the degree of cross-reactivity between avian 
IFNs from different species can be influenced by the level of genetic relatedness 
between species, but not in a predictable way.  
Several species of IFN have been described, which are divided into groups based 
on physical properties, structure, function and receptor. Acid labile IFN 
produced by human lymphocytes was described as “immune interferon” to 
distinguish it from the more stable “virus interferon” induced by virus infection 
of any kind of cell (Falcoff, 1972). After further physicochemical analysis on 
mouse IFN, these names were dismissed in favour of “Type II” and “Type I” 
interferons (Youngner & Salvin, 1973). Type I IFN is stable at pH 2 but 
degraded by heat treatment at 56 oC. Conversely, type II IFN is resistant to heat 
treatment but acid labile. Soon afterwards, these properties were confirmed for 
human type I and II interferons (Haahr et al., 1976). Within a species, type I 
interferons bind to the same receptor (Aguet & Blanchard, 1981), whereas type 
II IFN signals through a distinct receptor (Aguet et al., 1982). 
The physical properties of chicken interferon differ slightly from those of 
mammalian IFNs, in that chicken type I IFN is resistant to both heat and acid 
(Sekellick et al., 1994) whereas chicken type II IFN is sensitive to both 
treatments (Digby & Lowenthal, 1995). 
A novel IFN group, IFN-λ, has been designated as type III IFN by the 
Nomenclature Committee of the International Society for Interferon and 
Cytokine Research. Three subtypes of human IFN-λ were identified (Kotenko et 
al., 2003; Sheppard et al., 2003) but only two of the murine subtypes are 
expressed (Bartlett et al., 2005) whereas a single IFN-λ gene was identified in 
the chicken genome (Kaiser et al., 2005). Cloning of the chicken IFN-λ gene 
revealed that it is most similar to human IFN-λ2 (Karpala et al., 2008b). 
Human peripheral blood mononuclear cells produce IFN-λ in vitro in response 
to dsRNA or viral infection. In vitro, IFN-λ is directly antiviral, protecting cells 
from viral infection (Kotenko et al., 2003; Sheppard et al., 2003). In vivo studies 
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found that murine IFN-λ has antiviral properties (Bartlett et al., 2005), although 
this is restricted to virus families with DNA genomes (Ank et al., 2006). 
In avian species, as in mammals, type II IFN is represented by a single member, 
IFN-γ, which is secreted by activated lymphocytes and acts on immune cells 
(Lowenthal et al., 1995; Kaiser et al., 1998; Loa et al., 2001).  
In mammals, eight families of type I IFN have been described, including IFN-α, 
IFN-β, IFN-ω, IFN-ε and IFN-κ. Mice also possess limitin whilst IFN-δ is 
specific to pigs and IFN-τ to ruminants (Kontsek et al., 2003). No antiviral 
activity has been described for IFN-δ or IFN-τ. The best-characterised type I 
IFNs are IFN-α and -β. Mammals possess between 14 and 20 types of IFN-α 
depending on the animal species and a single IFN-β gene (Sen, 2001). 
 
1.2.1) Avian type I IFN 
A gene encoding chicken IFN (ChIFN) was first cloned in 1994 from primary 
chick embryo cells and found to have less than 25% amino acid identity with 
mammalian type I IFNs and only 3% amino acid identity with mammalian IFN-γ 
(Sekellick et al., 1994). Southern blot analysis on chicken liver DNA later 
identified at least 10 almost identical ChIFN genes designated the chicken IFN1 
family. These encode proteins of the same serotype (Sick et al., 1996). The same 
study also revealed a single gene that is 73% identical to the IFN1 genes, 
designated chicken IFN2. The ChIFN2 protein is 57% identical to the ChIFN1 
proteins and of a different serotype. Both ChIFN1 and ChIFN2 proteins have 
antiviral activity and like the mammalian genes, all the ChIFN genes lack introns 
(Sick et al., 1996). 
Phylogenetic analysis initially suggested that mammalian and chicken type I IFN 
genes arose from independent gene duplication events after the divergence of 
birds (Hughes & Roberts, 2000). However, similarities between the gene 
structures, expression profiles and functional studies suggest that the divergence 
of IFN-α and -β occurred before the divergence of mammals and birds. 
Mammals and chickens both have a cluster of IFN-α genes and a single IFN-β 
gene with antiviral activity. There are also similar regulatory elements in the IFN 
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promoters: binding sites for nuclear factor-κB (NF-κB) are present in the 
ChIFN-β but not ChIFN-α promoters, reflecting the situation with mammalian 
promoters (Staeheli et al., 2001). To reflect similarities between mammalian and 
chicken type I IFN, ChIFN1 is now referred to as ChIFN-α and ChIFN2 as 
ChIFN-β (Lowenthal et al., 2001). However, it remains controversial whether 
ChIFN-α and ChIFN-β are true orthologues of mammalian IFN-α and -β.  
 
1.3) The mechanism of IFN antiviral activity 
IFN is induced in response to viral infection, but is not directly antiviral itself. 
After secretion into the extracellular milieu, binding to the membrane-bound 
IFN receptor triggers a signalling cascade that induces transcriptional 
upregulation of IFN stimulated genes (ISGs). It is these ISGs that are directly 
antiviral. 
Although the original discovery of IFN was made in chick cells, interest focused 
on mammalian orthologues until more recently. Several recent, exhaustive 
reviews of IFN function are available (Sen, 2001; Haller et al., 2006; Randall & 
Goodbourn, 2008), and it is not intended to reproduce those here. Therefore each 
stage of the IFN system (induction, signalling, ISG effects and cellular 
regulation) as they are understood in mammals will first be described, followed 
by a discussion of the elements that have been identified in birds.  
 
1.3.1) IFN induction in mammalian cells 
The host cell recognises by-products of virus replication as foreign. For 
example, some DNA viruses produce cytoplasmic DNA and both RNA and 
DNA viruses generate dsRNA during replication and transcription. When these 
pathogen-associated molecular patterns (PAMPs) (Medzhitov & Janeway, 1997) 
are sensed by the cell, transcription factors translocate to the nucleus to induce 
IFN-β production. 
The serine/threonine protein kinase inducible by dsRNA (PKR) is constitutively 
expressed in mammalian cells. When the amino (N)-terminal dsRNA binding 
domains associate with dsRNA, a kinase domain is revealed on PKR, leading to 
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homodimerisation, autophosphorylation in trans and activation of the protein 
(Garcia et al., 2006). Activated PKR is multi-functional, and affects several 
signal transduction pathways, including activation of NF-κB. PKR activates 
Inhibitor of NF-κB (IκB) kinase (IKK) via members of the tumour necrosis 
factor receptor-associated factor (TRAF) family. IKK phosphorylates IκB, 
which becomes ubiquitinated and targeted for degradation by the proteosome 
(Garcia et al., 2006). Removal of IκB unmasks a nuclear localisation signal on 
NF-κB, freeing it to translocate to the nucleus (Fig. 1.1). Release from IκB 
inhibition also allows the DNA binding domain of NF-κB to reorientate into its 
functional conformation, enabling its transactivation functions (Jacobs & 
Harrison, 1998). 
 
Figure 1.1: Activation of NF-κB by PKR. In response to dsRNA, PKR dimerises 
and activates IKK via TRAF, which causes IκB to dissociate from NF-κB and 
become degraded. PAMP recognition molecules are in red, transcription factors 
are in green and inhibitors are in brown. 
 
Two helicases have been identified, retinoic acid inducible gene I (RIG-I) 
(Yoneyama et al., 2004) and melanoma differentiation-associated gene 5 (mda-
5) (Andrejeva et al., 2004) that bind cytoplasmic dsRNA through a helicase 
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domain. These also possess two N-terminal caspase recruitment domains 
(CARDs). 
The CARDs interact with an adaptor protein that was identified independently 
by several groups and given the names of IFN-β-promoter stimulator 1 (IPS-1) 
(Kawai et al., 2005), mitochondrial antiviral signalling (MAVS) (Seth et al., 
2005), virus-induced signalling adaptor (VISA) (Xu et al., 2005) and CARD 
adaptor inducing IFN-β (Cardif) (Meylan et al., 2005). 
RIG-I and mda-5 activation lead to phosphorylation and nuclear translocation of 
cytoplasmic interferon regulatory factor (IRF)-3 (Fig. 1.2). The exact 
mechanism downstream of IPS-1/MAVS/VISA/Cardif is not clear but may 
involve phosphorylation of IRF3 by TRAF family member associated NF-κB 
activator (TANK)-binding kinase 1 (TBK1) and IKKε. TRAF3 also complexes 
with TBK1 and IKKε (Hacker et al., 2006; Oganesyan et al., 2006). Upon 
activation, IRF-3 first translocates to the nucleus before becoming 
hyperphosphorylated and dimerised (Sarkar et al., 2004; Spiegel et al., 2005). 
Toll-like receptor (TLR) 3 can also detect dsRNA. Signalling through this 
endosomal receptor and its adapter protein TRIF (toll/interleukin-1 receptor 
domain containing adapter inducing IFN-β) also leads to IRF-3 and NF-κB 
activation (Kawai & Akira, 2006). 
Ishii et al. (2006) showed that cytoplasmic dsDNA can induce IFN-β 
production, in a manner dependent on IPS-1/MAVS/VISA/Cardif, TBK1 and 
IRF3. The cytoplasmic DNA sensor DAI (DNA-dependent activator of IFN-
regulatory factors) was then identified as a possible sensor of DNA virus or 
intracellular bacteria replication (Takaoka et al., 2007; Yoneyama & Fujita, 
2007). DAI binding to DNA led to IRF3-dependent IFN-β production. DAI is 
not thought to discriminate between host, pathogen or synthetic DNA, but 
activation is more likely to depend on the quantity and length of DNA (Takaoka 
et al., 2007) and its location, as host DNA should be confined to the nucleus. 
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Figure 1.2: Induction of IFN-β. Cellular sensing of dsRNA and cytoplasmic DNA 
leads to IRF3 nuclear translocation and homodimerisation and NF-κB 
activation, as described in Section 1.3.1. Binding of all the necessary 
transcription factors (including ATF-2/c-jun, not shown) to the IFN-β promoter 
results in IFN-β transcription. PAMP recognition molecules are in red and 
transcription factors are in green. Dotted line indicates where direct pathways 
are unclear. 
 
No cellular pathway operates in isolation from all others, and IFN induction 
pathways can overlap with and use the same molecular components as those of 
other cellular processes, including apoptosis and induction of other cytokines. 
NF-κB can be activated by a number of pathways, including those dependent on 
PKR, TLR3 and IPS-1/MAVS/VISA/Cardif. Presence of all the required 
transcription factors including NF-κB (Visvanathan & Goodbourn, 1989), a 
heterodimer of ATF-2 and c-jun (Kim & Maniatis, 1997) and IRF3 in the 
nucleus allows transcription of the IFN-β gene. In mouse fibroblasts, IFN-α4 as 
well as IFN-β is expressed immediately after induction by virus infection (Marie 
et al., 1998). 
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1.3.2) IFN induction in chicken cells 
When ChIFN was first cloned, it was induced by infection of primary chick 
embryo cells with ultra-violet (UV) irradiated avian reovirus (Sekellick et al., 
1994). In that study, ChIFN mRNA transcripts were detected between 3 and 24 h 
post infection (PI), with the strongest signal at about 9 h PI and a peak in protein 
production between 9 and 11 h PI. 
At least six chicken IRF (ChIRF) genes have been cloned, including chicken 
ICSBP (IFN consensus sequence binding protein), ChIRF-1 (Jungwirth et al., 
1995), ChIRF-2 (Marienfeld et al., 1997), ChIRF-3 (Grant et al., 1995), ChIRF-
4 and ChIRF-5.  
ChIRF-1 and ChIRF-3 synthesis is induced by type I and type II IFN as well as a 
synthetic dsRNA, poly(I:C) (polyinosinic:polycytidilic acid). ChIRF-3 may be 
induced downstream of ChIRF-1 but ChIRF-2 mRNA is not elevated by these 
stimuli (Grant et al., 1995; May et al., 2000). ChIRF-3 is not orthologous to 
mammalian IRF-3, and may be more similar to mammalian IRF-7, leaving no 
actual obvious orthologue of mammalian IRF-3 (S. Goodbourn, St. George’s; 
personal communication) 
Other components of the IFN induction pathways where an orthologue has been 
identified in the chicken are NF-κB (Ikeda et al., 1993) and PKR (Ko et al., 
2004a). A 40 kiloDalton (kDa) phosphoprotein, pp40, isolated from chicken 
cells was found to be functionally and structurally similar to human IκBβ (Kerr 
et al., 1991). 
Prior to the publication of the draft chicken genome (2004), an in silico analysis 
of chicken expressed sequence tags identified chicken orthologues of more than 
half of the known mammalian TLR components, including chicken TLR3, the 
TLR adapter MyD88, and the kinases IKKα and IKKβ (Lynn et al., 2003). 
Chicken TLR3 is upregulated in fibroblasts, brain lung and spleen in response to 
ChIFN-α (Karpala et al., 2008a). 
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1.3.3) IFN signalling in mammalian cells 
After induction, IFN-β is secreted and acts on nearby cells in a paracrine or 
autocrine manner. Both IFN-α and IFN-β bind to the same receptor, IFNAR, a 
member of the Class II cytokine receptor family (Langer et al., 2004). IFNAR 
consists of two subunits, IFNAR1 and IFNAR2. Each subunit has an 
intracellular domain that is constitutively associated with members of the Janus 
kinase family: IFNAR1 is associated with tyrosine kinase (Tyk)-2 whilst 
IFNAR2 is associated with Janus activated kinase (Jak)-1. Ligand binding 
induces dimerisation and tyrosine phosphorylation of the receptor subunits, and 
phosphorylation of the Jaks themselves. Signal transducers and activators of 
transcription (STATs) are also recruited, phosphorylated and form specific 
multimeric complexes that translocate to the nucleus (Platanias, 2005). The PKC 
protein kinase family contributes to regulation of STAT phosphorylation by Jaks 
(Fimia et al., 2004). 
Phosphorylated STAT1 and STAT2 associate with IRF9 to form the 
heterotrimeric ISG factor 3 (ISGF3) transcription complex, exclusive to type I 
and type III IFN stimulation. ISGF3 translocates to the nucleus and binds to 
IFN-stimulated response elements (ISREs) in the promoters of ISGs to activate 
their transcription (Fig. 1.3). 
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Figure 1.3: Type I IFN signalling and induction of antiviral mechanisms. Binding 
of IFN α/β to the membrane-bound receptor signals via the Jak/STAT pathway 
to upregulate ISG transcription. Positive feedback to IFNα/β production is 
dependent on virus-mediated IRF7 activation (not shown). Transcription factors 
are in green and antiviral effectors are in orange.  
 
The Jak/STAT pathway is regarded as ‘classical’, but does not account for all of 
the effects of IFN-receptor binding. Therefore other signalling pathways are also 
activated by IFNAR ligand binding (Platanias, 2005).  
 
1.3.4) IFN signalling in chicken cells 
The chicken orthologue of human IFNAR has been identified (Reboul et al., 
1999) as has a chicken Jak (Sofer et al., 1998) although it is not known whether 
this ChJak associates with the type I ChIFN receptor. High-throughput analysis 
of complementary DNA (cDNA) sequences for bursal lymphocytes identified 
chicken STAT1 and STAT2 gene transcripts (Caldwell et al., 2005). A murine 
ISRE transfected into a chicken cell responded to ChIFN (Zoller et al., 1992), 
suggesting functional conservation of transcription factors. 
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1.3.5) IFN effectors 
More than 300 ISGs are induced as a result of IFN signalling, but only a few 
have been characterised. These can vary between species and can be cell-type 
specific, but the general antiviral activities of some, with their chicken 
counterparts, are described below. 
 
1.3.5.1) PKR 
As well as playing a role in dsRNA sensing, PKR is also upregulated in response 
to IFN-β and has direct antiviral effects. After autophosphorylation as a result of 
dsRNA binding, activated PKR phosphorylates host eukaryotic initiation factor 
2α (eIF-2α).  
When eIF-2α is phosphorylated, its affinity for the guanine nucleotide releasing 
protein eIF-2B increases 100-fold. As a result, eIF-2α is not released from the 
complex to associate with guanosine triphosphate (GTP) and continue delivering 
methionyl initiator transfer-RNA to ribosomes. Further, eIF-2B is not able to 
recycle other spent eIF2-GDP molecules to active eIF2-GTP (Garcia et al., 
2006) (Fig. 1.4). The net result is non-specific inhibition of translation initiation, 
affecting host and viral protein synthesis. 
 
Figure 1.4: Recycling of eIF-2α by eIF2B. Phosphorylated PKR prevents 
dissociateion of eIF2B from eIF-2α, preventing recycling of eIF-2α required for 
translation initation. GDP: guanosine diphosphate. GTP: guanosine 
triphosphate. Adapted from Alberts et al (1994). 
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PKR activation can also contribute to induction of autophagy (Talloczy et al., 
2002). As already mentioned in Section 1.3.2, chicken PKR has been cloned and 
confers antiviral protection (Ko et al., 2004a). 
 
1.3.5.2) Oligoadenylate synthetases and RNase L 
The 2’-5’ oligoadenylate synthetases (OAS) are a class of enzymes that when 
activated by dsRNA, polymerise adenosine triphosphate (ATP) into 2’-5’-linked 
oligoadenylates of varying (at least dimeric) lengths. Humans have three OAS 
genes, in addition to the related OASL gene, which does not synthesise 2’-5’ 
oligoadenylates and may play a regulatory role (Hartmann et al., 1998).  
Two alleles of chicken OAS have been cloned (Yamamoto et al., 1998), 
although they lack a conserved motif required for 2-5A formation by 
mammalian OAS enzymes and are the most homologous to human OASL 
(Hartmann et al., 1998). The homology between chicken and mammalian OAS 
is 49.5% over the N-terminal 66% of the proteins (Yamamoto et al., 1998). 
In the mammalian system, oligoadenylates that are at least trimeric bind the 
latent cellular ribonuclease RNase L, causing it to dimerise and become 
activated for endoribonuclease activity (Sen, 2001). Activated RNase L cleaves 
heteropolymeric viral mRNA preferentially at single-stranded (ss) UA and UU 
dinucleotides. Cellular RNA is also degraded, especially ribosomal RNA 
(rRNA). The activity of RNase L is regulated by 2’-phosphodiesterase, which 
degrades 2’5’ oligoadenylates into ATP and adenosine monophosphate (Han & 
Barton, 2002; Silverman, 2007). Activated RNase L can also act as a 
transcription factor for antiviral genes (Malathi et al., 2005).  
 
1.3.5.3) Mx 
Mx proteins are IFN-inducible guanine triphosphatases that inhibit several virus 
families including ssRNA, dsRNA (Mundt, 2007) and DNA viruses. Rodents 
have nuclear and cytoplasmic forms of Mx, that inhibit viruses replicating in the 
respective compartments. In other vertebrates studied, Mx is limited to the 
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cytoplasm, but inhibits a broad spectrum of viruses, including those with nuclear 
replication. (Reviewed by Haller et al., 2007; Sadler & Williams, 2008).  
An Mx gene cloned from duck does not show any antiviral activity (Bazzigher et 
al., 1993). Chicken Mx was also cloned, and an ISRE was identified in the 
promoter (Schumacher et al., 1994) which responded to mammalian IFN when 
used in a luciferase reporter assay in monkey Vero cells (Schumacher et al., 
1994). When used as part of a luciferase reporter assay, the ISRE of the chicken 
Mx promoter was more sensitive than classic virus inhibition assays at detecting 
ChIFN-β (Schwarz et al., 2004). 
The mode of action is not completely understood but mammalian cytoplasmic 
Mx proteins probably work by affecting transport and distribution of capsid 
proteins, as they are involved in endocytosis and vesicle transport (Sen, 2001). 
The nuclear mouse Mx1 blocks influenza virus primary transcription (Pavlovic 
et al., 1992). 
Mutant human MxA protein that had lost GTPase activity was still antiviral 
(Janzen et al., 2000) whilst another mutant human MxA protein that retained its 
GTPase activity lost its antiviral activity against the chicken pathogen Infectious 
bursal disease virus in monkey Vero cells (Mundt, 2007). These studies indicate 
that the MxA antiviral activity is not solely determined by the GTPase activity. 
Sequencing of Mx from several chicken breeds identified much polymorphism 
in this allele, a subset of which showed antiviral activity (Ko et al., 2002). The 
antiviral phenotype in vitro of Mx variants is determined by the amino acid at 
position 631: asparagine is antiviral, serine is not (Ko et al., 2002; Ko et al., 
2004b; Watanabe, 2007). However, when a range of chicken Mx proteins were 
tested in vivo, none were found to confer resistance to influenza virus, 
irrespective of the amino acid at position 631 (Benfield et al., 2008). 
 
1.3.5.4) ADAR 
Mammalian adenosine deaminase acting on RNA (ADAR) edits viral and 
cellular RNA by catalysing C6 deamination of adenosine to inosine in dsRNA. 
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As well as mutating the RNA coding capacity, this also has the effect of 
destabilising secondary structures (Wagner et al., 1989). 
A partial mRNA for the ADAR gene in Gallus gallus was identified by genome 
mining (Accession no. AM179858) but this has not been characterised for 
any antiviral activity. 
 
1.3.5.5) Apoptosis 
As well as the mechanisms of host cell shutdown described above, IFN 
signalling can also increase sensitivity to apoptosis. The p53 protein arrests cell 
cycling to allow repair of damaged DNA (Kastan et al., 1991) and can initiate 
apoptosis (Kastan et al., 1991; Yonish-Rouach et al., 1991).  
Mouse and human p53 genes contain ISRE sites and IFN-β increases the level of 
p53 in mouse cells (Takaoka et al., 2003). Although IFN-α/β stimulation does 
not activate p53, virus infection can, which may lead to increased virus-induced 
apoptosis (Takaoka et al., 2003; Vilcek, 2003). Virus-induced p53 activation 
may involve IRF3, which when overexpressed activates p53 (Kim et al., 2006), 
or STAT1 which interacts directly with p53 and is required for optimal DNA 
damage-induced apoptosis (Townsend et al., 2004).  
Activated RNase L causes release of cytochrome c from mitochondria, possibly 
by cleavage of 28S rRNA, initiating a caspase cascade and apoptosis (Rusch et 
al., 2000).  
 
1.3.5.6) Induction of IFN-α  
Another effect of IFN signalling is the upregulation of IFN-α and IFN-β in a 
positive feedback loop. Marie and co-workers (1998) proposed a model where 
“early-phase” IFN (IFN-β or mouse IFN-α4) binding to the IFNAR induces 
upregulation of IRF7 in fibroblasts, entering the cell into an antiviral state. In the 
context of viral replication, IRF7 becomes activated and together with activated 
IRF-3 as a co-factor induces transcription of all IFN-α subtypes (Civas et al., 
2002).  
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Plasmacytoid dendritic cells constitutively express IRF7 and so can produce 
IFN-α rapidly in response to viral infection (Coccia et al., 2004). They can also 
synthesise IFN in the absence of viral infection, when ligand recognition by 
endosomal TLR7, TLR8 (ssRNA ligand) or TLR9 (CpG DNA ligand), causes 
the MyD88 adaptor of these receptors to interact directly with IRF7 to stimulate 
IFN-α promoters (Kawai et al., 2004).  
 
1.3.5.7) Other effects induced by type I IFN 
Type I IFN also has immunomodulatory properties affecting adaptive immunity 
i.e. that which protects against re-exposure to a specific pathogen. Almost all 
cells express major histocompatibility complex (MHC) class I molecules at the 
cell surface, which are complexed with peptides derived from protein 
degradation within the cell. IFN signalling upregulates MHC expression and 
other elements of antigen presentation (Heron et al., 1978; Jaitin & Schreiber, 
2007), increasing the likelihood that virally derived peptides will be presented to 
circulating antigen specific CD8+ cytotoxic T lymphocytes. Other outcomes of 
type I IFN signalling include: cell cycle arrest, upregulation of perforin and 
granzymes in NK cells, increased memory T cell division and DC maturation 
(Randall & Goodbourn, 2008). 
 
1.3.6) Endogenous inhibitors of the IFN system 
To prevent over-activation of IFN, which could potentially be dangerous to 
healthy cells that are not in danger of infection, the induction and signalling of 
IFN are regulated, and several inhibitors have been described (Fig. 1.5).  
The dsRNA sensors RIG-I and mda-5 share protein homology with a third 
member of their family, LGP2. This possesses a helicase domain to bind 
dsRNA, but lacks the CARDs for signalling to IPS-1/MAVS/VISA/Cardif. 
LGP2 has a much higher affinity for poly(I:C) than RIG-I or mda-5 (Yoneyama 
et al., 2005). 
The anti-apoptotic protein A20 blocks RIG-I activation of IRF-3 and inhibits 
NF-κB activation, although not by acting directly on RIG-I, IPS-
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1/MAVS/VISA/Cardif, TBK1 or IKKε (Lin et al., 2006). The authors 
hypothesise that it inhibits an as yet unidentified adaptor in the RIG-I dependent 
activation of IRF-3. 
The deubiquitinase DUBA interacts with TRAF3 to specifically reduce the 
production of type I IFN after stimulation of TLR3 or IPS-
1/MAVS/VISA/Cardif, without affecting NF-κB signalling (Kayagaki et al., 
2007). 
A yeast two-hybrid system identified a protein, designated SIKE, that interacts 
with human IKKε/TBK1 and inhibits IRF-3 activation by virus infection or 
TLR3 stimulation, although the exact mechanism is unknown (Huang et al., 
2005). SIKE and DUBA appear to regulate IFN induction at the same stage, but 
it is not yet clear if they are the same protein. 
The peptidyl-prolyl isomerase Pin-1 interacts with a phosphorylated residue on 
IRF-3 to trigger proteosome-dependent degradation of dimerised IRF-3. The 
residue in question is conserved in chicken (Saitoh et al., 2006). 
 
Figure 1.5: Endogenous inhibitors of IFN induction. PAMP recognition 
molecules are in red, transcription factors are in green and inhibitors are in 
brown. Dotted lines indicate where direct pathways are unclear. 
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As well as IFN induction, regulatory mechanisms also act on IFN signalling 
(Fig. 1.6). The suppressor of cytokine signalling (SOCS)-1 and SOCS-3 proteins 
inhibit tyrosine phosphorylation and nuclear translocation of STAT1, inhibiting 
the antiviral effect of IFN-α (Song & Shuai, 1998). 
The human protein inhibitor of activated STAT (PIAS)-1 directly associates 
with phosphorylated STAT1 and inhibits the STAT1 binding to DNA (Liu et al., 
1998). 
Inhibitors for the effectors themselves have also been described, such as the 
RNase L inhibitor (RLI) (Bisbal et al., 1995). 
 
Figure 1.6: Endogenous inhibitors of IFN signalling & effectors. Antiviral 
effectors are in orange, transcription factors are in green and inhibitors are in 
brown.  
 
Of the endogenous inhibitors and downregulators of the IFN system mentioned 
above, chicken orthologues have been identified for A20 (Gene ID 
LOC421684), SOCS2 (Accession no. AY509606), PIAS1 (Accession no. 
NM_001031456) and RLI (Accession no. AM050269). 
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1.4) Virus inhibition of IFN 
The sophistication and significance of the IFN system is reflected by the variety 
of mechanisms that diverse groups of viruses have evolved to suppress or evade 
it. As RNA viruses have a more limited genome size, their immune evasion 
proteins tend to be multifunctional. In contrast, immunomodulatory genes can 
account for more than 50% of the total genome in the large herpesviruses and 
poxviruses (Alcami & Koszinowski, 2000). PKR is a frequent target as 
inhibition affects initial induction of IFN-β and phosphorylation of eIF2-α. 
Viruses can modulate IFN in almost any way imaginable, preventing IFN 
induction, inhibiting IFN signalling or coping with the effector mechanisms, by 
inactivating signalling components or upregulating endogenous inhibitors. 
Several reviews are available on viral mechanisms of IFN modulation (Alcami 
& Koszinowski, 2000; Goodbourn et al., 2000; Levy & Garcia-Sastre, 2001; 
Katze et al., 2002; Haller et al., 2006; Randall & Goodbourn, 2008), so I shall 
limit discussion to poxviruses, avian viruses and others relevant to this study. 
 
1.4.1) Virus inhibition of IFN induction 
Many viruses shut off host protein synthesis to divert resources towards viral 
protein production, indirectly inhibiting IFN production, but IFN induction can 
also be inhibited specifically. 
Several viruses attempt to disrupt the interaction of dsRNA with PAMP 
receptors such as PKR and RIG-I to avoid detection by the host. Reoviruses 
never fully uncoat, maintaining their dsRNA genome within the viral core inside 
the cytoplasm (Dryden et al., 1993). Poxvirus genomes are arranged such that 
early gene transcription products have little complementarity to each other, 
reducing dsRNA formation (Moss, 2001). 
The Vaccinia virus (VACV) E3 protein binds and sequesters dsRNA (Davies et 
al., 1993). The avian reovirus dsRNA binding protein σA inhibits ChIFN 
activity in chick embryo fibroblasts (CEF) (Martinez-Costas et al., 2000) and 
also functions in mammalian cells, where it can complement E3 in VACV by 
inhibiting PKR activation (Gonzalez-Lopez et al., 2003). The NS1 protein of 
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influenza virus is multifunctional, and amongst other things it binds dsRNA 
(Garcia-Sastre, 2001).  
Some viruses produce dsRNA analogues to sequester PKR and other dsRNA 
sensors. Epstein-Barr virus (Clarke et al., 1991) and adenoviruses transcribe 
short RNA hairpins that are only long enough to bind a PKR monomer, 
preventing the kinase oligomerisation that is necessary for phosphorylation 
(Galabru et al., 1989; Mathews & Shenk, 1991).  
African swine fever virus (ASFV) is a member of Asfarviridae, a family of large 
dsDNA viruses with several replication and structural similarities to poxviruses 
that infects pigs. The ASFV A238L gene encodes a protein with 40% homology 
to porcine IκB, which binds NF-κB but is not degraded, retaining NF-κB in the 
cytoplasm (Tait et al., 2000) and preventing NF-κB-mediated transcription 
(Powell et al., 1996). 
 
1.4.2) Virus inhibition of IFN signalling 
VACV encodes soluble viroceptors, viral orthologues of cellular receptors, 
which compete for binding of extracellular IFN. The B18 protein has a high 
affinity for human, bovine, rat, mouse and rabbit type I IFN (Symons et al., 
1995). The B8R gene encodes a soluble 43 kDa protein that binds IFN-γ from 
human, cow, rabbit, rat and chicken, but not mouse (Alcami & Smith, 1995). 
The paramyxovirus Newcastle disease virus (NDV), which infects chickens, 
encodes a V protein that targets STAT1 for degradation, inhibiting the effects of 
IFN signalling (Huang et al., 2003) and also preventing apoptosis (Park et al., 
2003a). The V protein is present in virions (Samson et al., 1991) and is therefore 
available to inhibit IFN signalling before viral transcription occurs. This is 
consistent with this protein’s inefficiency at blocking the effects of IFN after an 
antiviral state has been established in vitro (Park et al., 2003b).  
VACV encodes a phosphatase, VH1, that can dephosphorylate activated STAT1 
and prevent its nuclear translocation, although this was initially characterised 
only in response to IFN-γ stimulation (Najarro et al., 2001). Recently, VH1 has 
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also been shown to inhibit STAT1 and STAT2 phosphorylation in response to 
IFN-β stimulation (Mann et al., 2008). 
 
1.4.3) Virus inhibition of IFN effectors 
Many viruses produce proteins to compete with eIF-2α for PKR binding. The 
VACV K3 protein has 28% amino acid identity with the N-terminal of eIF-2α 
and acts as a decoy target for PKR, although K3 does not become 
phosphorylated itself (Davies et al., 1992; Smith et al., 1998).  
ASFV encodes a protein that interacts with cellular protein phosphatase-1, that 
may serve to dephosphorylate eIF-2α (Rivera et al., 2007), whereas influenza 
activates the p58IPK cellular inhibitor of PKR in mammalian cells (Lee et al., 
1994) by promoting its dissociation from heat shock protein 40 (Melville et al., 
1999). A chicken homologue of p58IPK has been identified (GeneID 428122).  
The alphavirus Semliki Forest virus (SFV) activates PKR, but is able to continue 
translation in the presence of phosphorylated eIF-2α, by using a RNA hairpin 
loop to stall ribosomes on the mRNA initiation codon (Ventoso et al., 2006). 
 
1.5) Poxviruses 
The Poxviridae are a family of viruses with a single linear contiguous dsDNA 
genome in a large virion (typically 400 x 240 x 200 nm) with a complex 
structure. Virions are ovoid in shape, with a biconcave core enveloped by a 
varying number of membranes (Levy et al., 1994). 
They are classified into two subfamilies, Entomopoxvirinae, which contains 3 
genera that infect insect hosts, and Chordopoxvirinae, that infect vertebrates. 
The latter contains 8 genera, including Orthopoxvirus (with prototypal species 
VACV) and Avipoxvirus, with Fowlpox virus (FWPV) as the prototypal species. 
The remaining genera within Chordopoxvirinae are Parapoxvirus, 
Capripoxvirus, Leporipoxvirus, Suipoxvirus, Molluscipoxvirus and Yatapoxvirus 
(Moss, 2001). Poxviruses reported to infect reptiles, Nile crocodile pox and 
spectacled caiman pox, have not been assigned to a genus. According to the 
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International Committee on Taxonomy of Viruses, the only Chordopoxviruses 
that do not infect mammals are within Avipoxvirus, all of which infect birds. 
No specific cellular receptor for a poxvirus has been identified, and poxvirus 
entry into cells is the subject of much debate. VACV can enter cells through 
endosomes or through fusion with the plasma membrane (Townsley & Moss, 
2007), and the mode used may be strain specific (Bengali et al., 2008). 
After virus entry, poxvirus replication occurs in the cytoplasm, where early 
mRNA synthesis in the virion core is followed by early gene translation, 
uncoating and genome replication. The linear genomes have inverted terminal 
repeats (ITRs), 10 to 50 kilobase pairs (kbp) long, covalently closed with hairpin 
loops at both ends. The terminal 200 base pairs (bp) function as origins of 
replication for the virally encoded DNA polymerase and either or both origins 
may be used simultaneously.  
DNA replication is initiated by site-specific recognition and nicking at the 
origin, generating self-priming hairpins. This is followed by nucleotide addition 
to the free 3’ end and strand displacement (Moss, 2001). If only one origin at a 
time is used, replication results in the formation of concatemers, which are 
cleaved by the original nicking enzyme, then ligated into unit length genomes 
(Dimmock et al., 2001). After replication, intermediate genes are transcribed and 
translated into transcription factors for late genes, which are in turn transcribed 
and translated into structural proteins (Moss, 2001). 
Morphogenesis of poxviruses has been studied mainly in VACV. Assembly 
begins with formation of crescent-shaped membranes and genome packaging 
into non-infectious immature virions. Proteolysis of several capsid proteins and 
condensation of the virus core matures the particles into intracellular mature 
virus (IMV), which have one or two surrounding membranes (Smith & Law, 
2004). The host cell nucleus is required to facilitate particle maturation (Hruby 
et al., 1979). IMV are wrapped with a further double membrane by either the 
trans-Golgi network or endosomes to form intracellular enveloped virus (IEV). 
These are transported to the cell periphery on microtubules where the outer IEV 
membrane fuses with the plasma membrane. Virions that remain attached to the 
cell surface (cell-associated enveloped virus) can induce actin tail formation to 
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be propelled away from the cell. Other virions are released and known as 
extracellular enveloped virus (EEV). The IMV particle, released by cell lysis, is 
robust and persists in the environment to aid spread between hosts. In contrast, 
the extra membrane of the EEV particle renders it quite fragile, although 
resistant to antibody neutralisation, and probably contributes to long range 
spread within a host (Smith & Law, 2004). 
In contrast to VACV, wrapping of FWPV IMV by the trans-Golgi network is an 
extremely rare event, but approximately 50% of IMV particles exit the cell by 
budding directly from the plasma membrane (Boulanger et al., 2000). Budding 
is preceded by accumulation of virions just beneath the plasma membrane 
(Hatano et al., 2001). 
The convention for VACV protein nomenclature is to use the HindIII restriction 
endonuclease DNA fragment letter (A to P) followed by the open reading frame 
(ORF) number within the fragment. VACV ORFs take the name of the protein 
followed by L or R to reflect the transcription direction. Nomenclature used for 
other poxvirus genes generally number the ORFs along the genome from left to 
right, with a prefix indicating the virus name and a suffix indicating the direction 
of transcription. 
 
1.6) Modified Vaccinia virus Ankara 
Modified Vaccinia virus Ankara (MVA) is an attenuated strain of VACV, 
developed by over 570 passages of the parental strain, chorioallantois Vaccinia 
virus Ankara (CVA), in CEF (Mayr et al., 1975). Comparison of MVA with the 
parental CVA by restriction mapping revealed six major deletions (deletions I to 
VI; Fig. 1.7), reducing the genome to 177 kbp (Meyer et al., 1991). Deletions I 
and II were further characterised (Altenburger et al., 1989) prior to complete 
sequencing of the MVA genome, which also identified fragmentation of several 
genes (Antoine et al., 1998). Complete sequencing of CVA revealed that each of 
the major deletions occurred in regions that already contained fragmented ORFs, 
and that smaller mutations also occurred throughout the genome (Meisinger-
Henschel et al., 2007). 
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Figure 1.7: HindIII restriction map of the MVA (strain BN) genome, showing 
positions of major deletions (red lines) with respect to the parental CVA strain. 
The vertical blue lines indicate HindIII restriction sites. The letters below indicate 
the names of the resulting fragments, where alphabetical order places them in 
order of decreasing size. From Meisinger-Henschel et al (2007). 
 
Cells permissive for MVA replication are limited to CEF, a quail fibroblast line, 
the fibroblastic hamster BHK-21 (Carroll & Moss, 1997; Drexler et al., 1998) 
and rat IEC-6 (Okeke et al., 2006) cell lines. Carroll and Moss (1997) found that 
some canine and monkey cell lines are semi-permissive, i.e. allowing a low 
amount of replication, but mature particles were rarely seen in these cells by 
electron microscopy. A further 10 cell lines tested, from monkey, hamster, 
human, pig and rabbit, are non-permissive for MVA. There was no obvious 
requirement for a permissive cell line; all permissive cells are fibroblastic but so 
are some of the non-permissive cells. 
 
1.6.1) Immune evasion by MVA 
The genes encoding viral IFN receptors, B8R and B18R, are fragmented in 
MVA although full versions of the E3L (encoding the dsRNA binding protein) 
and K3L (encoding the eIF2-α mimic) genes are present (Antoine et al., 1998; 
Blanchard et al., 1998). An MVA virus with a deletion of E3L, MVA-ΔE3L, is 
able to grow in BHK-21 but can replicate only transiently in CEF from 5-day old 
embryos, and not at all in CEF from 10-day old embryos (Hornemann et al., 
2003), which have a more mature IFN system (Carver & Marcus, 1967). In 
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contrast, VACV lacking the E3L gene, VACV-ΔE3L, can grow in BHK-21 cells 
and CEF, although this is sensitive to pre-treatment with IFN. However, the host 
range of VACV-ΔE3L is restricted, and it cannot grow in Vero, HeLa or mouse 
L cells (Beattie et al., 1996; Jacobs et al., 1998). 
The different permissivity of CEF for VACV-ΔE3L and MVA-ΔE3L could be 
explained by an unidentified protein that can be complemented by E3 for growth 
in CEF and is present in VACV but has been lost in MVA. Several host range 
factors and immunomodulators have been lost in MVA; their role could be 
examined in double-deletion viruses that also lack  E3L. 
The phosphatase that dephosphorylates STAT1 is retained and functional in 
MVA (Najarro et al., 2001). The VACV host range gene K1L is disrupted in 
MVA by deletion II, although it is intact in the parental CVA virus (Altenburger 
et al., 1989; Meisinger-Henschel et al., 2007). Replacement of this gene rescues 
virus growth in rabbit RK-13 cells (Meyer et al., 1991; Carroll & Moss, 1997) 
and functions by blocking activation of the cellular transcription factor NF-κB 
(Shisler & Jin, 2004).  
 
1.7) Avipoxviruses 
Natural poxvirus infections have been reported in 232 bird species (Bolte et al., 
1999). It seems that all poxviruses extracted from avian hosts were historically 
dumped into the Avipoxvirus genus. Subsequent analysis at a single genetic 
locus showed diversity comparable to that across the seven genera of 
mammalian poxviruses. Genetic analysis grouped 22 avipoxviruses into 3 
clades: Fowlpox-like viruses, Canarypox-like viruses and Psittacinepox viruses 
(Jarmin et al., 2006). Within Avipoxvirus, complete genome sequences have 
been obtained for Canarypoxvirus (Tulman et al., 2004) and two strains of 
FWPV (Afonso et al., 2000; Laidlaw & Skinner, 2004). 
 
1.7.1) Fowlpox disease 
FWPV is the causative agent of fowlpox disease, which infects chickens and 
turkeys of all ages worldwide. There are two forms of clinical disease, probably 
- 46 - 
as a result of alternative modes of transmission. Mechanical transfer through 
wounds or by biting arthropods leads to the cutaneous disease, characterised by 
lesions on the unfeathered areas. Lesions are a result of the epithelial hyperplasia 
induced by the virus, where cell number increases 2.5-fold within 72 h 
(Tripathy, 1991). When uncomplicated by secondary bacterial infection, the 
disease is self-resolving in 3 weeks, when dried scabs containing infectious virus 
are shed (Murphy et al., 1999). Virus particles shed from lesions can become 
aerosolised, and inhalation of virus in droplets leads to the generalised, 
diphtheritic form of the disease. Lesions on the mucous membranes of the mouth 
and respiratory tract can cause asphyxiation and 15 to 50% mortality (Esposito 
& Fenner, 2001). Extensive infection within a flock may cause a decline in egg 
production and economic loss, although recovered birds are immune to 
subsequent infection (Murphy et al., 1999). 
An early in vivo viral transfer study showed that individual avipoxviruses varied 
in host range breadth (Kirmse, 1969). In that study, Fowlpox caused generalised 
infection in chickens and turkeys, and a mild cutaneous disease in ducks and 
geese. No clinical infection was observed in pigeons, wild birds or mammals. No 
other avipoxvirus tested caused disease in chickens, or gave cross-species 
protection to FWPV in chicken, although FWPV did show cross-strain 
protection in chicken (Kirmse, 1969). 
 
1.7.2) Fowlpox Virus 
In contrast to the wide in vitro host range of VACV, FWPV is only able to 
replicate fully in avian cells. Late stages of viral morphogenesis were observed 
in the Syrian golden hamster (Mesocricetus auratus) cell line BHK-21 (Weli et 
al., 2004), but serial propagation of FWPV in this cell line has not been 
demonstrated. 
The block at which replication occurs is cell line-dependent. In human MRC-5 
fibroblasts, no cytopathic effects (cpe) were visible and late transcription 
(occurring post-DNA replication) was not detectable (Taylor et al., 1988b) or 
was delayed and occurred at low levels (Somogyi et al., 1993). In monkey 
fibroblast Vero and CV-1 cell lines, late gene expression does occur, with 
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morphogenesis as far as immature virus formation. Mature FWPV was rarely 
seen by electron microscopy, and it is unclear whether the mature particles that 
were observed were from the initial inoculum (Somogyi et al., 1993). 
In dermal epithelia, infectious virus first appears 24 h PI and peaks between 72 
and 96 h PI. In CEF in vitro, the cpe induced are an initial rounding of cells 
followed by degeneration and necrosis (Tripathy, 1991). FWPV forms 
proteinaceous, cytoplasmic A-type inclusions known as Bollinger bodies. Within 
these the virus particles themselves, also known as Borrel bodies, are visible 
with the light microscope. FWPV also produces cytoplasmic virus factories, 
sometimes referred to as B-type inclusions. In contrast, VACV produces B-type 
but not A-type inclusions. The A-type inclusions consist of IMV particles in a 
dense protein matrix and are thought to contribute to environmental persistence 
(Moss, 2001), similar to the inclusion bodies of baculoviruses or 
Entomopoxviruses. 
The FWPV virions measure approximately 250 x 354 nm, with a random 
arrangement of surface tubules (Hyde et al., 1965) (Fig. 1.8).  
 
Figure 1.8: Negative stained electron micrograph of Fowlpox virus. (From Hyde 
et al., 1965). 
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Depending on the strain, the genome of FWPV is 260 to 309 kbp, much larger 
than the 191 kbp of VACV Copenhagen strain. Most of the increased size is due 
to multiple gene families containing multiple members, as identified by the 
complete sequencing of a highly pathogenic American strain of FWPV (Afonso 
et al., 2000). This strain, hereafter referred to as the USDA (United States 
Department of Agriculture) strain, is 288 kbp with 260 predicted genes and 9520 
bp ITRs. Like the other poxviruses, most FWPV open reading frames (ORFs) in 
the terminal 50 kbp of the genome transcribe towards the termini. In mammalian 
poxviruses, the genes essential for replication are located in the central 
conserved region of the genome, while virulence factors and immunomodulators 
are usually located in the terminal regions (Smith et al., 1998). However, major 
genome rearrangements, including inversions and translocations, have occurred 
in Avipoxviruses relative to the mammalian poxviruses since their divergence 
(Mockett et al., 1992; Afonso et al., 2000). Also, 33 of the genes in the central 
part of the FWPV genome do not have VACV orthologues and FWPV has 113 
unique genes not found in Chordopoxviruses  at all (Gubser et al., 2004).  
Almost all field isolate strains of FWPV have been found to contain integrated 
sequences from an avian retrovirus, Reticuloendotheliosis virus (REV) (Hertig et 
al., 1997). In many isolates, the ‘piggy-backing’ virus is viable, and REV RNA 
is detected in plasma after infection with FWPV (Wang et al., 2006b). In a 
recent report, out of 243 FWPV isolates tested, 7 were negative for REV proviral 
DNA by polymerase chain reaction (PCR) analysis (Davidson et al., 2008). 
However, these isolates were not subjected to Southern hybridisation to exclude 
REV integration at an alternative locus or degeneration of any REV proviral 
remnants. 
FWPV encodes photolyase, an enzyme that repairs UV-induced DNA damage 
and previously found in Entomopoxvirinae (Afonso et al., 2000). Although there 
is no evidence of FWPV replication in the insect vector, this enzyme may 
contribute to the robustness of the virus in the environment. 
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1.7.3) Fowlpox virus FP9 
The European pathogenic strain known as HP-1 was serially passaged in CEF 
438 times to derive the attenuated strain HP438 (Mayr & Malicki, 1966). This 
attenuated virus was passaged twice more in CEF at a low multiplicity of 
infection (MOI) and plaque-purified twice to obtain strain FP9 (Mockett et al., 
1992) which has been completely sequenced (Laidlaw & Skinner, 2004). The 
FP9 genome is 266 kbp, with 247 predicted ORFs, numbered as orthologues of 
FWPV USDA from left to right as FP9.002 to FP9.259. The ITRs are 10158 bp 
long, the terminal 3982 bp of which consist of 32 and 56 bp repeats. Comparison 
of the FP9 genome with the USDA genome and partial sequences of the HP-1 
strain identified passage-specific genetic mutations affecting 46 ORFs, but the 
basis for attenuation remains unclear. FP9 does not contain an entire REV 
provirus, but a residual long terminal repeat (Laidlaw & Skinner, 2004), 
indicating loss of a previously integrated REV sequence by homologous 
recombination. 
Eight ORFs, FP9.002 to FP9.009, are present in the left ITR and so are 
duplicated in the right ITR as FP9.252 to FP9.259. Genes FP9.010 and FP9.251 
span the boundaries between the ITR and the unique portion of the genome, so 
have identity at their carboxyl (C)-terminals only. 
 
1.7.4) Fowlpox vaccines 
Commercial vaccines for Fowlpox disease, consisting of laboratory attenuated or 
naturally occurring mild FWPV strains, have been available since the late 1920s 
but their molecular biology is ill defined. Attenuated laboratory strains such as 
FP9 are better characterised. Vaccine strains that contain viable REV, such as 
Webster’s standard vaccine S strain, are associated with generalised 
immunosuppression although they still stimulate an anti-FWPV response. The 
Steggles vaccine strain of FWPV, which lacks the REV envelope gene, does not 
cause immunosuppression (Wang et al., 2006b). 
VACV promoters maintain their temporal character in a FWPV background and 
early antigen expression generates both cellular and humoral responses. 
Recombinant Fowlpox viruses expressing antigenic determinants of avian 
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influenza have been generated (Taylor et al., 1988a), licensed in the United 
States of America and used commercially in Mexico and China, with 459 
million doses used over 7 years in Mexico alone (Villarreal-Chavez & Rivera-
Cruz, 2003). Recombinant FWPV expressing NDV antigens have also been 
developed for use in the poultry industry (Boursnell et al., 1990a; Boursnell et 
al., 1990b). 
This history of successful protection in poultry, large genome capacity for 
genetic modification, inability to replicate in mammalian hosts and heat stability 
make FWPV a candidate for use as a vaccine vector in non-avian species (Taylor 
& Paoletti, 1988), or as a vector for gene therapy. 
A recombinant FWPV expressing rabies virus glycoprotein induced protective 
immunity to rabies in several mammalian species, despite failing to replicate in 
vitro in non-avian cells (Taylor et al., 1988b). Recombinant FWPV vaccines 
expressing tumour associated antigens have been constructed (Hodge et al., 
1997) and used in clinical trials (Marshall et al., 2000; Zhu et al., 2000). 
Similarly, FWPV expressing human immunodeficiency virus (HIV) (Radaelli & 
De Giuli Morghen, 1994) or malaria (Anderson et al., 2004) antigens have been 
described and investigated clinically. Several studies have found that a 
heterologous prime-boost system induces greater specific immunity, as 
immunity to the vector is not boosted. 
Incorporating type I or type II ChIFN into a recombinant FWPV vaccine 
improved immunogenicity and protection against Newcastle disease 
(Rautenschlein et al., 1999). The same principle has been applied to a 
recombinant FWPV vaccine expressing HIV antigens and human IFN-γ, tested 
in macaques (Kent et al., 2000) although with limited success in humans (Emery 
et al., 2007). 
 
1.7.5) Immune evasion by FWPV 
FWPV is a poor inducer of IFN in CEF, and is much less sensitive to its effects 
than VACV (Asch & Gifford, 1970; Pollitt, 1997). Co-infection of FWPV could 
rescue replication of SFV in IFN-treated CEF (Pollitt, 1997), similar to the 
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rescue of vesicular stomatitis virus (VSV) by VACV in murine L cells 
(Whitaker-Dowling & Youngner, 1983). However, all these experiments used 
IFN that had been induced by SFV or NDV, which is generally more 
heterogeneous and at lower concentrations than recombinant ChIFN can be. 
The FWPV genome contains several putative immunomodulatory genes with 
similarity to cellular and other known poxvirus genes, mostly in the terminal 
regions. Potential orthologues of cytokines and chemokines including 
transforming growth factor β, β-nerve growth factor and CC-like chemokines, 
have been identified. Genes encoding proteins with amino acid similarity to G-
protein coupled receptors, an interleukin (IL)-18 binding protein and NK cell 
receptors have also been predicted (Afonso et al., 2000). However, no 
orthologues of VACV IFN modulators E3L, K3L, B8R or B18R have been 
predicted by sequence similarity. Sequence analysis has also failed to identify 
any orthologues of chicken genes relevant to IFN evasion. 
A biochemical approach was used to identify a FWPV IFN-γ binding protein, 
FPV016, which does not show significant amino acid similarity to any other 
cellular or viral IFN-γ binding proteins (Puehler et al., 2003). Species specificity 
experiments showed that it neutralised chicken, duck and human IFN-γ, although 
not that of mouse or rat. The chicken IFN-γ receptor had not been identified at 
the time, although it has since been cloned (Han et al., 2006; Han et al., 2008).  
The FWPV protein FPV039 has recently been identified as an anti-apoptotic 
protein, that has some homology to the anti-apoptotic cellular protein Bcl-2 
(Banadyga et al., 2007). FPV016 and FPV039 are intact in FP9 (Laidlaw & 
Skinner, 2004).  
 
1.8) Aims of the project 
Understanding the interactions between an avian virus and the avian IFN system 
could lead to a better understanding of general virus host range tropism, 
interspecies transmission and vaccine efficacy. Identification of gene products 
that cross-react with mammalian cells could be used for rational design of 
vaccines for non-avian species.  
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The aim of the project was to identify a gene that contributes to FWPV 
resistance to ChIFN, as indicated by Asch & Gifford (1970) and Pollitt (1997). 
FP9 has a similar resistance to ChIFN as more virulent strains of FWPV (M. 
Skinner, Imperial College; personal communication). Because FP9 has a smaller 
genome than HP-1 or the USDA strain of FWPV, and hence fewer gene 
candidates, the investigation was carried out using FP9. 
Unfortunately, a scarcity of biochemical reagents, data and sequences for the 
chicken innate immune system hamper biochemical or bioinformatic 
approaches. Therefore a genetic approach was taken to test the whole FP9 
genome for activity that counters ChIFN action.  
VACV is more sensitive than FWPV to ChIFN (Pollitt, 1997), and MVA lacks 
some of the immunomodulatory proteins of virulent strains of VACV. FP9 and 
MVA are both strains that have been attenuated by serial passage in CEF, and 
have restricted, overlapping host ranges, and can both be handled at ACDP 
Category 1. Therefore a gene library was to be constructed, of FP9 genomic 
fragments inserted into recombinant MVA viruses, and screened for an increased 
resistance to ChIFN. This process was to be reiterated until the FP9 fragments 
conferring increased resistance did not contain more than a single gene. 
 
1.9) Project Design 
The genomes of poxviruses are too large for direct manipulation, requiring the 
use of DNA shuttle vectors that are transfected into infected cells. As well as 
FP9 sequence, this DNA must also contain flanking sequences to direct 
homologous recombination with the infecting viral genome, and a gene to select 
for recombinant viruses. Due to the number of recombinants intended in the 
library, the method used for generating the DNA to be transfected had to be 
suitable for high-throughput use. 
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1.9.1) Consideration of marker retention versus transient dominant 
selection 
The selection marker used to identify recombinant viruses can remain in the 
genome, or it can be removed after purification of the recombinant. Transient 
dominant selection (TDS) (Falkner & Moss, 1990) allows the generation of 
viruses with only the single desired genetic change, as the selectable marker is 
not retained in the final genome. However, TDS is very time consuming and not 
feasible for a library of this scale. Leaving the marker gene in the recombinant 
virus was acceptable for the screening process as it was unlikely to negate the 
effect of an FP9 IFN modulator, and the recombinant viruses were not intended 
for in vivo use. In addition, a control virus was to be made to contain only the 
selection marker and a short stretch of non-coding FP9 DNA. 
 
1.9.2) Consideration of selection markers 
Markers used for selection of recombinant poxviruses fall into two broad 
categories: those that provide a visual marker for identification of infected cells, 
and those that provide a growth advantage to recombinants over parent viruses 
under certain conditions. 
Visual markers include LacZ, encoding β-galactosidase, which produces a blue 
product in the presence of 5-bromo-4-chloro-3-indolyl-β-D-galactopyransoside 
(X-gal) (Chakrabarti et al., 1985). Similarly, the GUS gene encodes the β-
glucuronidase protein, that produces a blue product in the presence of 5-bromo-
4-chloro-3-indolyl-β-glucuronide (Carroll & Moss, 1995; Howley et al., 1996). 
Both LacZ and GUS have been used in recombinant MVA (Sutter & Moss, 
1992; Ferrer et al., 2007). 
Fluorescent proteins such as green fluorescent protein (GFP) from the jellyfish 
Aequorea victoria or red fluorescent protein are visible under UV light. Cells 
infected with GFP-positive viruses can be sorted by flow cytometry (Dominguez 
et al., 1998), whereas LacZ or GUS recombinant viruses must be picked by 
hand.  
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It is possible to insert both a selection gene and a visual marker into recombinant 
viruses, but this would reduce the available capacity for FP9 DNA. For the 
MVA-FP9 library, a selection gene was preferable to a visual marker, although a 
parental strain of MVA that expresses LacZ (MVA-LZ) would aid visualisation 
of plaques.  
Holzer et al. (1998) generated a VACV lacking the essential gene D4R, by using 
a cell line stably expressing the D4 protein. D4R was used as a selection gene to 
allow recombinant viruses derived from this parent to grow in standard cell lines 
whereas non-recombinant viruses could not. Neomycin resistance has also been 
used to select for recombinant Vaccinia viruses (Franke et al., 1985), but neither 
D4R nor neomycin selection has been reported for MVA. 
Deletion of the F13L gene in MVA reduces cell-to-cell spread and causes a 
small plaque phenotype. Reintroduction of the F13L gene into an F13L-deleted 
parent virus has been used as a selection marker, but only in mammalian BHK-
21 cells (Sanchez-Puig & Blasco, 2005). 
The VACV K1L host range gene is fragmented in MVA (Altenburger et al., 
1989). Expression of this gene rescues the ability of MVA to grow in human 
MRC-5 (Perkus et al., 1989) or rabbit RK-13 cells (Meyer et al., 1991; Staib et 
al., 2000), however residual K1L sequences in MVA can increase the 
background of unwanted recombination events (Tscharke & Smith, 2002; Staib 
et al., 2003). Also, as K1L encodes a host range protein, using it as a selection 
gene may obscure any effects of FWPV host range genes. 
Boyle and Coupar (1988) developed the use of Escherichia coli xanthine-
guanine phosphoribosyl transferase (GPT) as a selectable marker that allows 
virus growth in the presence of mycophenolic acid (MPA). MPA blocks the de 
novo synthesis of purines, but GPT enables a salvage pathway for purine 
synthesis from xanthine to be used (Mulligan & Berg, 1981)(Fig. 1.9). Cells 
possess hypoxanthine-guanine phosphoribosyl transferase (HGPRT) to salvage 
purines from hypoxanthine and guanine (Krenitsky et al., 1969). Therefore in 
the presence of MPA, xanthine and hypoxanthine (MXH), only GPT-positive 
viruses will grow. GPT selection has been used together with LacZ to 
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successfully generate recombinant MVA where the selection marker was not 
retained (Scheiflinger et al., 1998). 
 
 
Figure 1.9: Inhibition of purine synthesis by MPA. A: Chemical structure of MPA 
(6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-
methyl-4-hexenoic acid). B: Salvage pathways for purine synthesis from free 
purine bases. Cellular enzymes HGPRT and adenine phophoribosyl transferase 
(APRT) can salvage hypoxanthine, guanine and adenine into their respective 
ribonucleotides (5’ monophosphates). Similarly, GPT can salvage guanine and 
hypoxanthine and additionally xanthine (Mulligan & Berg, 1981). 
 
The method chosen was to use GPT as the selection marker under control of the 
VACV p7.5 promoter, that is active at both early & late times after infection (i.e. 
A 
B 
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before and after DNA replication) (Davison & Moss, 1989b; Davison & Moss, 
1989a), relying on expression of LacZ from the parental MVA to aid 
identification of plaques (both parental and chimaeric). 
 
1.9.3) Consideration of insertion sites in the MVA genome 
The site of recombination is directed by homologous regions that flank the 
sequence to be inserted. The efficiency of recombination is proportional to the 
length of the homologous regions, which are usually designed to be 500 to 600 
bp (Sutter et al., 1995; Staib et al., 2000; Tscharke & Smith, 2002). 
The thymidine kinase (TK) gene has been used as the locus for insertion into 
MVA, but some workers found it necessary to compensate for the loss of TK 
function by insertion of the FWPV TK gene (Scheiflinger et al., 1996). To 
include this compensating gene together with the GPT cassette and 
recombination flanks would reduce the remaining capacity for the FP9 insert, 
hence increasing the number of recombinants required. 
Some of the major genomic deletions that MVA acquired during its attenuation 
from VACV strain Ankara have been used as insertion sites for foreign genes 
(Meyer et al., 1991; Staib et al., 2004). 
Deletion III, at the right end of the genome, led to the loss of 3.5 kbp, causing a 
fusion product of two ORFs into MVA164R and deleting part of the promoter 
for the haemagglutinin gene (Antoine et al., 1996). This has been used as the site 
to insert LacZ and GPT  (Sutter & Moss, 1992) but lies within MVA164R, close 
to the C-terminus. It is followed by a short (57 bp) intergenic region between the 
ORFs MVA164R and MVA165R. 
Deletion II, at the left end of the genome, resulted in the loss of 2.5 kbp and the 
premature termination of the MVA022L gene, orthologous to the VACV host 
range K1L gene (Fig. 1.10A). The 10 amino acids (aa) of MVA022L 
downstream of the deletion result from a frameshift (Altenburger et al., 1989; 
Meisinger-Henschel et al., 2007). There is an additional, smaller, deletion of 16 
bp in the MVA022L promoter, such that this gene is non-functional 
(Altenburger et al., 1989), leaving 530 bp between the functional genes 
MVA021L and MVA023L.  
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Deletion II is known to be a stable insertion site (Sutter et al., 1995) (G. Sutter, 
Paul-Ehrlich-Institut, personal communication) and near a relatively large 
intergenic region, making it the site of choice.  
Although previous workers have targeted foreign genes precisely to the deletion 
site (Sutter et al., 1995), I inserted at a point approximately equidistant from the 
end of MVA023L and the beginning of MVA021L (Fig. 1.10B). This should not 
affect MVA022L as it is non-functional (Altenburger et al., 1989). Rather, this 
takes advantage of the intergenic region, so any possible mutations introduced 
into the flanks during PCR amplification are less likely to disrupt any other 
genes adjacent to the insertion site. The genes adjacent to the insertion site are: 
MVA020L: orthologue of VACV Copenhagen N1L, which inhibits NF-κB 
signalling (DiPerna et al., 2004). 
MVA021L: orthologue of VACV Copenhagen N2L, an alpha-amanitin 
resistance gene (Tamin et al., 1991). 
MVA022L: disrupted orthologue of VACV K1L. 
MVA023L: orthologue of VACV Copenhagen K2L, a cell-cell fusion inhibitor 
(Law & Smith, 1992). 
 
Figure 1.10: Deletion II of MVA. A: ORFs lost from parental CVA to form 
deletion II site in MVA. Orange arrows represent intact ORFs, blue arrows 
represent fragmented or truncated ORFs. From Meisinger-Henschel et al 
(2007). B: Scale drawing of the region between MVA021L and MVA023L, 
showing relative positions of deletion II (red) and left and right flanks (purple) 
used in this study. Note the small gap between the left and right flanks. 
A 
B 
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The 21 bp gap between the left and right flanks, which will be lost in 
recombinant viruses, can be used to identify non-recombinant virus.  
 
1.9.4) Consideration of cloning versus PCR assembly approaches 
Two approaches could be used to assemble the recombination flanks, selection 
marker and FP9 fragment together. The flanks and selection marker could be 
cloned into a plasmid, with restriction sites to subsequently accept various FP9 
sequences. This would generate a library of plasmids for transfection or 
subsequent PCR amplification. Alternatively, PCR could be used to 
simultaneously assemble the flanks and selection marker with various FP9 
sequences into a linear construct. The method chosen affects the DNA topology 
and hence the efficiency of subsequent recombination. 
Boulanger et al. (2002a) found that transfection efficiency is the same with 
circular or linear DNA. Yao and Evans (2001) found that homologous 
recombination induced by a poxvirus is much higher with linear than with 
circular DNA. This higher frequency of recombinants with linear DNA could 
explain Boulanger’s finding that fewer rounds of selective passage are needed to 
eliminate parent virus when linear DNA has been transfected (Boulanger et al., 
2002a). This reduces time and the risk of random mutations in the viral genome 
caused by multiple passages.  
With circular DNA, a single crossover recombination event is possible, leading 
to integration of the whole plasmid sequence (Falkner & Moss, 1990). With 
plasmid DNA, single and double crossovers have roughly equal probabilities of 
occurring (Spyropoulos et al., 1988). This could occur at one of the MVA 
flanks, or at a region of unforeseen homology within an FP9 fragment, leading to 
insertion at an unexpected site. If a single crossover occurs, a second round of 
recombination can occur between the resulting repeats, excising a plasmid 
(Falkner & Moss, 1990). These excised plasmids that are a by-product of 
recombination can persist and potentially cause complications unless 
counterselected for (Kerr & Smith, 1991). Therefore it is preferable to transfect 
linear DNA, which requires a double recombination event to become 
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incorporated into the genome. A linear construct could be produced directly 
from a PCR assembly reaction, or from PCR amplification with a plasmid 
template. 
Assembly by sub-cloning would be complicated to design as suitable restriction 
sites would be limited to those absent or rare in the components being 
assembled, and would require techniques suitable for relatively large insertions. 
Available restriction sites are influenced by the relatively low GC content of the 
genomes: 30.8% in FP9 and 33.1% in MVA. The method of choice was to use 
PCR assembly to construct linear DNA cassettes for direct transfection into cells 
infected with MVA, for homologous recombination to insert the FP9 fragment 
and selection marker into the MVA genome. The main disadvantage of PCR is 
the possible introduction of point mutations by low fidelity polymerase 
potentially inactivating a gene product. This risk can be minimised by using a 
high fidelity polymerase and introducing redundancy into the library, such as 
including individual genes in multiple fragments and producing independent 
duplicates of fragments.  
 
1.9.5) Splice overlap extension PCR 
Splice overlap extension (SOE)-PCR was first described for site-directed 
mutagenesis (Higuchi et al., 1988; Ho et al., 1989) and later for engineering 
hybrid genes (Horton et al., 1989). Individual fragments are synthesised by PCR 
using primers that are modified at their 5’ ends to incorporate complementary 
sequences (Fig. 1.11A). When these PCR products are mixed, denatured and 
reannealed, the strands with matching sequences at their 3’ ends overlap and act 
as primers for each other (Fig. 1.11B). Primers that anneal to the ends of the 
fusion product then amplify this linear “assemblicon” (Fig. 1.11C).  
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Figure 1.11: Schematic outlining the SOE-PCR process, showing the splicing of 
two different PCR amplicons (in red and black) into a single DNA product. A: 
PCR products are synthesised in separate reactions using primers with 5’ tails 
to introduce short overlapping sequences. B: PCR products are combined in a 
further reaction, where the overlap acts as an internal primer. Extension only 
occurs from strands that have annealed in the correct orientation. C: Addition of 
the outer primers used in step A amplifies the final assemblicon. 
 
Synthesis of single-chain variable fragment (scFv) antibodies is a prominent 
application of this approach (Hayashi et al., 1994). 
 
1.10) Summary 
The IFN system is a potent aspect of innate antiviral immunity, but historically it 
has been less well characterised in avian hosts. Viruses inhibit or cope with the 
IFN system using a wide variety of mechanisms. Poxviruses are large dsDNA 
viruses and immunomodulatory genes can account for a large proportion of their 
genomes. MVA is an attenuated strain of VACV, which is more sensitive to 
ChIFN than FWPV is. 
FWPV is the causative agent of fowlpox disease, is restricted to avian hosts in 
vitro and in vivo, and yet has vaccine applications in both poultry and mammals. 
A 
B 
C 
- 61 - 
The virus exhibits resistance to ChIFN, but despite availability of the FWPV 
genome sequence, there are no obvious clues to the genetic basis of this 
resistance. Due to the paucity of biochemical reagents suitable for the avian IFN 
system, a genetic approach was taken, with the aim of identifying FWPV genes 
that contribute towards ChIFN resistance. 
The experimental approach taken was to insert fragments of FP9 genomic DNA 
(gDNA) into MVA at the Deletion II site. Recombinant viruses were to be 
rescued by the co-insertion of GPT and culture in MPA. The library of 
recombinant viruses was then to be screened to identify any FP9 genetic 
elements that bestowed an increased resistance to ChIFN. 
Chapter 3 describes the design of the FP9 genomic fragments and optimisation 
of their assembly by SOE-PCR into linear cassettes.  
Chapter 4 describes optimisation of transfection and MPA selection protocols, 
followed by generation of the recombinant MVA viruses using the cassettes 
described in Chapter 3. 
Chapter 5 describes optimisation of a screening protocol that was then used to 
screen the recombinant library for any viruses that showed an increased 
resistance to ChIFN. 
Chapter 6 describes the further characterisation of two recombinant viruses that 
had shown a positive phenotype for ChIFN resistance, and attempts to reiterate 
the whole process in order to identify individual genes that were responsible. 
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CHAPTER 2 
Materials and Methods 
 
Unless otherwise stated, all plastic consumables were from Greiner (Stonehouse, 
UK), all tissue culture media and supplements were from Invitrogen (Paisley, 
UK), and all chemicals were from Sigma-Aldrich (Gillingham, UK).  
 
2.1) Poxviral DNA extraction 
CEF were infected with FP9 or MVA at 0.01 plaque forming units (pfu) per cell 
and were cultured in E199 2% newborn bovine serum (NBBS) at 37 oC 5% CO2 
for 5 to 7 days, until extensive cpe were visible. Cells and culture medium were 
collected, freeze-thawed three times to release intracellular virus, then 
centrifuged at 1500 g for 15 min to remove cellular debris. Supernatant was 
centrifuged at 218000 g for 30 min to pellet virus particles, which were then 
resuspended in 2 ml TE (10 mM Tris-Cl, 1 mM ethylenediaminetetra-acetic acid 
(EDTA), pH 8.0) and stored overnight at 4 oC. 
DNA was extracted as described in Boulanger et al. (1998). An equal volume of 
2x extraction buffer (20 mM Tris-Cl, 20 mM EDTA, 200 mM NaCl, 1% sodium 
dodecyl sulphate (SDS), 4% 2-mercaptoethanol, 2.5 mg/ml proteinase K) was 
added to the virus suspension and incubated at 55 oC for 2 h. An equal volume of 
phenol saturated with 10 mM Tris-Cl at pH 8.0 was added before agitation at 
room temperature for 195 min and centrifugation at 1500 g for 5 min. The 
aqueous layer was transferred to an equal volume of phenol-chloroform-isoamyl 
alcohol (25:24:1, saturated with 10 mM Tris, pH 8.0), agitated at room 
temperature for 1 h and centrifuged at 1500 g for 5 min. The aqueous layer was 
transferred to an equal volume of 24:1 chloroform-isoamyl alcohol, agitated at 
room temperature for 1 h and centrifuged at 1500 g for 5 min. The aqueous layer 
was agitated in the presence of 0.1x volume 3 M sodium acetate and 2.5x 
volume ethanol and then centrifuged at 1500 g for 15 min. The DNA pellet was 
washed in 70% ethanol, air-dried, dissolved in 200 µl 10 mM Tris-Cl, pH 8.5 
and stored at -80 or -20 0C. 
- 63 - 
Alternatively, gDNA was purified with the Wizard® SV Genomic DNA 
Purification System (Promega; Southampton, UK) by mixing 150 µl of infected 
cell lysate with an equal volume of Wizard® SV Lysis Buffer and proceeding 
according to the manufacturer’s instructions. DNA was eluted in 250 µl nuclease 
free water and stored at -20 oC. 
 
2.2) Primer design 
Published genome sequences of MVA (Accession no. AJ581527) and FP9 
(Accession no. U94848), or pGNR (Boulanger et al., 1998), were used as input 
sequence for primer design using the Primer3 program at 
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi (Rozen & Skaletsky, 
2000). Unless stated otherwise, parameters altered from the default values were 
as listed in Table 1. 
Primer3 setting Minimum Optimum Maximum 
Primer Size 18 (15) 20 22 (25) 
Primer Tm 48 (45) 50 52 
Primer GC% 20 30 40 (45) 
GC clamp 1 n/a n/a 
Tm difference n/a n/a 2 
Table 1: New Primer3 settings changed from default values for primer design. 
Where 2 values are given, bracketed values were used for FP9 primers. Tm: 
melting temperature. n/a: not applicable. 
 
The suggested oligonucleotide pair with the lowest predicted complementarity 
was used for further analysis and annotated onto the genome sequences using 
DNannotator at http://sky.bsd.uchicago.edu/primer_compact.htm (Liu et al., 
2003) and viewed in Artemis 8 (© The Sanger Centre). 
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Primers incorporating a restriction endonuclease recognition site included a 
minimum of two 5’ thymidine bases at the 5’ end. Oligonucleotides were 
supplied lyophilised (Sigma Genosys; Gillingham, UK), reconstituted in water to 
100 µM and diluted in TE to 10 µM and stored at –20 oC. Melting temperatures 
(Tm) of primers were calculated using the formula: (59.9+(41x(%GC/100))-
675/size)). 
 
2.3) Standard polymerase chain reaction 
All PCRs were carried out in Techne Progene or Genius thermal cyclers using 
AccuPrime Taq High Fidelity polymerase (Invitrogen), except where stated. 
Products were synthesised with 0.02 IU/µl polymerase (< 2 kbp products) or 
with 0.04 IU/µl polymerase (> 2 kbp products). The supplied polymerase buffer 
II was used for gDNA templates; buffer I for plasmid, cDNA and PCR product 
templates. Buffers contained MgSO4 (20 mM) and deoxy nucleotide 
triphosphates (dNTPs; 2 mM each). Reactions also contained primers (300 nM 
each).  
Initial denaturation was at 94 oC for 90 s followed by 30 cycles; each cycle 
consisted of denaturation for 30 s at 94 oC, annealing for 30 s at 2 to 3 oC below 
the lower Tm, and extension at 68 oC for one minute per kilobase (unless 
otherwise stated). A final extension step at 94 oC was 10 min for products less 
than 2 kbp, or 20 min for longer products. 
 
2.4) Assembly PCR 
Fragments were assembled using Splice Overlap Extension PCR (SOE-PCR) 
(Horton et al., 1989). Complementarity between fragments was provided by a 20 
to 22 nt 3’ tail on the initial primers. Reaction conditions were as described for 
standard PCR, except that annealing time was 1 min for template overlaps. 
Priming occurred at overlap regions, for production of a full length splice 
product. This was amplified by primers terminal to the desired “assemblicon”. 
The stages at which components were added were developed as described in 
Chapter 3. 
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2.5) Electrophoresis of PCR products 
DNA products were resolved by agarose gel electrophoresis in Tris - borate - 
EDTA (TBE) (100 mM Tris, 90 mM boric acid, 1 mM EDTA) with ethidium 
bromide (0.5 µg/ml) and then visualised in 302 nm wavelength UV light on a 
ChemiDoc system (BioRad; Hercules, USA). Samples were loaded in 6x loading 
buffer (50% glycerol, 125 mM EDTA, 0.1% sodium dodecyl sulphate, 20 µg/ml 
bromophenol blue, 20 µg/ml xylene cyanol). 
Alternatively, DNA products were resolved in agarose gels in TBE containing 
crystal violet (10 µg/ml). Samples were loaded in 6x crystal violet loading buffer 
(30% glycerol, 20 mM EDTA, 100 µg/ml crystal violet). A stock crystal violet 
solution (10 mg/ml) was prepared in Tris acetate - EDTA (TAE) (40 mM Tris 
acetate, 1 mM EDTA) for gel and buffer preparation. Crystal violet gels were 
visualised in white light. 
Electrophoresis in a 50 ml gel was carried out at 90 V for 25 to 35 mins. 
Products were assessed against a quantitative 1 kbp DNA ladder (Invitrogen).  
 
2.6) Quantification of DNA 
DNA was quantified by comparison against a quantitative 1 kbp DNA ladder 
(Invitrogen) after gel electrophoresis, or by spectrophotometry on a NanoDrop 
(Thermo Scientific; Wilmington, USA). 
 
2.7) Purification of PCR products 
Enzymes and nucleotides were removed from PCR products using one of the 
following methods: 
- QIAquick PCR purification kit (Qiagen; Crawley, UK). PCR mixes were 
treated according to the manufacturer’s directions. 
- QIAquick gel extraction kit (Qiagen) or QiaexII kit (Qiagen). DNA bands were 
excised with a scalpel from an agarose gel after electrophoresis and treated 
according to the manufacturer’s directions. 
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- Recochip (Takara Bio Inc; Shiga, Japan). The disposable chip containing a 
cellulose dialysis membrane was dipped in electrophoresis buffer and pushed 
into an agarose gel on the anode side of the band of interest, with the black side 
facing the DNA. Electrophoresis of a 50 ml gel was continued at 90 V for 10 
min to electro-elute DNA onto the membrane. The chip was removed and 
centrifuged at 3000 g for 15 sec. The resulting solution (~55 µl) was treated with 
the QIAquick gel extraction kit post-enzymatic reaction protocol: an equal 
volume of isopropanol and 3x volume of buffer QG (Qiagen) were added and 
the mixture was loaded onto a QIAquick column and centrifuged. The column 
was washed with 750 µl proprietary buffer PE (Qiagen) and centrifuged dry 
before elution of DNA. 
For all treatments, DNA was eluted into 30 to 50 µl elution buffer (10 mM Tris-
Cl pH 8.5), TE or nuclease free water and stored at -20 oC. 
 
2.8) Plasmids 
Plasmids pGNR, containing the GPT gene downstream of the VACV p7.5 
promoter (Boulanger et al., 1998), and pCMV-β, containing the LacZ gene 
under a cytomegalovirus (CMV) promoter, were provided by M. Skinner 
(Imperial College). Plasmid pGFP184x, containing the GPT and GFP genes 
with flanks for homologous recombination into the ITR of FP9 was provided by 
S. Laidlaw. 
Plasmid pEFplink2 is a derivative of pEF-BOS (Marais et al., 1995), a 
mammalian expression vector containing the human polypeptide chain 
elongation factor 1α (EF1α) promoter and the poly-adenylation signal from 
human granulocyte colony-stimulating factor cDNA (Mizushima & Nagata, 
1990). Plasmid pEFplink2FLAG, containing a FLAG tag in-frame and two 
codons downstream of the initiation codon of pEFplink2 and an ampicillin 
resistance gene was provided by S. Laidlaw. 
All plasmids were stored at -20 oC. 
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2.9) Ligation 
For blunt-end ligations, purified DNA (20 to 50 ng) was ligated into 10 ng pCR-
BluntII-TOPO (Invitrogen) using the Zero Blunt TOPO PCR Cloning Kit 
(Invitrogen) according to the manufacturer’s directions. The ligation mix was 
incubated at room temperature for 30 min. 
For sticky-ended ligations, purified digested DNA to be inserted was mixed with 
purified digested vector in a molar ratio of 3:1. Also present in the 20 µl reaction 
were 2000 U T4 DNA ligase (New England Biolabs; Hitchin, UK) and 1x 
ligation buffer (50 mM Tris-HCl, 10 mM MgCl2, 10 mM DTT, 1 mM ATP, 25 
µg/ml bovine serum albumin). The ligation mix was incubated at 15 oC for 18 to 
20 hours. 
 
2.10) Transformation 
Immediately after ligation, 5 to 50 ng DNA was transformed into chemically 
competent cells (TOP10, DH5-α (Invitrogen) or XL1-Blue (Stratagene; La Jolla, 
USA)) according to the manufacturers’ directions. 
After 1h at 37 oC in SOC medium with shaking, cells were spread on a Luria-
Bertani (LB) agar plate containing the appropriate selection antibiotic (50 µg/ml 
kanamycin or ampicillin) and incubated at 37 oC until colonies were visible. For 
α-complementation screening, plates also contained 20 mg/ml X-gal (Sambrook 
& Russell, 2001). 
 
2.11) Plasmid extraction (mini-preps) 
Colonies were picked into 5 to 10 ml LB broth containing selection antibiotic 
and incubated overnight at 37 oC with shaking. At this point, an aliquot (850 µl) 
was mixed with autoclaved glycerol (150 µl), vortexed and kept at -80 oC for 
long-term storage. The remainder of each culture was centrifuged at 1500 g for 
10 min, and then plasmids were extracted with the QIAprep spin miniprep kit 
(Qiagen) according to the manufacturer’s directions. 
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2.12) Plasmid digestion 
DNA (15 to 20 µg) was digested with 50 U of restriction enzyme (New England 
Biolabs) in a total volume of 50 µl. The buffer used and supplementation with 
100 µg/ml bovine serum albumin were as recommended by the manufacturer. 
Digestions were incubated for 2 to 30 h at 37 oC followed by heat inactivation at 
65 oC for 20 min. Digestion was confirmed by gel electrophoresis. 
 
2.13) Sequencing 
Plasmid DNA or PCR product (150 to 300 ng per 3 kb) with 3.2 pmol primer in 
a total volume of 10 µl was sequenced by the MRC CSC Genomics Core 
Laboratory, Hammersmith Hospital. Results were analysed with the nucleotide-
nucleotide (BLASTN) tool at http://www.ncbi.nlm.nih.gov/BLAST.  
 
2.14) Cells 
CEF prepared from 10 day old specific pathogen free embryonated eggs were 
obtained from the Institute for Animal Health (Compton, UK) or were made in-
house with embryos from the same source. 
Embryos were decapitated, eviscerated, washed in phosphate buffered saline 
(PBS) and passed through a 20 ml syringe. Trypsin (50 ml of 0.05% in PBS) was 
added to the resulting homogenate, stirred for 2 min and allowed to settle. The 
supernatant was decanted and discarded. Further trypsin solution was added, 
stirred for 4 min and the supernatant decanted into 50 ml NBBS. This was 
repeated until only jelly and limb fragments remained in the original 
homogenate. Digested cells were passed through a metal gauze with 0.31 mm 
aperture pores (Potter & Soar; Banbury, UK) and centrifuged for 5 min at 500 g. 
Cells were resuspended in culture medium and passed through a 70 µm cell 
strainer before seeding at 2.22 cells/cm2 or 1.11 cells/cm2, for confluency after 
24 or 48 h, respectively. 
P1 CEF were prepared by storing CEF as described above, at 30 oC 5% CO2 in 
Dulbecco’s modified Eagle medium (DMEM) 2% foetal bovine serum (FBS), 
for up to 4 days before a single passage. 
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The DF-1 chicken fibroblast cell line (Himly et al., 1998) was obtained from the 
ATCC (no. CRL-12203). 
All cells were manipulated in a laminar flow microbiological safety cabinet and 
incubated in a humidified incubator at 37 oC 5% CO2 in DMEM supplemented 
with 100 U/ml penicillin and 100 µg/ml streptomycin and 8% FBS (DMEM 
8%), except where stated. 
 
2.15) Cell passage 
When confluent, cells were washed with PBS and a minimal volume of trypsin-
EDTA (0.25% w/v trypsin, 0.02% w/v EDTA in PBS) added. After loss of 
adherence, cells were centrifuged at 500 g for 5 min in DMEM 2% FBS. The 
pellet was resuspended in an appropriate volume of DMEM 8% for sub-
culturing in fresh flasks. 
 
2.16) Viruses 
The derivation of the attenuated FP9 strain of Fowlpox virus has been described. 
FP9 was provided by M. Skinner. A recombinant FP9 expressing GPT 
(vGFP174) was provided by S. Laidlaw (Imperial College). 
MVA strain II/85 was obtained from A. Mayr (Munich University). MVA 
containing the LacZ gene (MVA-LZ) was donated by S. Gilbert (Oxford 
University). MVA expressing beta-galactosidase and guanine phosphoribosyl 
transferase (MVA-LZgpt4) as described in Sutter & Moss (1992) was donated 
by G. Sutter (Paul-Ehrlich-Institut).  
A virulent strain of SFV was obtained from F. Davison (Institute for Animal 
Health). The avirulent A7(74) strain of SFV was donated by J. Fazakerley 
(Edinburgh University).  
VACV VTN, a Western Reserve (WR) recombinant virus expressing the porcine 
Transmissible gastroenteritis virus (TGEV) nucleoprotein in the TK locus 
(Pulford & Britton, 1991), was a gift from P. Britton (Institute for Animal 
Health). 
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All viruses were stored at -80 oC. SFV and VACV VTN were handled under 
ACDP Category 2 conditions. 
 
2.17) Virus infection 
Viruses were de-aggregated in an Ultrasonics W-375 cuphorn sonicator at 25% 
output power (pulsed) for 30 sec (MVA only) or vortexed for 10 sec, diluted in 
serum-free DMEM and adsorbed to cells by incubation at 37 oC for 90 min in a 
minimal volume. Cells were then aspirated and covered with either DMEM 2% 
FBS or a solid overlay. 
Solid overlay was prepared by mixing equal volumes of 2x MEM (supplemented 
with 4% FBS, 200 U/ml penicillin and 200 µg/ml streptomycin) and molten 
Type VII agarose (2%), giving a final concentration of 1x MEM, 2% FBS, 100 
U/ml penicillin, 100 µg/ml streptomycin and 1% agarose. After addition to cells, 
solid overlay was allowed to solidify at room temperature before incubation. 
Prior to transfection, cells were infected with virus at 3 pfu/ml. 
 
2.18) Virus titration by plaque assay 
Confluent CEF were infected in duplicate with three serial 10-fold dilutions of 
virus and overlaid with solid overlay. SFV was allowed to grow for 30 h, FP9 
and MVA for 4 days PI. 
Plaques of viruses expressing beta-galactosidase were visualised by addition of 
solid overlay containing X-gal (0.4 mg/ml) at 3 days PI and were counted 24 h 
later. 
For LacZ negative plaques, the solid overlay was removed and the monolayer 
was fixed with formaldehyde (10% in PBS). Cells were then stained with a 
solution of 2% crystal violet, 20% ethanol in PBS for 15 min. Plates were 
washed in tap water, air-dried and visible plaques counted.  
The original virus stock concentration was calculated and expressed as pfu/ml. 
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2.19) Plaque purification and amplification 
Plaques were picked from under a solid overlay into 500 µl serum-free DMEM, 
vortexed and freeze-thawed three times. Confluent CEF (in 2 cm2 wells) were 
infected with 20% of the plaque harvest and overlaid with DMEM 2% FBS (1 
ml). When cpe were visible, cells and supernatant were harvested by pipetting 
up and down and were freeze-thawed three times. 
 
2.20) Virus stock preparation 
To prepare stocks of plaque-purified virus, CEF were infected with 5 to 10% of 
the plaque amplification harvest. For other virus stock preparations, CEF were 
infected at 0.01 pfu/cell. Where the virus titre was not determined, CEF were 
infected with 5% of an MXH passage harvest. Virus was diluted in a minimal 
volume of DMEM 2% FBS or serum-free DMEM and adsorbed for 90 mins. 
Infected cells were incubated for 4 to 6 days until cpe were visible, when cells 
and tissue culture medium were harvested and freeze-thawed three times. 
 
2.21) Growth curves 
Confluent cells were infected at 0.01 pfu/cell for multi-step growth curves or 3 
to 5 pfu/cell for single-step growth curves. At various time-points post-infection, 
cells and supernatant were collected separately and freeze-thawed 3 times prior 
to plaque assay titration.  
 
2.22) Transfection 
Salmon sperm DNA was provided by P. Farrell (Imperial College). Cells were 
transfected with one of the following methods: 
- Lipofectin (Invitrogen). Lipofectin (4% in Optimem) was incubated at room 
temperature (RT) for 30 mins, mixed with an equal volume of DNA and 
complexed at RT for 10 mins. Transfection mix was further diluted in either 
growth medium with 2% serum or Optimem (for transfections without serum) 
and added to cells that had been washed with serum-free medium. After 5 hours, 
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cells were aspirated and medium was replaced with growth medium with 2% 
serum. 
- Lipofectamine (Invitrogen). DNA was mixed with an equal volume of 4% 
lipofectamine in Optimem, complexed at RT for 15 mins and diluted to 1% 
lipofectamine in Optimem. Cell medium was replaced with a minimal volume of 
either growth medium with 2% serum, or Optimem (for transfections in the 
absence of serum). An equal volume of transfection mix was added and after 5 
hours cells were aspirated and medium was replaced with growth medium with 
2% serum. 
- GeneJuice (Novagen; Darmstadt, Germany). GeneJuice (3% in Optimem) was 
incubated at RT for 5 mins before complexing with DNA at RT for 5 mins. 
Transfection mix was added to cells in growth medium with 2% serum. 
- FuGene 6 (Roche; Indianapolis, USA). FuGene 6 (6% in Optimem) was 
incubated at RT for 5 mins before complexing with DNA at RT for 15 mins and 
addition to cells in growth medium with 2% serum. 
- Polyfect (Qiagen). DNA was mixed with 12% (except where stated) Polyfect in 
Optimem or serum-free DMEM and complexed at RT for 5 to 15 mins. 
Transfection mix was added to cells in growth medium with 2% serum.  
 
2.23) Quantitation of transfected cells 
Cells expressing β-galactosidase (β-gal) were histochemically stained as 
described (Drexler et al., 1998). Cells were washed twice with PBS 24 to 48 h 
post-transfection and briefly fixed with 0.2% glutaraldehyde, 2% formaldehyde. 
After being washed with PBS, cells were incubated with a minimal volume of 
staining solution (0.6 mg/ml X-gal, 5 mM potassium ferrocyanide, 5 mM 
potassium ferricyanide and 2 mM MgCl2 in PBS) at 37 oC for 2 h. Blue cells in 
each field of view (FOV) per well at 100x or 200x magnification were counted. 
 
2.24) MXH passage 
After infection, cells were cultured in DMEM 2% FBS with MXH (MPA, 250 
µg/ml xanthine, 15 µg/ml hypoxanthine). The concentration of MPA was 25 
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µg/ml unless stated otherwise. As xanthine was prepared as a 10 mg/ml stock 
solution in 0.1 N NaOH, a volume of 0.1 N HCl equal to that of xanthine was 
added to MXH.  
 
2.25) SDS-PAGE 
SDS-polyacrylamide gel electrophoresis (PAGE) was performed using the 
principle described (Laemmli, 1970). A discontinuous polyacrylamide gel 
consisted of a 10% acrylamide resolving gel (0.375 M Tris-HCl pH 8.8, 10% 
37.5:1 acrylamide:bisacrylamide (National Diagnostics; Hessle, U.K.), 0.1% 
SDS, 0.05% ammonium persulphate, 0.05% N,N,N,N’-
tetramethylethylenediamine) below a stacking gel (0.13 M Tris-HCl pH 6.8, 3% 
37.5:1 acrylamide:bisacrylamide, 0.05% SDS, 0.1% ammonium persulphate, 
0.001% N,N,N,N’-tetramethylethylenediamine).  
Cell lysates, prepared by freeze-thawing, were heated at 94 oC for 4 mins with 
2x volume of sample buffer (0.06 M Tris-HCl pH 6.8, 25% glycerol, 2% SDS, 
0.01% bromophenol blue, 5% β-mercaptoethanol) and centrifuged at 5000 g for 
3 secs. 
Samples were electrophoresed at 200 V for 40 mins and compared to a 
prestained protein marker (New England Biolabs), prepared according to the 
manufacturer’s directions. 
 
2.26) Western blot 
The electrophoretic transfer of proteins and immunoblotting followed the 
principles described (Towbin et al., 1979). A “Mini Trans-Blot” electrophoretic 
transfer cell (BioRad) was used according to the manufacturer’s directions to 
transfer proteins from a SDS-PAGE gel to a Hybond ECL membrane (GE 
Healthcare; Little Chalfont, U.K.). Proteins were electrophoretically transferred 
at 100 V for 1 h in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, 
pH 8.3). 
The membrane was gently agitated in blocking buffer (PBS, 5% dried skimmed 
milk, 0.1% Tween-20 ) at 4 oC for 16 h and then incubated with primary 
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antibody in antibody buffer (PBS, 2% dried skimmed milk, 0.1% Tween-20) at 4 
oC for 1 h with agitation. Unbound primary antibody was removed by 3 washes 
with PBS, 0.1% Tween-20, each wash at 4 oC for 15 mins with agitation. The 
membrane was then incubated with secondary antibody, conjugated to 
horseradish peroxidase, in antibody buffer at 4 oC for 1 h with agitation. 
Unbound antibody was removed as before. 
Membrane-bound secondary antibody was detected with the ECL Plus Western 
Blotting Detection System (GE Healthcare) according to the manufacturer’s 
directions, and visualised by exposure to Hyperfilm ECL (GE Healthcare) 
autoradiography film. 
 
2.27) Interferon 
Recombinant ChIFN obtained from P. Staeheli (Freiburg University) (P.S. 
ChIFN) or recombinant ChIFN-α2 donated by S. Goodbourn (St George’s) 
(S.G. ChIFN) was divided into 5, 10 or 50 µl aliquots and stored at -20 oC.  
Aliquots were thawed once and used or discarded, as purified ChIFN is known 
to be very heat labile (Lampson et al., 1963). 
Supernatant from a COS cell line expressing the single type III ChIFN protein 
(Kaiser et al., 2005) (ChIFN-λ) was provided by P. Kaiser (Institute for Animal 
Health), along with control cell supernatant. Supernatants were stored at 4 oC. 
 
2.28) Type I ChIFN quantification 
Serial 5-fold or 10-fold dilutions of ChIFN in growth medium with 2% serum 
were added to confluent CEF in 6-well tissue culture plates. Cells were 
incubated for 16 to 18 h at 37 oC, before aspiration. Cells were infected with 
SFV at 25 to 50 pfu/well with adsorption for 1 h in serum-free medium. Virus 
was aspirated and replaced with solid overlay. Cells were fixed and stained with 
crystal violet 24 to 30 h PI. 
The number of plaques at each ChIFN dilution was calculated as a percentage of 
the number of plaques formed in cells that had been treated with medium alone. 
One Unit of ChIFN was taken as the amount that inhibited SFV plaque 
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formation to 50% that of mock-treated cells (IC50) (Pestka & Meager, 1997). 
Concentration of ChIFN was expressed as U/ml. 
 
2.29) Type III ChIFN quantification 
Serial 2- to 10-fold dilutions of supernatant from COS cells expressing ChIFN-λ 
were added to confluent CEF in 6-well tissue culture plates. Cells were 
incubated for 16 to 18 h at 37 oC before aspiration. Cells were infected with SFV 
or MVA-LZ at 5 to 50 pfu/well in serum-free medium. Virus was aspirated and 
replaced with solid overlay. Plaques were counted 30 h PI (SFV) or 4 days PI 
(MVA-LZ). 
 
2.30) ChIFN inhibitory concentration titrations 
The IC50s of ChIFN for viruses other than SFV were calculated using the same 
assay as type I IFN quantification.  
Serial 10-fold dilutions of ChIFN in growth medium with 2% serum were added 
to confluent CEF in 6-well tissue culture plates. Cells were incubated for 16 to 
18 h at 37 oC before aspiration. Cells were infected with virus at 50 to 100 
pfu/well with adsorption for 60 to 90 mins in serum free medium. Virus was 
aspirated and replaced with solid overlay. Plaques were counted 3 to 4 days PI 
and expressed as a percentage of plaques in mock treated cells. 
 
2.31) ChIFN resistance screening 
CEF were incubated with a single concentration of ChIFN in DMEM with 2% 
FBS, or mock treated, in triplicate for 18 h. Cells were then infected with 
sufficient recombinant virus to form plaques in ChIFN-treated wells (50 to 375 
pfu/well). The numbers of plaques formed in ChIFN-treated wells were 
expressed as a percentage of plaques formed in mock-treated wells for each 
virus. 
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2.32) Statistical analysis 
All statistical analyses were conducted with Prism (© GraphPad Software Inc) 
version 4 or 5.0a. 
 
2.33) Bioinformatic analysis 
Fasta nucleotide or protein sequences were used as queries in BLASTN or 
BLASTP searches against the nucleotide collection (nr) database using the 
BLAST tool at http://blast.ncbi.nlm.nih.gov/Blast.cgi (Altschul et al., 1990).  
For prediction of signal peptides, fasta protein sequences were submitted to 
SignalP 3.0 at http://www.cbs.dtu.dk/services/SignalP/ for analysis with both 
neural networks and hidden Markov models (Bendtsen et al., 2004). 
Protein family domains in amino acid sequences were predicted with Pfam 
version 23.0 at http://pfam.sanger.ac.uk/ (Finn et al., 2008).  
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CHAPTER 3 
Preparation of Insertion Cassette DNA to be Transfected for Construction 
of the Recombinant Library 
 
3.1) Preparation of FP9 and MVA genomic DNA 
FP9 gDNA was extracted from 30 infected T175 flasks using the phenol-
chloroform extraction method described in Section 2.1. MVA gDNA was 
extracted from 2 infected T175 flasks by the same method. The final yields of 
FP9 and MVA gDNA, estimated by gel electrophoresis, were approximately 150 
µg and 800 ng respectively. 
The functional quality of the FP9 gDNA was confirmed by PCR with primers to 
the FWPV gene encoding P4b (Huw Lee & Hwa Lee, 1997). A band of the 
expected size (578 bp) was amplified from 1 ng and 100 ng template by 
AccuPrime Taq High Fidelity Polymerase (Invitrogen) but only from 100 ng by 
AccuPrime Pfx (Invitrogen) (Fig. 3.1). 
 
Figure 3.1: Confirmation of functional quality of FP9 gDNA by amplification of 
P4b with AccuPrime Taq (lanes 1-2) or AccuPrime Pfx (lanes 3-4). Template 
was 100 ng (lanes 1 & 3) or 1 ng (lanes 2 & 4) gDNA. 
 
As AccuPrime Taq High Fidelity was more sensitive to low amounts of 
template, this polymerase was used in all subsequent reactions. It also claimed to 
give efficient amplification over a broad size range up to 20 kbp, with high 
fidelity (2.5 x 10-6 error rate) and yield. 
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3.2) Amplification of the GPT cassette and MVA flanks 
Flanks for homologous recombination to the left (FLL) and right (FLRb) of the 
insertion site in the MVA genome were designed. The forward primer to amplify 
FLL (KB1F) was designed by Katie Hughes (Institute for Animal Health) to 
bind the MVA genome at bases 20406 to 20426. A reverse primer for this flank 
was designed using the Primer3 software, and designated primer KB1R. This 
bound the MVA genome at bases 20873 to 20894.  
Primers to amplify FLRb (557 bp) were also designed, and designated KB4F-3’ 
(forward primer) and KB4Rb (reverse primer). Artemis software was used to 
confirm that all primers only had a single predicted annealing site within the 
MVA genome, at bases 20916 to 20935 for KB4F-3’ and bases 21453 to 21472 
for KB4Rb, and no predicted annealing with the FP9 genome. 
Primers to amplify the GPT gene downstream of the VACV p7.5 early/late 
promoter as a single cassette of 833 bp from the pGNR plasmid were designed 
by Katie Hughes (Institute for Animal Health) and designated KB3F (forward 
primer) and KB3R-3’ (reverse primer) (Fig. 3.2). These primers were confirmed 
to have no matching binding sites within the MVA or FP9 genomes. 
 
Figure 3.2:  Plasmid map of pGNR, from which the GPT cassette is derived, 
showing positions of primers KB3F and KB3R-3’ relative to the VACV p7.5 
promoter and GPT gene. The plasmid also contains a bacterial origin of 
replication (Ori) and ampicillin resistance gene (AmpR) for propagation in 
transformed cells. 
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To provide overlaps between the GPT cassette and FLRb, the reverse 
complement sequence of KB4F-3’ was added to the 5’ end of KB3R-3’, to make 
the complete oligonucleotide KB3R. Similarly, the reverse complement of 
KB3R-3’ was added to the 5’ end of KB4F-3’, to make the complete 
oligonucleotide KB4F. This had the overall effect of generating two 
oligonucleotides that were completely complementary (Fig. 3.3). Primer 
sequences are given in Appendix 1. 
 
Figure 3.3: Schematic showing complementarity between GPT and FLRb 
fragments provided by primers KB3R and KB4F. Actual sequences of KB3R 
and KB4F are displayed. Note that primers KB3R and KB4F therefore have a 
GC clamp at both the 3’ and 5’ ends. GPT sequence is shown in red, FLRb 
sequence is shown in black. 
 
The FLL (489 bp) and FLRb (577 bp including the GPT extension) fragments 
were each amplified from 20 ng of purified MVA gDNA using primers KB1F 
and KB1R, or KB4F and KB4Rb, respectively. The GPT cassette was amplified 
from 100 ng pGNR using primers KB3F and KB3R. The 20 bp overlap with 
FLRb increased the total size of the GPT amplicon to 853 bp.  
Gel electrophoresis confirmed that a sample from the completed PCRs contained 
a single product of the expected sizes. The remainder of the reactions were 
treated with the QIAquick PCR Purification kit (Qiagen) according to the 
manufacturers directions and eluted into 50 µl elution buffer. 
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3.3) PCR assembly of the GPT and FLRb fragments 
Because KB3R and KB4F are completely complementary, they produce a 40 bp 
overlap between the GPT and FLRb amplified fragments (Fig. 3.3). This overlap 
region had a Tm of 60.5 oC. Roughly equivalent masses of GPT and FLRb were 
initially combined in a PCR with primers KB3F and KB4Rb. This was initially 
successful, but with a low yield (approximately 125 ng as estimated by 
comparison to a marker of known mass) and unassembled GPT was still visible. 
To optimise the ratio of components, the proportion of GPT was decreased. To 
encourage annealing of the templates to each other, the annealing temperature of 
the first 5 cycles was 57 oC, followed by 30 cycles at 43 oC for primer annealing. 
To further encourage initial annealing of overlaps rather than primers, reactions 
were compared where primers were added at the beginning of the reaction, or 
only after the first 5 cycles. 
 
Figure 3.4: Increase in yield of RHSb by addition of primers after the first 5 
cycles. Arrowhead shows RHSb (1390 bp) assembly product. Lane 1: Primers 
present from the beginning. Lane 2: Primers added after 5 cycles. 
 
Under these adapted conditions, unassembled GPT (853 bp) was still visible. 
However, addition of primers after the component templates had been allowed to 
anneal to each other (Fig. 3.4 lane 2) increased the yield of the assembled 1390 
bp product of GPT-FLRb (RHSb) and decreased the amount of unassembled 500 
to 1000 bp components, compared to when primers were present from the 
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beginning (Fig. 3.4 lane 1). The GPT fragment was orientated such that 
transcription was directed away from FLRb. 
 
3.4) Cloning of FLL and RHSb 
To provide stable stocks of FLL and RHSb, these fragments were blunt-end 
ligated into the pCR-II-Blunt-TOPO vector (Invitrogen), which contains a 
kanamycin resistance gene. Ligated plasmids were transformed into TOP10 
(FLL) or Max Efficiency DH5-α (RHSb) competent cells. Sequencing of 
extracted miniprep plasmid DNA confirmed there were no mutations in the 
inserts of the resulting pFLLseq1 and pRHSb(1) vectors. 
 
3.5) Determination of FP9 genome fragment size 
The size of the required library is affected by the size of FP9 fragment contained 
in each recombinant virus. Large fragments that contain many ORFs would 
require a lower number of recombinants, but would require at least an extra 
iteration to identify single target genes. In contrast, small fragments that 
contained a few or single ORFs would require a library with more recombinants, 
but would require fewer iterations. To balance between these extremes, a library 
containing 50 to100 recombinants (with 1 to 10 ORFs each) would be optimal. 
Allowance for two, offset, passes through the 266 kbp genome indicates 5 to 10 
kbp per insert. 
To identify the maximal amplicon size that could be produced by PCR, primers 
to amplify different sized products of 2, 6 or 10 kbp from the central region of 
the FP9 genome were designed.  
With 100 ng template DNA, 38 oC annealing temperature and 1 min per kbp 
extension time, 2 and 6 kbp products, but not 10 kbp, were amplified (Fig. 3.5, 
lanes 1 to 3). 
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Figure 3.5: Amplification of large PCR products. Extension time was 1 min/kbp 
(lanes 1 to 3), 8 min (lane 4) or 9 min (lane 5). Product sizes were 2.3 kbp (lane 
1), 6.3 kbp (lane 2) or 10.3 kbp (lanes 3 to 5). 
 
As the failure to amplify 10 kbp could be due to inactivation of the polymerase 
when held at the extension temperature for 10 min, the extension time was 
reduced. Decreasing the extension time to 9 min yielded a large amount of 10 
kbp product (Fig. 3.5, lane 5), and decreasing it to 8 min appeared to yield even 
more (lane 4). Therefore AccuPrime Taq was capable of amplifying 10 kbp 
fragments from 100 ng input DNA with an extension time of 8 or 9 min. To 
allow 1.9 kbp for the flanks and GPT cassette, this left approximately 8 kbp for 
the FP9 fragments within the final constructs. 
 
3.6) Design of FP9 genome fragments 
To incorporate redundancy into the recombinant library, the FP9 genome would 
effectively be covered twice, in two overlapping tiling paths. Each 8 kbp 
fragment would overlap those adjacent by 4 kbp each (Fig. 3.6). These large 
overlaps would ensure that any ORFs truncated by one tiling path would remain 
intact in an alternative fragment. The 4 kbp fragments formed by the overlaps 
could be used as alternative recombination substrates for any problematic 8 kbp 
fragments. In addition, the overlapping pattern of the FP9 fragments places 
primer binding sites, for adjacent fragments, in the centre of each fragment. 
These internal primer binding sites could be used to test assembled PCR 
products and recombinant viruses.  
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Figure 3.6: Schematic of a typical linear PCR construct consisting of a variable 
FP9 fragment (blue) with GPT cassette (red), flanked by FLL and FLRb (black). 
FLL is amplified with primers KB1F and KB1R. Each FP9 fragment is amplified 
with a specific primer pair indicated by ‘n’. For example, fragment 8 is amplified 
by primers KB2F-8 and KB2R-8. Within each FP9 fragment lie primer binding 
sites for adjacent FP9 fragments (KB2F-9 and KB2R-7 in this example). Each 
KB2F primer has a 5’ tail that is complementary to primer KB1R. Each KB2R 
primer has a 5’ tail that is complementary to primer KB3F. The tails of the 
internal primers will not anneal, indicated by the diagonal lines. The GPT 
cassette, containing the GPT gene under the p7.5 promoter (P) transcribing 
leftwards, is amplified with primers KB3F and KB3R. FLRb is amplified with 
primers KB4F and KB4Rb. Primers KB3R and KB4F are completely 
complementary, as indicated in Fig. 3.3. 
 
As only one of the ITRs would be contained within the library, and the terminal 
3182 bp repeat regions would be avoided, FP9 bases 3980 to 256440 were used 
for primer design. This was too long to be used in the Primer3 program, so it 
was divided into sections 51300 - 54666 bp long, referred to as a ‘page’, for 
input into Primer3. Each page overlapped by 4 kbp with adjacent pages. To 
design primers for 8 kbp products, values changed from the default were as in 
Table 1. 
The initial submission requested primers around an 8 kbp target product, at a 
position 24 bases from the beginning of the sequence, i.e. base 4004 of the FP9 
genomic sequence. Each subsequent submission increased the target position by 
4000 bases, in order to generate the 4 kbp overlaps between fragments. At the 
final submission of genomic base 252004 the target product length was reduced 
to 4 kbp. 
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The first primer pair suggested by Primer3 for each submission was checked 
visually for repetitive nucleotides before being used for further analysis. In two 
cases, the first primer pair suggested was rejected, and replaced with a more 
heterogeneous alternative. The compiled primer list, containing 66 possible 
pairs, was annotated onto the FP9 genome with DNannotator. Positions of 
primer binding sites were then compared to positions of FP9 ORFs using 
Artemis, to confirm that all ORFs would be captured by at least one primer pair, 
and that all primer pairs contained a unique set of complete ORFs. Four primer 
pairs that only captured ORFs already contained by other pairs were deleted, as 
were 3 pairs that did not capture any complete ORFs. Specific primers had to be 
designed to capture the largest ORFs (FP9.097/098 and FP9.122, of 5.3 and 5.6 
kbp, respectively). As the genomic sequence had been divided into pages, it was 
also necessary to confirm that each primer was predicted to have only one 
annealing site in the genome. An exception to this was primers that annealed 
entirely within the ITR, which would have two binding sites.  
Finally, each FP9 primer had a 5’ tail added, complementary to primer KB1R 
(20 bp) or KB3F (22 bp), depending on whether it was a forward or reverse 
primer, respectively (Fig. 3.7). Melting temperatures were calculated for both 
the 3’ ends and the full-length primers.  
 
Figure 3.7: Schematic showing complementarity between FP9 primer tails and 
adjacent fragments. FLL sequence is shown in black, FP9 is in blue and RHSb 
sequence is in red. Actual sequences of primers KB1R and KB3F are displayed. 
Not to scale. 
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The final primer list contained 61 pairs, given in Appendix 1 where primer 
names are given as KB2F or KB2R with a suffix indicating the fragment 
number. Fragment 61 was produced with primers KB2F-61 and KB2F-2, as the 
latter primer was positioned within the ITR and could therefore act as a reverse 
primer at the right-hand end of the genome. In addition, primers KB2F-3 and 
KB2R-1 were “mis-paired” to amplify a 339 bp intergenic region between 
FP9.011 and FP9.012, to be used as a control. 
Amplicon product sizes ranged from 6687 to 8491 bp, with the median size at 
8394 bp. Each fragment contained 1 to 12 intact ORFs. As each FP9 fragment 
would be amplified in duplicate as a fidelity control, there would thus be a 
maximum of 124 recombinant viruses in the recombinant library. 
 
3.7) Amplification of FP9 genome fragments 
The library of 8 kbp fragments and a control 339 bp fragment were amplified 
using the primer set described in Section 3.6, with 100 ng FP9 gDNA per 
reaction as template. The reactions were performed batchwise for high-
throughput, so the annealing temperature was initially set at 35 oC to allow 
binding of the primer with the lowest Tm. Extension time was 8 min. Under these 
conditions, only four 8 kbp fragments, numbers 55, 56, 57 and 60, failed to 
amplify. However, most primer pairs generated spurious products, possibly due 
to the low annealing temperature used (Fig. 3.8).  
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Figure 3.8: Amplification of a range of 8 kbp fragments from FP9 gDNA. 
Numbers indicate fragments amplified in duplicate independent PCRs. 20% of a 
50 µl PCR was loaded into each lane of a 0.8% agarose gel. 
 
The 339 bp control fragment gave a single band on a gel and was therefore 
purified with the QIAquick PCR purification kit and eluted into 50 µl elution 
buffer.  
For those fragments that did not amplify, amplification of the individual 4 kbp 
products formed by the overlaps within the 8 kbp fragments was attempted. 
Within each 8 kbp fragment was a ‘left hand’ (55L, 56L, 57L, 60L) and a ‘right 
hand’ (55R, 56R, 57R, 60R) 4 kbp fragment. Because of the overlaps, 56L and 
55R are identical, as are 57L and 56R. Fragments 57L, 57R, 60L and 60R were 
amplified successfully, but 55L and 56L failed to amplify under the conditions 
used. As the forward primers for 55L and 56L failed to work with reverse 
primers known to be functional, there may have been a problem with their 
manufacture. Alternatively, there may have been mis-priming difficulties with 
this region of the genome, which contains several repeating motifs.  
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3.8) Assembly of the control fragment 
The three components, FLL, RHSb and the FP9 variable fragment, could be 
combined in a single reaction containing all 3 components to make 
FLL+FP9+RHSb, or by a choice of two consecutive reactions each combining 2 
components i.e. to make FLL+FP9 followed by the addition of RHSb, or to 
make FP9+RHSb followed by the addition of FLL. 
To test if a single reaction was possible, 50 ng of the short (339 bp) control FP9 
fragment was assembled with FLL (50 ng) and RHSb (150 ng). The mass of 
each component was in proportion to its size. Assemblies containing 2 of the 
components (FLL and FP9, or FP9 and RHSb) were also compared (Fig. 3.9). 
Primers were added after the first 5 cycles, as described in Section 3.3. 
 
Figure 3.9: Comparison of assembly reactions containing 2 or 3 components. 
Expected assemblicon or amplicon sizes are given in brackets. Lane 1: 
FLL+FP9, amplified with primers KB1F and KB2R-1 (807 bp). Lane 2: 
FP9+RHSb, amplified with primers KB2F-3 and KB4Rb (1.7 kbp). Lane 3: 
FLL+FP9+RHSb, amplified with primers KB1F and KB4Rb (2.2 kbp). Lanes 4-6: 
Amplification of FP9 fragment (339 bp) with primers KB2F-3 and KB2R-1 from 
templates as in reactions 1-3 respectively, as controls. 
 
Lanes 4 to 6 of Figure 3.9 confirm that sufficient FP9 fragment was present in 
each reaction for re-amplification. Lanes 1 to 3 of Figure 3.9 show expected 
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product sizes in each of the assembly reactions, confirming that assembly of 2 or 
3 components simultaneously was possible. 
Because fewer rounds of PCR reduce the chance of mutations being introduced, 
and due to the large number of recombinants to be made, a single reaction to 
assemble 3 components simultaneously was preferred. 
 
3.9) Attempted assembly of 10 kbp linear recombination substrates using 
template components purified from ethidium bromide agarose gels 
Molar equivalents of FLL, RHSb and FP9 fragment 8 that had been purified 
with a QIAquick gel extraction kit from an ethidium bromide gel were combined 
to a total of 100 ng in an assembly PCR. Five cycles with annealing of the 
overlaps at 43 oC were followed by primer addition and annealing of primers at 
35 oC for 30 cycles. All cycles had an extension time of 8 min and were 
followed by one final extension step of 20 min, but no product was amplified. 
 
3.10) Optimisation of assembly reaction 
Although simultaneous assembly of 3 components was successful with the short 
control fragment (Fig. 3.9), there may have been some sort of reaction inhibition 
occurring specifically with large or unevenly sized templates. To try and 
overcome this, ways of improving the yield of assembly reactions were 
investigated, initially with short components. 
It is possible that during assembly of 3 components, whilst the polymerase 
extends from one overlap, it ‘collides’ with the further component, with 
detrimental effects on overall yield. Adding templates stepwise might avoid or 
reduce this and potentially increase the yield (Fig. 3.10). 
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Figure 3.10: Schematic showing stepwise template addition for ‘splicing’ 
multiple components. (A) In an assembly with 3 components, polymerase could 
collide with the opposite flank annealed to the current template. (B) (1) Initial 
cycles with 2 templates allows extension from one overlap. (2) Addition of a 
third component allows extension from the other overlap. (3) Addition of primers 
for amplification of full assemblicon. 
 
Using modified FLL and GPT components, that had a 10 bp overlap between 
them, the effect of adding FLRb after 5 cycles was tested (Fig. 3.11). All 
components were extracted from an ethidium bromide gel. Primers were added 
5 cycles after all components were present, and the reactions continued until 
there had been a total of 35 cycles. The resultant product was called LINK2. 
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Lane 1 Lane 2 
FLL 
GPT 
FLRb 
32 oC annealing 
1 min extension 
5 cycles 
FLL 
GPT 
32 oC annealing 
1 min extension 
5 cycles 
  + FLRb 56 oC annealing 
1.5 min extension 
5 cycles 
+ primers 47 oC annealing 
2 min extension 
30 cycles 
+ primers 47 oC annealing 
2 min extension 
25 cycles 
Figure 3.11: Stepwise template addition before final primer addition increases 
yield of multiple component assembly. Conditions of each reaction are shown in 
the table. Components were modified to provide a 10 bp overlap between FLL 
and GPT. The entirety of a 50 µl PCR was loaded across 2 lanes for each 
reaction. 
 
Yield of the final product was much higher when FLRb was added after the first 
5 cycles (Fig. 3.11, lane 2), even though primers were present for fewer cycles in 
this reaction.  
Using stepwise template addition, it was still not possible to assemble an 8 kbp 
FP9 fragment with the GPT cassette and flanks. One reason for this failure may 
have been damage to the 8 kbp template during gel extraction. 
 
3.11) Functional comparison of DNA fragments recovered from crystal 
violet or ethidium bromide agarose gels 
During extraction from ethidium bromide gels, DNA is exposed to UV light 
which can damage DNA by causing pyrimidine dimers and strand breaks, at a 
rate proportional to the length of DNA (Franklin et al., 1982). Use of longer 
wavelength UV light might not completely eliminate this damage. An alternative 
to ethidium bromide is crystal violet, which intercalates with DNA in a similar 
way (Yang et al., 2001) but can be visualised in visible light, eliminating 
exposure to UV. 
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In order to confirm the sensitivity of crystal violet, known quantities of 
molecular weight markers (1 kbp ladder; New England Biolabs), were loaded 
onto a 0.6% agarose gel pre-stained with 10 µg/ml crystal violet (Fig. 3.12). 
 
Figure 3.12: Sensitivity of a 0.6% agarose gel stained with 10 µg/ml crystal 
violet. Mass of total DNA and 3 kbp band in each lane is displayed. 
 
The minimum amount of DNA detectable with this staining was 62.5 ng of 3 
kbp dsDNA, although it was possible to increase this sensitivity by increasing 
the concentration of crystal violet. The effect of eliminating UV illumination 
during gel extraction on the efficiency of DNA reamplification was then 
assessed on 2.3, 6.3 or 10.3 kbp PCR products amplified from FP9 gDNA that 
had been treated to remove enzymes and oligonucleotides by one of 3 different 
methods (lane 1, Figs. 3.13A, 3.12B, 3.12C). One treatment was to use the 
QIAquick PCR Purification kit directly on the reaction mix (hereafter referred to 
as ‘PCR purification’. Alternatively, PCR products were electrophoresed and 
excised from agarose gels stained with 10 µg/ml ethidium bromide (and viewed 
by UV) or 10 µg/ml crystal violet (viewed by visible light), then extracted from 
the agarose using a QIAquick gel extraction kit. Presence of each size product 
was confirmed after each of these treatments, which gave similar yields (lanes 2, 
3 and 4, respectively; Figs 3.13A, 3.13B and 3.13C). After quantification, 
aliquots (10 ng) of each treated product were reamplified with the original 
primers in a second PCR (lanes 5, 6 and 7, respectively; Figs. 3.13A, 3.13B and 
3.13C). 
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Figure 3.13: Large PCR products can be reamplified after extraction from a 
crystal violet stained gel, but not from an ethidium bromide stained gel. (A) 2.3 
kbp PCR product. Lane 1: Initial amplification. Lane 2: Initial amplification after 
PCR Purification treatment. Lane 3: Initial amplification after ethidium bromide 
gel extraction. Lane 4: Initial amplification after crystal violet gel extraction. Lane 
5: Reamplification after PCR Purification treatment. Lane 6: Reamplification 
after ethidium bromide gel extraction. Lane 7: Reamplification after crystal violet 
gel extraction. (B) 6.3 kbp PCR product.  Lanes as (A). (C) 10.3 kbp PCR 
product. Lanes as (A). 
 
All 2.3 kbp PCR products could be reamplified, irrespective of their treatment 
(Fig. 3.13A, lanes 5, 6, 7). All 6.3 kbp products could also be reamplified, 
although relatively weakly after ethidium bromide extraction (Fig. 3.13B, lane 
6). In addition, a spurious 1 kbp product was also present after PCR purification 
and especially after ethidium bromide gel extraction (Fig. 3.13B, lanes 5 & 6). A 
short product of 1080 bp was predicted by the Amplify 3X program (© William 
Engels, 2005, University of Wisconsin), caused by mis-priming of the reverse 
oligonucleotide. However, after crystal violet extraction the 6.3 kbp product was 
reamplified well with no by-products (Fig. 3.13B, lane 7).  
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In contrast, following PCR purification the 10.3 kbp product was reamplified 
only weakly (Fig. 3.13C, lane 5), and not at all after ethidium bromide gel 
extraction (Fig. 3.13C, lane 6). Yet after crystal violet gel extraction, the 10.3 
kbp product was clearly reamplified (Fig. 3.13C, lane 7). 
These results indicate that high molecular weight PCR products are reamplified 
more favourably and with fewer by-products after extraction from crystal violet 
stained gels than after extraction from ethidium bromide stained gels or PCR 
purification. 
 
3.12) Assembly of 10 kbp linear recombination substrates 
Further rationalisation of the stepwise template addition, to allow for the unequal 
sizes of component templates involved in the 10 kbp construct, was investigated 
using FP9 fragment 6. This 8 kbp FP9 fragment was extracted from a crystal 
violet stained gel with the Qiaex II kit, or was electro-eluted with a Recochip 
followed by agarose removal with a QIAquick column. 
As the variable fragment (8 kbp) was 16x longer than FLL (0.5 kbp), FP9 
fragment 6 and FLL were assembled without primers for 16 cycles with 30 sec 
extension, leading to an expected FLL+FP9 assemblicon (8.5 kbp), 5.6x longer 
than RHSb (1.5 kbp). RHSb was then added to the reaction tube, for 6 cycles 
with 90 sec extension. Finally, primers KB1F and KB4Rb were added for 15 
cycles with 9 min extension to amplify the desired 10 kbp product, 
FLL+FP9+RHSb (Fig. 3.14).  
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Figure 3.14: Schematic to illustrate use of stepwise template addition and 
reduced extension times before primer addition to splice unevenly sized multiple 
components. (1) Whilst annealing at the first overlap, extension is optimised for 
the shorter (FLL) fragment, for a number of cycles required to reach the far end 
of the longer fragment (FP9). (2) After addition of the third component for 
annealing at the second overlap, extension is again optimised for the shorter 
fragment (now RHSb), for a number of cycles required to reach the far end of 
the longer fragment (FLL+FP9). (3) After addition of primers, cycles are 
optimised for amplification of the spliced product (FLL+FP9+RHSb).  
 
Visualisation of the final assembly on an ethidium bromide gel showed 10 kbp 
products using either of the techniques for preparation of the FP9 fragment 
template from crystal violet agarose (Fig. 3.15). 
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Figure 3.15: Assembled 10 kbp linear recombination substrates produced using 
FP9 template fragment 6 extracted from crystal violet agarose by Qiaex II (lane 
1) or by Recochip followed by agarose removal with a QIAquick column (lane 
2). 
 
The yield of the linear recombination substrates was further improved by 
ensuring equimolar amounts of each component template. For further testing, the 
majority of the 10 kbp products in Fig. 3.15 were electrophoresed on a crystal 
violet gel and extracted with the same technique used for the initial FP9 
fragment 6 preparation. That is, the reaction depicted in Fig. 3.15 lane 1 was 
extracted using Qiaex II whilst the reaction depicted in lane 2 was extracted with 
a Recochip followed by a QIAquick column to remove residual agarose. 
 
3.13) Confirmation of assembly of 10 kbp construct 
The overlapping FP9 primers that bound to the middle of the FP9 variable 
fragment were used for diagnostic PCR analysis to confirm annealing of the 
components. These internal primers, together with a flanking primer, yielded 
products specifically from assembled linear recombination substrates (Fig. 
3.16). 
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Figure 3.16: Schematic showing PCR analysis to demonstrate correct assembly 
of linear recombination substrates. Brackets indicate expected PCR products. 
Annotations and colour-scheme are as in the legend to Fig. 3.6. 
 
These internal primers amplified products from the 10 kbp construct made with 
FP9 fragment 6, where both the FP9 8 kbp fragment and the final 
FLL+FP9+RHSb assemblicon were extracted from crystal violet agarose with a 
Recochip (Fig. 3.17). Similar results were obtained using Qiaex II extraction 
from crystal violet agarose.  
 
Figure 3.17: Confirmation of complete assembly of FP9 fragment 6 with FLL 
and RHSb, using PCR analysis as shown in Fig. 3.16. Both FLL+FP9+RHSb 
template and FP9 fragment 6 used to make it were electroeluted from crystal 
violet agarose with a Recochip followed by QIAquick column treatment. Lane 1: 
FLL + FP9 splice, with primers KB1F and KB2R-5. Lane 2: FP9 + GPT splice, 
with primers KB2F-7 and KB3R. Lane 3: FP9 + RHSb splice, with primers 
KB2F-7 and KB4Rb.  
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Although the product sizes did not appear exactly correct, this may have been 
due to an artefact of the gel. The products had correct sizes relative to each 
other, and as products are specific to assembled products, the presence of bands 
was interpreted as successful assembly of this particular 10 kbp construct. 
 
3.14) High-throughput production of 10 kbp constructs 
The variable FP9 fragments were extracted from crystal violet stained gels using 
a Recochip followed by cleanup on a QIAquick column and elution into a 
minimal volume of elution buffer. Gel electrophoresis confirmed that single 
bands were present, with a total yield of at least 150 ng. FLL and RHSb 
components used were not exposed to UV light during their preparation. 
To reduce a possible cross-reaction that had been occurring with some 
components, the forward primer used in assembly reactions was changed to 
KB1F-seq. This primer annealed to MVA gDNA 61 bp to the right of KB1F, 
reducing the size of the left flank in the 10 kbp assemblicon by this amount. 
The total yield of each 8 kbp FP9 variable fragment was initially assembled with 
10 ng FLL for 16 cycles, with 43 oC annealing and 30 s extension. RHSb (30 ng) 
was then added for a further 6 cycles with 45 oC annealing and 90 s extension. 
Primers KB1F-seq and KB4Rb were then added for a final 20 cycles with 
annealing at 39 oC and 9 min extension. Assembled 10 kbp products were 
extracted from a crystal violet stained gel in the same way as the variable 
fragments, and eluted into 40 µl TE. 
Some fragments did not assemble, or assembled only poorly, even with amounts 
of variable fragment that were routinely sufficient. After at least two attempts for 
these fragments that failed to assemble, the 4 kbp internal alternatives were 
assessed for their inclusion of ORFs. Some fragments did not contain any intact 
ORFs and several ORFs were disrupted by splitting the large fragments into two. 
There were eighteen 8 kbp fragments that would not properly assemble, four that 
could not be amplified (Section 3.7), and two that were initially assembled but 
could not be duplicated. From these, twenty-three 4 kbp fragments were 
attempted as alternatives. However, 3 of these alternatives could not be 
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amplified (including 2 described in Section 3.7) and a further 3 would not 
assemble. Therefore a total of seventeen 4 kbp fragments were assembled using 
adjusted extension times for these shorter fragments, but otherwise similar 
methods to the 8 kbp assemblies. In addition, the 339 bp control fragment, 
described in section 3.6, was successfully assembled. The amplification and 
assembly of the major fragments is summarised in tables 2 and 3. 
8 kbp 
Fragment Intact ORFs Amplified? Assembled? 
1 
.002-.011 & .252-
.259 yes yes 
2 
.007-.014 & .252-
.254 yes yes 
3 .012-.017 yes no 
4 .015-.021 yes no 
5 .019-.023 yes yes 
6 .022-.026 yes yes 
7 .025-.029 yes yes 
8 .028-.032 yes yes 
9 .031-.039 yes could not repeat 
10 .034-.043 yes no 
11 .040-.047 yes yes 
12 .045-.050 yes yes 
13 .048-.053 yes yes 
14 .052-.057 yes yes 
15 .056-.060 yes yes 
16 .059-.066 yes no 
17 .061-.071 yes no 
18 .067-.078 yes no 
19 .071.1-.081 yes yes 
20 .079-.084 yes no 
21 .083-.090 yes yes 
22 .085-.093 yes no 
23 .092-.096 yes yes 
24 .095-.097/098 yes yes 
25 .099 yes yes 
26 .100-.104 yes no 
27 .101-.106 yes yes 
28 .105-.107 yes yes 
29 .108-.110 yes no 
30 .109-.114 yes yes 
31 .112-.118 yes yes 
32 .115-.121 yes yes 
33 .120-.122 yes yes 
34 .123-.126 yes no 
35 .126-.132 yes yes 
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8 kbp 
Fragment Intact ORFs Amplified? Assembled? 
36 .128-.136 yes yes 
37 .133-.139 yes yes 
38 .138-.142 yes yes 
39 .141-.147 yes no 
40 .144-.153 yes could not repeat 
41 .147-.157 yes no 
42 .154-.162 yes no 
43 .161-.164 yes yes 
44 .163-.168 yes yes 
45 .165-.171 yes no 
46 .170-.175 yes yes 
47 .173-.182 yes no 
48 .176-.187 yes yes 
49 .184-.189 yes yes 
50 .189-.192 yes yes 
51 .190-.198 yes yes 
52 .194-.204 yes yes 
53 .200-.209 yes no 
54 .205-.215 yes no 
55 .210-.218 no  
56 .217-.226 no  
57 .222-.229 no  
58 .228-.232 yes yes 
59 .230-.239 yes yes 
60 .234-.250 no  
61 
.238-.254 &.007-
.009 yes yes 
Control 
(339 bp) none yes yes 
Table 2: Ability to amplify and assemble 8 kbp and control FP9 fragments, and 
intact ORFs within each fragment. 
 
4 kbp 
Fragment Intact ORFs Amplified? Assembled? 
3L .012-.14 yes yes 
4L .015-.017 yes yes 
4R .019-.021 yes yes 
9L .031-.032 yes yes 
9R .034-.039 yes yes 
17L .061-.066 yes yes 
17R .067-.071 yes yes 
20L .079-.081 yes yes 
20R .083-.084 yes yes 
22L .085-.090 yes no 
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4 kbp 
Fragment Intact ORFs Amplified? Assembled? 
22R .092-.093 yes yes 
34R .126 yes yes 
40L .144-.147 yes no 
40R .147-.153 yes yes 
42L .154-.157 yes yes 
42R .161-.162 no  
54L .205-.209 yes yes 
55L .210-.215 no  
56L .217-.218 no  
57L .222-.226 yes yes 
57R .228-.229 yes yes 
60L .234-.239 yes yes 
60R .238, .240-.250 yes no 
Table 3: Ability to amplify and assemble 4 kbp FP9 fragments, and intact ORFs 
within each fragment. 
 
3.15) Summary 
A recombinant library was designed to insert fragments of the FP9 genome into 
the Deletion II locus of MVA. These fragments were amplified and assembled 
into linear recombination substrates containing a GPT cassette and MVA flanks 
by SOE-PCR. SOE-PCR was initially only successful for assembling short 
components, of less than 2 kbp. The use of crystal violet stained agarose gels to 
eliminate exposure to UV light allowed assembly of large, 8 to 10 kbp 
fragments. Sequential addition of templates optimised assembly of 3 
components in a single reaction, making this process suitable for high-
throughput production of multiple constructs. 
Using this improved method, 90% of all FP9 ORFs were amplified and 
assembled into 56 different fragments, ready to be transfected into cells and used 
to make recombinant MVA viruses. 
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CHAPTER 4 
Generation of the Recombinant MVA Library 
 
This chapter describes production of the library of recombinant MVA carrying 
segments of the FWPV genome. The first part of the chapter describes the 
establishment of optimised protocols for the process, in particular for 
transfection of linear DNA and selection of recombinant MVA viruses. The 
suitability of these protocols was tested with the production of a pilot 
recombinant virus. Further sections describe generation of the library itself, 
using the DNA fragments produced as described in Chapter 3, and confirmation 
of FP9 protein expression by representative recombinant viruses. 
 
4.1) Cell lines permissive for MVA 
For homologous recombination to take place, the transfected cells must be at 
least partially permissive to MVA. Cells reported to be fully permissive to MVA 
are primary CEF (Mayr et al., 1975), the hamster kidney cell line BHK-21 
(Drexler et al., 1998) and the IEC-6 rat epithelial cell line (Okeke et al., 2006). 
As FWPV is restricted to avian cells, and cell lines are more easily manipulated 
than primary cells, an avian cell line would be preferred. Therefore the chicken 
cell line DF-1 (Himly et al., 1998), permissive to many avian viruses (Schaefer-
Klein et al., 1998), was evaluated for MVA propagation. 
It was not possible to plaque MVA or FP9 in DF-1, for reasons that are not 
apparent. DF-1 or P1 CEF were infected with MVA-LZ at 3 pfu/cell for single-
step growth curves, and virus at each time point was quantitated by plaque assay 
in CEF (Fig. 4.1). 
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Figure 4.1: Yield of MVA-LZ in cell lysates and cell-free supernatants following 
single-step replication in DF-1 and P1 CEF cells. Confluent CEF were stored at 
30 oC in DMEM 2% FBS for 4 days and then reseeded at a ratio of 1:3 to 
generate P1 CEF. DF-1 and P1 CEF in 25 cm2 flasks were infected with MVA-
LZ at 3 pfu/cell in 1 ml/flask DMEM 2% FBS. After 1 h adsorption virus was not 
aspirated, but 6 ml of DMEM 2% FBS was added to flasks. At each time point, 
cells were harvested, separated from supernatant (s/n) by centrifugation at 500 
g for 5 mins and resuspended in 1 ml serum-free E199. Cells and s/n were 
freeze-thawed 3 times before virus quantification by plaque assay in CEF. Each 
time point represents a single sample. 
 
The results showed replication of virus in DF-1 cells at similar rates and to 
similar levels as in P1 CEF cells. A repeat of the experiment in DF-1 cells, 
alongside a multi-step growth curve, confirmed this observation (Fig. 4.2).  
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Figure 4.2: Single-step and multi-step growth curves of MVA-LZ in DF-1 cells. 
DF-1 in 25 cm2 flasks were infected with MVA-LZ at 3 (single-step) or 0.01 
(multi-step) pfu/cell, in 1 ml/flask DMEM 2% FBS, with adsorption for 1 h. Virus 
was not aspirated, but 6 ml of DMEM 2% FBS was added to flasks. At each 
time point, cells were harvested, separated from supernatant by centrifugation 
at 500 g for 5 mins and resuspended in 1 ml serum-free E199. Cells were 
freeze-thawed 3 times before virus quantification by plaque assay in CEF. Each 
time point represents a single sample (there is no data point for the single-step 
growth curve at 72 h PI). 
 
These growth curves showed that DF-1 were permissive for MVA replication, 
even though they do not support plaque formation. DF-1 were then investigated 
for transfection efficiency. 
 
4.2) Comparison of transfection reagents 
Various commercial transfection reagents were assessed for efficiency in both 
CEF and DF-1 avian cells. The pCMV-β plasmid, containing the LacZ gene 
under a CMV promoter was transfected into cells using a range of reagents and 
protocols in duplicate.  
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Figure 4.3: Transfection efficiencies of commercial reagents in avian cells in 2 
independent experiments. CEF were seeded in E199 2% NBBS without 
antibiotics. DF-1 were seeded in DMEM 2% FBS without antibiotics. Cells (in 9 
cm2 wells) were transfected in duplicate with 1 µg pCMV-β as described in 
Section 2.22. Cells were fixed and stained with X-gal 1 day after transfection as 
described in Section 2.23. The number of blue cells per field of view (FOV) at 
100x magnification is shown. Each point is a mean of 2 counts per well. For 
comparison, transfection with lipofectamine in the presence of serum was 
carried out the same way in both experiments. 
 
- 105 - 
Figure 4.3 shows that DF-1 were consistently better transfected than CEF and 
responded best to lipofectamine in the presence of serum. Variation in the 
number of cells transfected with lipofectamine and serum between experiments 
was probably due to variation in cell confluency. Polyfect gave comparable 
results to lipofectamine with serum in DF-1, but also transfected CEF. Therefore 
Polyfect was chosen for further optimisation and was used in all subsequent 
experiments. 
 
4.3) Comparison of DNA preparation techniques 
As DNA extracted from crystal violet gels was a better template for 
reamplification (Section 3.11), this technique was also assessed for its effect on 
transfection efficiency of extracted DNA. After extraction from crystal violet or 
ethidium bromide gels with the QIAquick gel extraction kit, pCMV-β was 
transfected into DF-1 using Polyfect (Fig. 4.4). 
 
Figure 4.4: Transfection of plasmid after extraction from ethidium bromide (EtBr) 
or crystal violet (CrV) stained agarose gels. DF-1 were seeded in DMEM 2% 
FBS without antibiotics. Cells (in 9 cm2 wells) were transfected with 0.5 µg 
pCMV-β extracted from EtBr or CrV stained agarose gels, with 1 µg salmon 
sperm DNA as carrier, in triplicate. Cells were fixed and stained with X-gal 43 h 
after transfection, as described in Section 2.23. The number of blue wells in a 
single FOV per well at 200x magnification is shown. 
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DNA extracted from a crystal violet gel was transfected with a higher efficiency 
than DNA extracted from an ethidium bromide gel. The wells transfected with 
plasmid extracted from a crystal violet gel were visibly bluer after staining with 
X-gal, and an estimated 90% of cells were transfected, compared to an estimated 
10% after ethidium bromide extraction. 
This supported the decision to extract final assembled 10 kbp SOE-PCR 
products from a crystal violet gel (Chapter 3) prior to transfection. 
 
4.4) Optimisation of MPA concentration for selection 
After recombination of GPT into a viral genome, non-recombinant virus is 
reduced or eliminated by selection with MPA, together with xanthine and 
hypoxanthine (MXH). MPA was used by Boyle & Coupar on mammalian CV-1 
cells at 25 µg/ml (Boyle & Coupar, 1988), but as the appropriate dose may vary 
with cell type, CEF (cultured in E199 with NBBS) and DF-1 were compared for 
tolerance to a range of MPA concentrations (Table 4). Xanthine and 
hypoxanthine concentrations were kept constant. 
MPA 
 (µg/ml) 
CEF 
(4 days) 
DF-1 
(4 days) 
DF-1 
(5 days) 
     0 * Healthy Very confluent Very confluent 
12 N/D No growth No growth 
25 Healthy No growth No growth 
50 Healthy No growth Some cell death 
100 Some cell death No growth Widespread cell death 
250 Widespread cell death No growth 
Widespread cell 
death 
500 Widespread cell death No growth N/D 
Table 4: Cytopathic effects observed in DF-1 and CEF after 4 or 5 days culture 
in medium supplemented with MPA, xanthine (250 µg/ml) & hypoxanthine (15 
µg/ml). CEF were cultured in E199 2% NBBS without antibiotics. DF-1 were 
cultured in DMEM 2% FBS. *Negative control, without MPA, xanthine or 
hypoxanthine. N/D: Not determined. 
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CEF tolerated MPA up to 50 µg/ml, and possibly 100 µg/ml for shorter periods. 
DF-1 did not fully tolerate any dose of MPA used, so were not suitable for MXH 
selection. 
The minimum amount of MPA required to inhibit non-recombinant MVA 
growth was tested in CEF using a plaque assay with MXH present in the solid 
overlay. After 3 days plaques were counted by crystal violet staining. At the 
lowest concentration of MPA used, 12.5 µg/ml, no virus plaques were visible 3 
days PI. Plaque formation by the positive control MVA-LZgpt4, that expresses 
GPT, was not inhibited by 12.5 to 50 µg/ml MPA. 
From these results, the optimal dose of 25 µg/ml reported for CV-1 (Boyle & 
Coupar, 1988) was tolerated and effective in CEF, and so this concentration was 
used in subsequent experiments. Hereafter, MXH refers to the mixture of MPA 
(25 µg/ml), xanthine (250 µg/ml) and hypoxanthine (15 µg/ml). 
 
4.5) Optimisation of transfection protocol 
The transfection protocol needed to be optimised for linear DNA, but no cells 
expressed β-gal after transfection with a pCMV-β plasmid linearised by 
digestion with EcoRI. Therefore a recombination experiment was conducted, 
using linear DNA to recombine with FP9, for which a positive control virus, 
vGFP174, was available at the time. 
Plasmid pGFP184x (20 µg), containing the GPT gene with flanks for 
homologous recombination into the ITR of FP9, was linearised by digestion for 
30 h with XhoI at a unique restriction site. After linearisation was confirmed, cut 
plasmid was extracted from an ethidium bromide-stained agarose gel with the 
QIAquick gel extraction kit and eluted into 200 µl water. Linearised plasmid was 
transfected under a range of conditions into subconfluent CEF (in 9 cm2 wells) 
that were infected with FP9 at 5 pfu/cell. A high MOI was used to maximise 
chances of transfection and infection occurring in the same cell. Salmon sperm 
DNA was used as a carrier. Controls were untransfected FP9 or a recombinant 
FP9 virus expressing GPT, vGFP174. After 4 days, total virus (cells and 
supernatant) was harvested into a volume of 2.5 ml, of which 83 µl (3.3%) was 
inoculated onto confluent CEF (25 cm2). This volume was estimated to infect at 
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0.01 pfu/cell. After 6 days of culture in MXH in DMEM 2% FBS, total virus 
was harvested and titrated with MXH in the solid overlay (Fig. 4.5). 
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A 
B 
C 
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Figure 4.5 (previous page): Titres of FP9 transfected with GPT after 1 selection 
passage. CEF (in 9 cm2 wells) were infected with FP9 at 5 pfu/cell or vGFP174 
at 2 pfu/cell with adsorption for 90 mins. Virus was aspirated and replaced with 
DMEM 2% FBS without antibiotics (2.5 ml). Cells were then transfected with 
pGFP184x and salmon sperm carrier DNA as shown. Except where stated, all 
transfections used 12% Polyfect. No transfection with “FP9 only” or “vGFP174 
only” infections. After 4 days, all cells and supernatant were harvested and 
freeze-thawed 3 times. An aliquot (83 µl) was inoculated onto CEF, and cultured 
in MXH for 6 days. Cells and supernatant were combined, freeze-thawed 3 
times and titrated by plaque assay on CEF, with MXH in the solid overlay. Each 
column is a single data point. “FP9 only” shows the same datum in each graph. 
A) 1 µg supercoiled or linearised pGFP184x was transfected with 0.5 µg carrier 
DNA. B) 0.5 µg linearised pGFP184x was transfected with 1 µg carrier DNA 
using a range of Polyfect concentrations. C) 0.5 µg linearised pGFP184x was 
transfected with 1 or 2 µg carrier DNA, for a total of 1.5 or 2.5µg total DNA. 
 
Figure 4.5A shows that non-recombinant FP9 was not completely eliminated by 
one passage in MXH, and was still able to plaque under selective conditions, but 
only a very low amount formed plaques compared to the positive control virus. 
More virus was recovered after transfection with pGFP184x, as expected, but 
there was little difference in the titre of virus from transfection with linearised 
versus supercoiled plasmid. 
Figure 4.5B shows that most virus was recovered with 12% Polyfect in the 
transfection mix. This was the concentration recommended by the manufacturer, 
and had been used in all previous Polyfect transfections. Double this amount of 
Polyfect generated a lower amount of recombinant virus. When only 6% 
Polyfect was used, less virus was recovered than from the negative control. The 
reason is unclear, but toxic effects of transfection may have reduced the amount 
of harvested virus. This toxicity would have been present in all transfections, but 
could have been compensated for by recombinant virus growth in MXH. 
Figure 4.5C shows that when the amount of specific DNA for recombination is 
kept constant, a higher amount of carrier DNA increased virus recovery. 
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In summary, best results were obtained from transfection of 0.5 µg specific 
DNA with 2 µg of carrier DNA, in 12% Polyfect. 
 
4.6) Passage protocol to recover GPT-positive virus 
Plaque purification and PCR assessment of each recombinant virus after each 
round of MXH selection was considered too labour-intensive to handle such a 
high number of recombinants, so total harvests were passaged ‘blind’ to enrich 
for recombinant virus. Using a protocol of 3 sequential passages in MXH, the 
volume passaged at each stage was compared to identify a protocol that reduced 
non-recombinant virus as much as possible. 
Frequency of recombination between VACV and transfected DNA has been 
reported at 0.005 to 1.7% after infection at 0.1 pfu/cell and transfection 1 h PI 
(Kriajevska et al., 1993). To represent this scenario under conditions likely to be 
used, MVA-LZ was spiked with the GPT-positive virus MVA-LZgpt4 at 10-3, 
10-4 or 10-5. CEF (in 9 cm2 wells) were infected with mixed or pure virus at 3 
pfu/cell and harvested 3 days PI. A proportion of the harvest volume (0.1%, 1% 
or 10%) was inoculated onto fresh CEF and cultured in MXH for 4 days. If the 
virus had initially replicated 100x, these volumes were estimated to give MOIs 
of 0.01, 0.1 or 1 respectively. Culture in MXH was repeated for a total of 3 serial 
passages, using the same harvest volume as initially. Final virus recovered was 
titrated by plaque assay in the absence of MXH. 
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Figure 4.6: Titre of virus after 3 passages in MXH. CEF (in 9 cm2 wells) were 
infected at 3 pfu/ml with MVA-LZgpt4 only (proportion = 1), MVA-LZ only 
(proportion = 0), or a mixture of MVA-LZ with a proportion of 10-5, 10-4 or 10-3 of 
MVA-LZgpt4. Cells were cultured in DMEM 2% FBS for 4 days, then harvested 
into 1.5 ml supernatant and freeze-thawed 3 times. Either 1.4 µl (0.1% harvest 
volume), 14 µl (1% harvest volume) or 140 µl (10% harvest volume) were 
inoculated onto fresh CEF (25 cm2) and cultured in 7 ml DMEM 2% FBS with 
MXH. After 4 days, cells were harvested into 1 ml supernatant and freeze-
thawed 3 times. Inoculations onto fresh CEF (25 cm2) were repeated, using the 
same volume as initially, for a total of 3 MXH passages. The 3rd MXH passage 
was harvested 5 days PI. Final harvests were titrated by plaque assay in the 
absence of MXH on P1 CEF, except 1% passage volume of MVA-LZgpt4 only 
which was titrated on CEF. P1 CEF were prepared by reseeding CEF at a ratio 
of 1:3 1 day after initial preparation from embryos. For clarity, 10% harvest 
volume and 10-3 and 10-4 proportion spikes are not shown. 
 
Unspiked non-recombinant MVA-LZ was completely eliminated only when 1.4 
µl (0.1% harvest volume) was passaged (Fig. 4.6). More passages of a higher 
volume may eliminate MVA-LZ, but this was not tested. Three serial MXH 
passages of 14 µl (1% harvest volume) or 140 µl (10% harvest volume) did not 
eliminate the GPT-negative MVA-LZ. 
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When 1.4 µl (0.1% harvest volume) of virus spiked with 10-5 (i.e. 11 pfu in the 
initial spike) was passaged, ~2x106 pfu/ml was recovered, confirming that a low 
amount of recombinant virus could be well enriched by this passage protocol. 
All passage protocols also recovered virus after 3 MXH passages of MVA-LZ 
spiked with 10-4 or 10-3 MVA-LZgpt4. 
When cpe at each passage were scored subjectively, cytopathology of the 10-5 
spiked virus decreased and then increased. This could be explained by inhibition 
of the non-recombinant virus followed by expansion of the recombinant. 
 
4.7) Mass of DNA required for recombination 
The yield of assembled PCR product limited the mass of specific DNA that 
could be transfected. To determine the minimum amount of specific transfected 
DNA required to recover recombinant virus, all parent virus had to be removed. 
DF-1 were infected with MVA-LZ at 3 pfu/cell and transfected with a linear 
DNA construct, LINK2, that contained the GPT cassette between the FLL and 
FLRb flanks. Total DNA in each transfection was increased to 2.5 µg with 
salmon sperm DNA as a carrier. After 4 days, cells were harvested, passaged 3 
times in MXH (0.1% harvest volume) and titrated by plaque assay in the absence 
of MXH. 
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Figure 4.7: Titre of recombinant MVA from DF-1 transfections with LINK2 PCR 
product. DF-1 (in 9 cm2 wells) at 70% confluency were infected with MVA-LZ at 
3 pfu/cell with adsorption for 90 mins. Virus was aspirated and replaced with 
DMEM 2% FBS. Cells were then transfected with 0 to 170 ng LINK2 PCR 
product. Each transfection was made up to a total of 2.5 µg with salmon sperm 
DNA. After 4 days, cells were harvested into 1 ml supernatant and freeze-
thawed twice. CEF were inoculated with 1.4 µl of this harvest, cultured in DMEM 
2% FBS with MXH for 6 days and harvested as before. The MXH passage was 
repeated a total of 3 times. Final harvests were titrated by plaque assay in the 
absence of MXH and plaques were visualised by X-gal staining. 
 
No virus was recovered from mock-transfected cells, but similar titres were 
obtained after transfection with 35 to 170 ng of LINK2 (Fig. 4.7). This 
confirmed that recombinant MVA could be produced using this optimised 
protocol, with low amounts of DNA that represented typical yields of assembled 
PCR product. 
Recombinant MVA produced with LINK2 was propagated in the absence of 
MXH and denoted MVA-LZGPT-KB. 
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4.8) Characterisation of recombinant MVA-LZGPT-KB 
The gDNA of MVA-LZGPT-KB was extracted with the Wizard® SV Genomic 
DNA Purification kit, and the GPT insertion was confirmed by PCR and 
sequencing. 
 
 
Figure 4.8: PCR analysis of MVA-LZGPT-KB, with GPT inserted at Deletion II. 
A: Schematic showing expected PCR products from recombinant (MVA-LZGPT-
KB) and parental (MVA-LZ) MVA. B: Actual PCR products from MVA-LZGPT-
KB or MVA-LZ gDNA templates, on a 0.8% agarose gel stained with ethidium 
bromide. Lane numbers are reactions in A. Primers used for numbered PCRs 
were: 1) Out_F and Out_R. 2) Out_F and KB3Rc-3’. 3) KB3F and Out_R. 4) 
KB3F and KB3Rc-3’. 5) BridgeF and Out_R. 
 
Flanking primers Out_F and Out_R annealed outside the flanks used for 
recombination, so were specific for the Deletion II site of the viral genome. 
Primers flanking the insertion site produced a long product for recombinant virus 
and a short product for parental MVA-LZ (Fig. 4.8, PCR 1). PCRs 2 to 4 were 
A 
B 
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specific for recombinant virus and did not give any product with parental MVA-
LZ. PCR 5 used a primer, BridgeF, that bound gDNA in the small gap between 
the flanks and so was specific for parental virus. PCR analysis of MVA-LZGPT-
KB confirmed insertion of GPT at the deletion II site, and elimination of all 
parental MVA-LZ (Fig. 4.8B).  
Sequencing at the edges of the insertion further confirmed that the GPT cassette 
had inserted into the correct locus without disruption of the sequence 
immediately adjacent (Fig. 4.9). 
 
Figure 4.9: Sequencing of the insertion site in recombinant MVA-LZGPT-KB 
(upper panels) and parental MVA-LZ (lower panels). MVA-LZ and MVA-LZGPT-
KB PCR products from reaction 1 (Fig. 4.8B) were excised from a 0.8% agarose 
ethidium bromide gel, extracted with the QIAquick gel extraction kit and 
sequenced with primers KB1F-seq and KB4R-seq. 
 
The sequence between FLL and FLRb in MVA-LZ was replaced by the 
insertion. All these results confirmed insertion of GPT at Deletion II in MVA-
LZGPT-KB, and showed no contaminating parental virus present. 
 
4.9) Investigation of MVA-LZGPT-KB enrichment with MXH passage 
To identify how many passages were required for detection of recombinant 
virus, and loss of parental virus, each stage of the passage history was analysed 
using the PCRs in Fig. 4.8A (Fig. 4.10). 
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Figure 4.10: PCR analysis of passage history of MVA-LZGPT-KB. For each 
harvest, gDNA was extracted using the Wizard® SV Genomic DNA Purification 
kit, PCR analysed using the same reactions as shown in Fig. 4.8A and 
visualised on a 0.8% agarose gel stained with ethidium bromide. Lane numbers 
are reactions in Fig. 4.8A. L: ladder. TnIn: Transfection-infection harvest. Red 
box: First appearance of recombinant virus. Green box: Last detection of parent 
virus. After passage 3, virus was amplified without MXH to generate MVA-
LZGPT-KB. 
 
In the transfection-infection harvest, only parental virus was detected; the 
product in PCR 4 was directly amplified from transfected DNA.  
After 1 MXH passage, PCR 1 amplified two bands of different sizes but similar 
magnitude, representing both recombinant (Fig. 4.10, red box) and parental 
MVA. PCRs 2 and 3 confirmed the presence of recombinant virus at this stage.  
After 2 MXH passages, parent virus product was faintly visible (Fig. 4.10, green 
box) which disappeared after 3 MXH passages. There was no difference 
detectable by PCR between virus after passage 3 or after subsequent growth 
without MXH (MVA-LZGPT-KB). 
 
4.10) High-throughput production of recombinant MVA viruses 
A protocol suitable for mass production of recombinant MVA viruses with linear 
DNA had been developed and optimised. In summary, DF-1 cells were infected 
with MVA-LZ at 3 pfu/cell, then transfected with at least 35 ng of crystal violet 
gel-extracted assembly PCR product (Chapter 3) with 2.5 µg salmon sperm 
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carrier DNA in 12% Polyfect. After 3 days, cells were harvested and 0.1% was 
passaged in CEF in MXH with 25 µg/ml MPA for 6 days, for a total of 3 
passages (Fig. 4.11). 
This optimised protocol was then applied to the isolation of recombinants 
carrying different fragments of FP9 gDNA. For several fragments, no virus was 
recovered after 3 MXH passages. To enrich any recombinant present at a very 
low frequency, transfection-infection harvests from 9 of these fragments were 
repassaged twice in MXH using 1% volume followed by two standard MXH 
passages of 0.1% harvest volume. This allowed successful recovery of a further 
7 viruses. 
When no virus was recovered after 3 separate transfections of fragment 48, it 
was split into two 4 kbp fragments, as described in Section 3.7. This was a 
successful strategy as recombinant viruses containing fragment 48L or 48R were 
recovered. Of the 59 different fragments that were successfully assembled into 
linear cassettes for transfection, recombinant viruses containing 48 different 
fragments were recovered.  
Final virus was titrated by plaque assay in the presence and absence of MXH to 
estimate the proportion of any persisting parental virus detected by PCR. After 3 
MXH passages, some of the viruses indicated as ‘mixed’ by this analysis were 
subjected to a single round of plaque purification from a plaque under an MXH 
overlay prior to further analysis.  
All the recovered chimaeric viruses are listed in Appendix 2. 
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Figure 4.11: Overview of the method for chimaeric virus generation. A: PCR 
assembly of DNA cassette (Chapter 3). B: Simultaneous transfection & infection 
in DF-1 cells leads to homologous recombination and incorporation of the FP9 
fragment and GPT cassette into the Deletion II site of the MVA-LZ genome. C: 
Selection of GPT-positive recombinants by 3 serial passages with MPA (with 
xanthine & hypoxanthine) in CEF.  
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Extracted gDNA from the third MXH passage of each chimaeric virus was PCR 
analysed to confirm recombination and loss of parental virus. The internal 
primer binding sites from the overlapping FP9 fragments were used for 
recombinant-specific PCR, together with the parent-specific and flanking PCRs 
shown in Fig. 4.8A.  
A result of these analyses is shown in Fig. 4.12, where PCR analysis of the 
recombinant virus MVA-f25b is shown as a typical example. 
 
Figure 4.12: Typical PCR analysis of a chimaeric virus. Coloured segments to 
the left represent amplified products from recombinant or parent viruses. MVA-
f25b gDNA from the 4th MXH passage cell lysate was extracted using the 
Wizard® SV Genomic DNA Purification kit, PCR analysed and products were 
visualised on a 0.6% agarose gel with ethidium bromide. Primers used, in lanes 
from left to right, were: Out_F & Out_R; KB2F-26 & Out_R; Out_F & KB2R-24; 
BridgeF & KB4Rb. 
 
As all potential products are visible on the gel, this preparation still represents a 
mixture of recombinant and parental viruses. MVA-f25b was recovered after 2 
passages of 1% volume, followed by 2 passages of 0.1% volume. As passaging 
1% of harvest volume was not expected to fully inhibit MVA-LZ growth (Fig. 
4.6), this may explain the persistence of parental virus. However, this could not 
explain all the occasions where parental virus persisted.  
Some 8 kbp recombinant viruses were labelled as unstable because they gave 
slightly shorter PCR products than expected, or no product in a recombinant-
specific PCR. Viruses made with 4 kbp insertion fragments were not fully 
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analysed for potential instability, as internally-binding primers were not already 
available and alternative primers were not synthesised.  
In total, 65 recombinant viruses were recovered, detailed in Appendix 2 and 
summarised in Table 5. 
 
8 kbp 
‘stable’ 
Insertion 
8 kbp 
‘unstable’ 
insertion 
4 kbp 
insertion 
339 bp 
insertion* Total 
Pure 
recombinant 13 14 7 1 35 
Mix of 
recombinant 
& parental 
12 4 13 1 30 
Total 25 18 20 2 65 
Table 5: Final number and status, according to PCR analysis, of viruses in the 
recombinant MVA library. * Control insertion. 
 
Most of the recovered viruses were ‘pure’, but many still contained parental 
MVA-LZ. Although some of these may be explained by the reduced number of 
0.1% volume passages, as MVA-f25b, not all can. Two viruses were made that 
contained the control 339 bp insertion, from an FP9 intergenic region. One of 
these still contained parental MVA-LZ, the other did not.  
Most of the viruses that were recovered after 4 MXH passages had a stable insert 
but still contained parental virus, although one was a pure recombinant and 
another was unstable. None of the viruses that had been plaque purified 
contained any parental virus. 
A substantial number of viruses (42%) contained an unstable insertion, which 
appeared to have an internal deletion. The reason for this was unclear. 
The positions on the FP9 genome of the fragments recovered in the library are 
depicted in Fig. 4.13.  
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Figure 4.13: Positions on the FP9 genome of fragments transfected to make 
viruses in the final recombinant MVA library. Stable or unstable inserts were as 
identified by PCR analysis. Where duplicate viruses containing a particular 
fragment were recovered, the fragment is classified here as a “stable insert” if at 
least one virus was stable. Regions of the FP9 genome that were not present in 
the recombinant MVA library are highlighted as ‘uncloned genome’. To scale. 
Diagram by M. Skinner. 
 
Of the 247 FP9 ORFs, 161 (65%) were present in at least one stable recombinant 
virus. A further 46 ORFs were only included in an unstable virus, and only 40 
ORFs were not in the library at all. In total, 84% of ORFs were present in some 
form in the library. Of the 161 ORFs in stable viruses, 44 were duplicated in 1 or 
2 unstable viruses, and 61 were in 2, 3 or 4 stable viruses. 
 
4.11) Confirmation of expression from a recombinant MVA 
The paucity of antibodies to FWPV proteins prevented confirmation of protein 
expression by the majority of recombinant MVA viruses. Monoclonal antibodies 
(mAb) are available to some structural FWPV proteins (Boulanger et al., 
2002b).  
Lysates of cells infected with viruses recombinant for FP9 fragment 50 were 
tested by immunoblotting against protein FP9.191. Controls included uninfected 
cells, and lysates from control viruses MVA-LZ, MVA-fC2b and FP9 (Fig. 
4.14).  
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Figure 4.14: Immunoblot confirming expression of FP9.191 by recombinant 
viruses MVA-f50a and MVA-f50c. Lysates of uninfected or infected CEF were 
electrophoresed by SDS-PAGE on a 10% acrylamide gel. Proteins were then 
transferred to a Hybond ECL membrane as described in Section 2.26. Primary 
antibody was murine mAb DE9 (Boulanger et al., 2002b) diluted 1:200 in 
antibody buffer. Secondary antibody was goat anti-mouse IgG (Sigma-Aldrich), 
diluted 1:25000 in antibody buffer. Following protein detection, autoradiography 
film was exposed for 34 mins. Lane 1: Uninfected CEF. Lane 2: FP9 infected 
CEF. Lane 3: MVA-LZ CEF. Lane 4: MVA-f50a infected CEF. Lane 5: MVA-f50b 
infected CEF. Lane 6: MVA-f50c infected CEF. Lane 7: MVA-fC2b infected 
CEF. To compare viral protein concentrations, a cell equivalent was calculated 
for each infected cell lysate by dividing the surface area of infected cells by the 
volume of harvested lysate. Cell equivalents were then normalised to that of the 
FP9-infected lysate (lane 2). 
 
The faint band in lane 2 (Fig. 4.14) indicates that the protein expressed by FP9 
had a similar migration to that expressed by MVA (lanes 4 and 6). The faintness 
of the band in lane 2 compared to lanes 4 and 6 can be explained by the 
normalised cell equivalent, which indicates that the viral proteins in lane 2 were 
6.4-fold more dilute than those in lanes 4 to 6. 
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The bands in lanes 2, 4 and 6 had an apparent molecular weight of slightly less 
than 62 kDa, by comparison with the molecular weight marker. This corresponds 
well with the reported molecular weight of 63 kDa of FPV191 (Boulanger et al., 
2002b) and the small difference may be due to an artefact of the gel used. The 
previous report of these mAb described reactions with FP9 proteins, but as the 
work predated the availability of the FP9 genomic sequence, gene nomenclature 
followed that of the virulent FWPV strain.  
This Western blot confirmed expression of FP9.191 by two viruses, MVA-f50a 
and MVA-f50c, which were recombinant for FP9 genomic fragment 50, 
containing genes FP9.189 to FP9.192. These two viruses were both indicated to 
have a full, stable, insertion by PCR analysis. 
Another virus, MVA-f50b, was also recombinant for fragment 50, but PCR 
analysis indicated that the insertion was unstable. Interestingly, FP9.191 
expression was not detected from this virus (Fig. 4.14, lane 5). PCR analysis of 
this virus indicated up to 3.6 kbp was lost within the insertion, including lost 
primer binding sites within ORFs FP9.189 and FP9.190. It is therefore feasible 
that a region extending into the 3’ end of FP9.191 had been deleted from the FP9 
fragment in MVA-f50b.  
 
4.12) Summary 
The DF-1 avian cell line was shown to be fully permissive for growth of MVA, 
although it was not suitable for plaque assays. DF-1 cells were easily 
transfected, with best results by lipofectamine or Polyfect.  
DNA extracted from a crystal violet agarose gel was transfected more efficiently 
than after extraction from ethidium bromide gels, supporting the finding in 
Section 3.11 that crystal violet is more suitable for downstream DNA 
applications. A transfection-infection to recombine linearised DNA into FP9 
supported the use of Polyfect and indicated that carrier DNA assisted 
transfection in a dose-responsive manner.  
CEF were found to tolerate MXH selection better than DF-1, and 3 passages of 
0.1% total cell lysate volume in 25 µg/ml eliminated non-recombinant MVA 
whilst allowing recovery of GPT+ virus.  
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Using this transfection and selection protocol, a pilot recombinant virus was 
recovered after transfection with 35 ng PCR product. This was followed by mass 
production of 65 viruses recombinant for FP9 genomic fragments, representing 
84% of FP9 ORFs. PCR analysis identified a number of these recombinants as 
containing an unstable or incomplete insertion, and several had persisting 
parental MVA-LZ. Persistence of a low amount of parental virus should not 
prevent identification of an IFN resistant recombinant. 
Insertions were not sequenced, which would be equivalent to sequencing the 
FP9 genome 1.5 times. Recombinant protein expression by all viruses was not 
confirmed due to lack of available reagents but a Western blot confirmed 
expression of a structural protein, FP9.191, by representative recombinant 
viruses. To circumvent the risk of introduced mutations, 13 fragments, 
representing 43% of ORFs, were duplicated into independent recombinant 
viruses.  
The library was then screened for increased resistance to IFN, as described in 
Chapter 5. 
- 126 - 
CHAPTER 5 
Screening of the Recombinant MVA Library for Increased Resistance to 
ChIFN 
 
5.1) Quantification of type I ChIFN biological activity 
The requirement to be able to test ChIFN in homologous cells, and the limited 
host ranges of FP9 and MVA, restricted the choice of suitable cells for ChIFN 
assays to CEF or DF-1. Wagner et al. (1968) point out that primary cell cultures 
are generally more susceptible to IFN, so CEF were used for all ChIFN assays.  
SFV was used as an indicator virus to quantify ChIFN, as described by Pollitt 
(1997). The attenuated strain A7(74) was used for increased operator safety, 
although VSV was a potential alternative. 
ChIFN was quantified using a plaque-inhibition assay, which is more precise 
and reproducible than alternative methods such as inhibition of virus yield or 
cpe, although it is less sensitive (Wagner et al., 1968). The method used was 
essentially as described (Wagner et al., 1968). One unit of ChIFN was defined as 
the amount that inhibited plaque formation by SFV by 50%. 
Two samples of ChIFN, from P. Staeheli (P.S. ChIFN) and S. Goodbourn (S.G. 
ChIFN) were titrated against SFV (Fig. 5.1). 
  
Figure 5.1: Titration of ChIFN in an SFV plaque inhibition assay on CEF. A non-
linear curve fit was plotted for each graph (black lines) to calculate the IC50. A: 
CEF were incubated in duplicate with 5-fold serial dilutions of P.S. ChIFN in 
E199 2% NBBS for 16 h. Cells were then infected with 50 pfu/well SFV with 1 h 
adsorption. Plaques were counted 30 h PI and expressed as a percentage of 
A B 
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plaques formed in mock treated cells. Each green point is a replicate, 
connected by the mean (green line). B: CEF were incubated in triplicate with 10-
fold serial dilutions of S.G. ChIFN in DMEM 2% FBS for 18 h. Cells were then 
infected with 25 pfu/well SFV A7(74) with 1 h adsorption. Plaques were counted 
24 h PI and expressed as a percentage of plaques formed in mock treated cells. 
Mean ± SEM are plotted in green. 
 
All visible plaques were scored, although qualitative differences were observed 
between ChIFN dilutions: SFV plaques were smaller in higher concentrations of 
ChIFN. 
S.G. ChIFN was less potent than P.S. ChIFN as it needed less dilution to inhibit 
SFV plaques by 50% (Fig. 5.1B).  The line connecting the data points was very 
close to the non-linear regression curve. The curve calculated 50% inhibition as 
occurring at x=-4.405 in Fig. 5.1B. The antilog of this corresponded to a dilution 
factor of 3.93x10-5, the reciprocal of which was 25,410 U/ml S.G. ChIFN. 
Connecting the data points in the P.S. ChIFN assay identified 50% inhibition as 
occurring at x=-6.19 in Fig. 5.1A. The antilog of this corresponded to a dilution 
factor of 6.4x10-7 (Fig. 5.1A, green line). This was slightly different to the value 
of 4.98x10-7 calculated by the non-linear regression (Fig. 5.1A, black line). As 
the regression curve did not fit so closely to the plotted means, the value 
interpolated from the data points (green line) was used. The reciprocal of the 
dilution factor gave an original stock concentration of 1,562,500 U/ml P.S. 
ChIFN. 
Differences between the titres could be due to variations in the quantification 
assays, or the way the ChIFNs were produced, or a difference in the ChIFN 
subtypes. S.G. ChIFN is the α2 subtype, but information on the P.S. ChIFN 
subtype is not available. 
 
5.2) Investigation of type III ChIFN activity 
A single type III IFN gene has been identified in chickens (Kaiser et al., 
2005)(ChIFN-λ). A plaque inhibition assay was conducted to test supernatant 
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from a COS cell line expressing ChIFN-λ for antiviral activity in CEF, in the 
same way as for type I ChIFN.  
CEF were incubated in duplicate with 10-fold serial dilutions, from 0.01 to 1x10-
6, of ChIFN-λ or control supernatant in DMEM 2% FBS for 18.5 h. Cells were 
then infected with 5 pfu/well SFV A7(74) with adsorption for 90 mins. Plaques 
were fixed, stained with crystal violet and counted 30 h PI and compared to 
plaques in mock treated wells. There was no significant difference in the number 
of plaques between any treatment, supernatant or dilution. Results ranged from 1 
to 9 pfu/well across all treatments, including controls.  
The low amount of virus used would have prevented accurate determination of 
the IC50, but if any antiviral activity were present, it would be expected to inhibit 
all SFV plaques at low dilutions. 
VACV is known to be susceptible to murine IFN-λ in vivo (Bartlett et al., 2005), 
so the assay was repeated using MVA-LZ as the indicator virus. CEF were 
incubated in duplicate with serial dilutions ranging from 0.2 to 1x10-4 of ChIFN-
λ or control supernatant in DMEM 2% FBS for 17 h. Control wells were treated 
with DMEM 2% FBS only. Cells were then infected with MVA-LZ (50 
pfu/well) with adsorption for 3 h. Plaques were stained with X-gal and counted 4 
days PI. 
The number of plaques in mock treated wells was much lower than expected: 8 
and 9 pfu/well. The numbers of plaques in wells treated with ChIFN-λ 
supernatant at all dilutions were very similar to the number in mock treated wells 
(range of 8 to 13 plaques). Plaques in wells treated with control supernatant 
ranged from 6 to 24. 
These assays did not reveal any inhibition of SFV or MVA-LZ plaque formation 
in CEF by ChIFN-λ. Potential explanations include loss of activity during 
storage, insufficient concentration of ChIFN-λ in COS cell supernatant, or 
insufficient incubation time of ChIFN-λ on CEF. The IFN-λ mode of action is 
poorly characterised, and it may have no effect on fibroblasts, or function 
through recruitment of leukocytes, which would not be effective in this in vitro 
assay. Alternatively, chickens may lack the IFN-λ receptor, which has not been 
annotated on the chicken genome. 
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5.3) Inhibition of virus plaque formation by type I ChIFN 
Sensitivity of FP9 and MVA (strain II/85) to type I ChIFN were compared using 
a plaque inhibition assay in the same way as for SFV (Section 5.1). Figure 5.2 
shows photographs of ChIFN treated plates infected with FP9 or MVA. 
 
Figure 5.2: Photographs of ChIFN inhibition titrations of FP9 and MVA II/85. 
CEF were pre-treated for 16 h with P.S. ChIFN was diluted in E199 2% NBBS, 
in duplicate. Cells were then aspirated and infected at 50 pfu/well. Virus was 
aspirated after 90 mins and solid overlay was added to cells. Plaques were 
fixed and stained with crystal violet 4 days PI.  
 
Cells treated with 15625 U/ml ChIFN were uniformly less intensely stained, 
possibly indicating cell toxicity of this dose.  
Both FP9 and MVA plaques were irregularly shaped, but MVA plaques had a 
densely stained internal ‘ring’. FP9 plaques were only mildly inhibited at 1563 
U/ml ChIFN, whereas no MVA plaques appeared in cells treated with more than 
156 U/ml.  
The titration for ChIFN inhibition of FP9 was repeated, with 0.2 to 1563 U/ml 
P.S. ChIFN, and compared to VACV. A recombinant VACV was used, 
expressing the TGEV nucleoprotein in a WR background (VACV VTN).  Again, 
FP9 plaques were inhibited by less than 50% at the highest ChIFN concentration 
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used. The data from both FP9 titrations were pooled, and compared with MVA 
and VACV VTN (Fig. 5.3). The SFV curve from Fig. 5.1A is included for 
reference. Note that 1 U/ml ChIFN inhibits 50% of SFV plaques by definition. 
 
Figure 5.3: Titrations of ChIFN inhibition for a range of viruses. CEF were pre-
treated for 16 h with P.S. ChIFN diluted in E199 2% NBBS in duplicate. Cells 
were then aspirated and infected at 50 pfu/well. Virus was aspirated and solid 
overlay was added to cells. Plaques were fixed and stained with crystal violet, 3 
(VACV VTN only) or 4 days PI, and expressed as a percentage of mean (n=3) 
plaques formed in mock-treated wells. Each point represents an individual well, 
except FP9 where points are the mean (4 wells from 2 independent 
experiments) ± SD. SFV data from Fig. 5.1A is included for reference. 
 
Non-linear regressions for MVA and VACV VTN calculated their IC50 as 5 and 
176 U/ml P.S. ChIFN, respectively. Although 64% of FP9 plaques formed at 
1563 U/ml, non-linear regression predicted the IC50 at 2570 U/ml. The 35-fold 
difference between VACV and MVA is probably due to the loss of genes during 
the derivation of MVA (Meyer et al., 1991), although an effect by the 
recombinant protein expressed by VACV VTN (a porcine coronavirus 
nucleoprotein) is theoretically possible. 
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5.4) Comparison of MVA II/85 with MVA-LZ 
Because MVA-LZ was actually used to generate recombinant viruses, resistance 
of this virus was compared to MVA II/85, without the LacZ gene (Fig. 5.4). 
 
Figure 5.4: Comparison of MVA with MVA-LZ inhibition by P.S. ChIFN. MVA 
(II/85) data are from Fig. 5.3. For MVA-LZ, CEF were pre-treated for 16 h with 
P.S. ChIFN diluted in DMEM 2% FBS, in duplicate. Cells were then aspirated 
and infected at 100 pfu/well. Virus was aspirated and solid overlay was added. 
Plaques were fixed and stained with crystal violet 4 days PI and expressed as a 
percentage of plaques formed in mock-treated wells. Each point represents an 
individual well. 
 
The MVA-LZ ChIFN inhibition profile was very similar to that of MVA II/85. 
Plaque morphology (Fig. 5.2) was also similar for both strains. 
At a low ChIFN concentration, MVA-LZ plaque formation was higher than in 
mock treated cells. This may be an artefact of counting, which could be 
improved by staining MVA-LZ plaques with X-gal. Non-significant variation 
cannot be ruled out as causing the difference between the P.S. ChIFN IC50 of 
MVA (5 U/ml) and MVA-LZ (8 U/ml). A paired t-test confirmed that MVA and 
MVA-LZ were not significantly different (p=0.354). 
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The large difference between MVA and FP9 resistance to ChIFN supported the 
choice of MVA-LZ background for insertion of FP9 fragments.  
If FP9 requires more than one gene for its ChIFN resistance, and no recombinant 
contains all the genes required, the full level of resistance may not be conferred 
by a single insertion. However it is possible that a recombinant expressing any 
gene contributing to ChIFN resistance will have elevated plaque formation 
compared to controls. The recombinant library may therefore be screened with a 
concentration of ChIFN, such as 10 U/ml, that inhibits MVA but not FP9.  
 
5.5) Screening of the recombinant library 
5.5.1) Screening assay 
Only recombinant viruses that indicated a stable insertion (Section 4.10) were 
screened. For each virus, plaques formed in cells treated with a single 
concentration of ChIFN were expressed as a percentage of plaques formed in 
mock-treated cells. This “percentage plaque formation” for each recombinant 
virus was compared to the equivalent value for a control recombinant containing 
GPT and non-coding FP9 DNA at the deletion II locus, MVA-fC2a. 
 
Figure 5.5: Recombinant virus resistance to 10 U/ml P.S. ChIFN. CEF were pre-
treated in triplicate with 10 U/ml P.S. ChIFN, or mock treated with DMEM 2% 
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FBS, for 18 h. Cells were aspirated and infected with recombinant virus at 100 
to 300 pfu/well. Virus was aspirated after 90 mins and solid overlay was added. 
A second overlay containing X-gal was added 3 days PI. Plaques formed in 
ChIFN-treated wells were expressed as a percentage of plaques formed in 
mock-treated wells for each virus. Mean of 3 wells ± SEM. 
 
The control recombinant virus, MVA-fC2a, formed 5.5% of plaques with 10 
U/ml (Fig. 5.5), compared to 23% of plaques with 16 U/ml by MVA-LZ (Fig. 
5.4).  
This reduced resistance by MVA-fC2a relative to MVA-LZ may be due to a 
reduction of viral fitness by GPT expression in the absence of MPA. DNA 
insertion at the deletion II locus may increase the time required for a replication 
cycle, or affect expression of adjacent viral genes. In either case, MVA-fC2a is a 
more appropriate control than MVA-LZ for screening the recombinant library. 
 
5.5.2) Results of MVA-f3La 
Most recombinant viruses plaqued less efficiently than MVA-fC2a, or at similar 
levels. Virus MVA-f3La formed 24% of plaques in ChIFN-treated cells 
compared to mock-treated cells. This was clearly greater than the MVA-fC2a 
control (t-test, p<0.0001). 
 
5.5.2.1) Fourth MXH passage of MVA-f3La 
The result in Fig. 5.5 was obtained with cell lysate from the third passage of 
MVA-f3La, which PCR had shown to still contain residual parental MVA-LZ. 
This was given a fourth MXH passage followed by growth without MXH. This 
“p4” stock was confirmed by PCR to be free of parental MVA-LZ, and was 
included in a subsequent screen as a positive control. 
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Figure 5.6: Recombinant virus resistance to 10 U/ml P.S. ChIFN. CEF were pre-
treated in triplicate with 10 U/ml P.S. ChIFN, or mock treated with DMEM 2% 
FBS, for 18 h. Cells were aspirated and infected with recombinant virus at 50 to 
200 pfu/well. Virus was aspirated after 90 mins and solid overlay was added. A 
second overlay containing X-gal was added 3 days PI. Plaques formed in 
ChIFN-treated wells were expressed as a percentage of plaques formed in 
mock-treated wells for each virus. Mean of triplicate wells ± SEM. MVA-f3La 
virus was harvest from 4th MXH passage (p4). 
 
In this experiment, MVA-fC2a formed 3% and MVA-f3La formed 15% of 
plaques. Both these figures are slightly lower than in Fig. 5.5, but in both 
experiments MVA-f3La plaque formation is 4 to 5 times higher than MVA-
fC2a.  
The ChIFN concentration used may be a major contributor to the variability 
between experiments. The IC50 curves (Fig. 5.3) showed a sharp change in MVA 
plaque formation between 2 to 15 U/ml ChIFN. Therefore any variation in the 
exact dose of ChIFN or non-significant variability by the viruses could produce 
a notable change in plaquing efficiencies. 
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5.5.2.2) Plaque purification of MVA-f3La 
As an alternative to the ‘p4’ stock, an MVA-f3La plaque from ChIFN-treated 
cells infected with cell lysate from the third MXH passage was picked and 
amplified. This plaque-purified virus was confirmed by PCR to be free from 
parental MVA-LZ.  
After plaque purification, MVA-f3La resistance to ChIFN was re-examined 
using a lower concentration of S.G. ChIFN. 
 
Figure 5.7: ChIFN resistance of MVA-f3La after plaque purification. CEF were 
pre-treated with 6 U/ml of S.G. ChIFN, or medium alone, for 18 h. Cells were 
aspirated and infected at 90 pfu/well (MVA-LZ), 180 pfu/well (MVA-fC2a) or 135 
pfu/well (plaque purified MVA-f3La (pp)). Virus was aspirated after 90 mins and 
solid overlay was added. A second overlay containing X-gal was added 3 days 
PI. Plaques formed in ChIFN-treated wells were expressed as a percentage of 
the mean number of plaques formed in 3 mock-treated wells for each virus. 
Each bar is the percentage plaquing in a single well. 
 
After cells had been treated with 6 U/ml S.G. ChIFN, MVA-LZ and MVA-fC2a 
had similar plaquing efficiencies, of 37% and 30% respectively. These were 
consistent with the IC50 of 8 U/ml for MVA-LZ, which was obtained with P.S. 
ChIFN. 
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In contrast, MVA-f3La formed 63% of plaques, 2.1-fold higher than MVA-
fC2a. This reduced differential, compared to 4 to 5-fold in Figs. 5 and 6, 
between viruses could be due to plaque purification, the slightly lower dose of 
ChIFN used in this experiment, or intrinsic differences in the antiviral effects of 
S.G. and P.S. ChIFNs. 
 
5.5.2.3) Plaque purification of MVA-fC2a 
MVA-fC2a was also plaque purified. A plaque was picked from CEF infected 
with cell lysate from the third MXH passage of MVA-fC2a, and amplified. PCR 
confirmed this plaque-purified MVA-fC2a to be free of parental MVA-LZ. 
The effects of plaque purification on MVA-f3La and MVA-fC2a ChIFN 
resistance were compared with 27 U/ml S.G. ChIFN. 
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Figure 5.8: Effect of plaque purification on resistance to 27 U/ml S.G. ChIFN. 
CEF were pre-treated in triplicate with 27 U/ml of S.G. ChIFN, or medium alone, 
for 20 h. Cells were aspirated and infected with 100 pfu/well (MVA-f3La (p4) or 
plaque-purified (pp)) or 375 pfu/well (plaque purified MVA-fC2a (pp)). Virus was 
aspirated after 90 mins and solid overlay was added. A second overlay 
containing X-gal was added 3 days PI. Plaques formed in ChIFN-treated wells 
were expressed as a percentage of plaques formed in mock-treated wells for 
each virus. Mean of triplicate wells ± SEM. Data with non-plaque purified MVA-
fC2a from Fig. 5.7 is included for reference. 
 
In CEF treated with 27 U/ml of S.G. ChIFN, plaque purified MVA-fC2a formed 
0.4% of plaques, similar to 0.85% obtained with virus prior to plaque 
purification. 
MVA-f3La formed 5.6% (before plaque purification) or 7.4% (after plaque 
purification) of plaques with this concentration of S.G. ChIFN. A 1-way 
ANOVA confirmed there was no significant difference between these two MVA-
f3La results, but both were significantly different from the plaque-purified 
MVA-fC2a. The non-plaque-purified MVA-fC2a was not included in the 
analysis because there was only one replicate. 
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These results showed that plaque purification, and hence removal of all parental 
virus, did not significantly affect plaquing efficiency of MVA-fC2a or MVA-
f3La, after treatment with 6 or 27 U/ml S.G. ChIFN. This supports the decision 
not to plaque purify all recombinants before screening, as it was possible to 
identify a recombinant with a positive phenotype even if traces of parental 
MVA-LZ were still present. 
 
5.5.2.4) FP9 genes encoded by MVA-f3La 
The fragment inserted into virus MVA-f3La encoded genes FP9.012, FP9.014 
(both predicted ankyrin repeat proteins) and FP9.013 (unannotated).  
Because fragment 3L contained the first genes identified to contribute towards 
FP9 resistance to ChIFN, this locus was called Fowlpox Interferon Resistance 
locus 1 (FIR1). 
In the original library design, these genes were also present in fragment 2, but no 
virus containing this fragment was recovered. Therefore to identify the gene or 
genes conferring resistance at FIR1, recombinant viruses containing each of 
these genes in isolation needed to be made and tested. 
 
5.5.3) Results of MVA-f6b 
Recombinant virus MVA-f6b was also found to have significantly higher 
resistance to ChIFN than controls. This virus was originally recovered after the 
transfection-infection harvest was given two passages in MXH of 1% harvest 
volume, followed by two passages in MXH of 0.1% harvest volume. PCR 
showed that this “p4” preparation contained a mixture of recombinant and 
parental virus.  
A plaque was picked from CEF infected with cell lysate from the fourth MXH 
passage and amplified. PCR confirmed this plaque-purified MVA-f6b to be free 
of parental MVA-LZ. 
Both the p4 and plaque-purified (pp) preparations of MVA-f6b were compared in 
the same experiment as that shown in Fig. 5.8. 
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Figure 5.9: Recombinant virus MVA-f6b resistance to 27 U/ml S.G. ChIFN. CEF 
were pre-treated in triplicate with 27 U/ml of S.G. ChIFN, or medium alone, for 
20 h. Cells were aspirated and infected with 100 to 375 pfu/well. MVA-f6b (p4 or 
plaque-purified (pp)) was infected at 100 pfu/ml. Virus was aspirated after 90 
mins and solid overlay was added. A second overlay containing X-gal was 
added 3 days PI. Plaques formed in ChIFN-treated wells were expressed as a 
percentage of plaques formed in mock-treated wells for each virus. Mean of 
triplicate wells ± SEM. Data for MVA-fC2a and MVA-f3La are as in Fig. 5.8. 
 
MVA-f6b also had a significantly increased efficiency of plaque formation, both 
before and after plaque purification. Three other viruses in the same experiment 
formed plaques at similar levels to the control. Because fragment 6 was the 
second fragment identified that contributed to ChIFN resistance by FP9, this 
locus was called FIR2. 
 
5.5.3.1) FP9 genes encoded by MVA-f6b 
The fragment inserted into MVA-f6b included genes FP9.022, FP9.023, 
FP9.024, FP9.025 and FP9.026, all transcribed in a leftward direction. All of 
these genes are predicted ankyrin repeat proteins, except FP9.025, which is 
unannotated. Fragment 6 also includes the last 208 bases of FP9.021, which is a 
predicted member of the G-protein coupled receptor (GPCR) family. If 
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translation began at the first start codon of this gene fragment, the last 45 aa of 
this protein would be produced in frame. 
Fragment 6 also included the first 729 bp, encoding the N-terminal 243 aa of 
FP9.027, a predicted member of the GPCR family. FP9.021 and FP9.027 are 
both transcribed towards the right end of the genome. 
 
 5.5.3.2) Other viruses including FP9 genes from fragment 6 
Fragment 6 was one of the 13 fragments inserted in duplicate into independent 
recombinant viruses. The other recombinant virus containing this fragment was 
MVA-f6a. PCR had failed to amplify any parental MVA-LZ from this virus 
preparation, but unfortunately the insertion seemed to be unstable.  
Viruses were also recovered from transfections with adjacent fragments. Virus 
MVA-f5b was a pure recombinant, with a stable insertion and no parental virus. 
This fragment included intact genes FP9.019 to FP9.023. It also included the first 
766 bp, encoding the N-terminal 255 aa, of FP9.018. This fragment also included 
the last 993 bp of FP9.024, which could potentially express the C-terminal 280 
aa of this 596 amino acid protein, transcription signals permitting (Fig. 5.10). 
Virus MVA-f7a was recovered in the same way as virus MVA-f6b, with two 
MXH passages of 1% harvest volume, followed by two standard MXH passages 
of 0.1% harvest volume. PCR of this virus indicated an unstable insertion, and 
presence of parental MVA-LZ. 
Fragment 7 was designed to contain intact versions of FP9.025 to FP9.029. It 
also contained the first 1119 bp, encoding the N-terminal 373 aa, of FP9.024. At 
the other end of fragment 7 were the final 2153 bp of FP9.030. This could 
potentially encode the C-terminal 693 aa of this 817 amino acid protein. 
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Figure 5.10: Diagram showing positions and orientations of FP9 genes in 
fragments 5, 6 and 7, inserted into viruses MVA-f5b, MVA-f6a, MVA-f6b and 
MVA-f7a. 
 
5.5.3.3) Screening of other viruses containing fragment 6 genes. 
In an attempt to reduce the number of candidate genes causing the phenotype of 
virus MVA-f6b, the other viruses containing overlapping insertions were 
assessed for ChIFN resistance. 
MVA-f5b and MVA-f6a were included in the experiments shown in Figs. 5.6 
and 5.99, where they were not significantly different to the control virus in cells 
treated with 10 U/ml P.S. ChIFN or 27 U/ml S.G. ChIFN.  
Two further independent experiments where cells were treated with 2 U/ml S.G. 
ChIFN were carried out (Fig. 5.11).  
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Figure 5.11: Resistance to 2 U/ml S.G. ChIFN by viruses recombinant for genes 
from the FIR2 locus. In two independent experiments, CEF were pre-treated in 
triplicate with 2 U/ml S.G. ChIFN, or mock treated with DMEM 2% FBS, for 18 h. 
Cells were aspirated and infected with recombinant virus at 100 to 200 pfu/well. 
Virus was aspirated after 90 mins and solid overlay was added. A second 
overlay containing X-gal was added 3 days PI. Plaques formed in ChIFN-treated 
wells were expressed as a percentage of plaques formed in mock-treated wells 
for each virus. Mean of triplicate wells ± SEM. All viruses used except MVA-LZ, 
MVA-f6a and MVA-f7a were plaque-purified. 
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The negative result of MVA-f5b was reproduced in both experiments (Fig. 5.11A 
& 5.11B). MVA-f6b was more resistant than both MVA-LZ and MVA-fC2a in 
both experiments. However, MVA-f6a and MVA-f7a, the two viruses with 
unstable insertions, gave variable results. In Fig. 5.11A, MVA-f7a plaqued at a 
level intermediate between MVA-f6b and MVA-fC2a, whilst MVA-f6a was 
closer to the control virus. In Fig. 5.11B, MVA-f7a had the same plaquing 
efficiency as MVA-fC2a, whilst MVA-f6a was almost at the level of MVA-f6b. 
These variable results could be due to the unstable insertions of MVA-f6a and 
MVA-f7a, which could be expressing a protein at suboptimal levels. In addition, 
the relatively low dose used in Fig. 5.11 may not be exerting a strong enough 
pressure to distinguish between ChIFN-resistant or susceptible viruses. 
 
5.5.3.4) Gene at FIR2 locus causing phenotype 
Of the five candidate genes within fragment 6 that were causing a ChIFN-
resistant phenotype, only FP9.022 and FP9.023 were present in fragment 5. As 
MVA-f5b had a similar level of resistance as the control virus, these genes were 
unlikely to be causing the phenotype of MVA-f6b. However, they cannot be 
ruled out because expression of these genes has not yet been confirmed by 
MVA-f5b. 
Fragment 7 was only designed to contain FP9.025 and FP9.026 from the FIR2 
locus. However, it is not certain whether these genes are included in virus MVA-
f7a due to the instability of the insertion. Also, the lack of expression studies and 
variability of this virus’s ChIFN resistance cannot confirm whether these genes 
contribute towards resistance or not. 
To identify which gene at this locus is causing the phenotype of MVA-f6b, the 
genes encoded and expressed by the viruses with overlapping insertions need to 
be confirmed. In addition, a set of recombinant viruses containing each of the 
candidate genes in isolation should be made. 
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5.6) Summary 
An assay was set up to quantify the antiviral activity of recombinant type I 
ChIFN. One unit was defined as the amount added to cells 16 to 18 h prior to 
infection, which inhibited SFV plaque formation by 50%.  
Type III ChIFN was investigated, but no antiviral activity was found against 
SFV or MVA in an in vitro assay. Results may have been limited by the ChIFN-
λ tested, or the assay used. 
Poxviruses were found to have a higher resistance to type I ChIFN than SFV. 
The IC50 for MVA-LZ was 8 U/ml, compared to 176 U/ml for a recombinant 
VACV. In contrast, the IC50 of FP9 was greater than 1563 U/ml, possibly 2570 
U/ml. The large difference between MVA-LZ and FP9 was exploited to screen 
the recombinant MVA library for increased resistance to ChIFN, conferred by 
the inserted FP9 fragments. 
The first fragment identified to increase ChIFN resistance was 3L, containing 
genes FP9.012, FP9.013 and FP9.014, collectively called FIR1 (Fowlpox 
Interferon Resistance locus 1). This fragment significantly increased resistance 
of the recombinant virus compared to a control recombinant MVA, but not to the 
level of FP9.  
Plaque purification of control virus, or the virus containing fragment 3L, MVA-
f3La, did not significantly alter resistance to ChIFN. This confirmed the ability 
to identify a recombinant with a positive phenotype, even if low amounts of 
parental MVA-LZ were still present. 
A second virus was found to have significantly increased resistance to ChIFN, 
MVA-f6b. This virus contained genes FP9.022 to FP9.026, collectively called 
FIR2. Plaque purification of this virus also had no significant effect on ChIFN 
resistance. Other viruses containing fragments overlapping with FIR2 were 
recovered and screened, but it was not possible to draw firm conclusions 
regarding which genes were contributing to the FIR2 phenotype without 
expression studies on the FP9 proteins. 
The exact amount of virus growth was variable between experiments, but the 
trend was consistent with the amount of ChIFN used in each experiment. To 
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overcome this variability, the negative control virus MVA-fC2a was included in 
each experiment. 
To identify individual genes causing the FIR1 and FIR2 phenotypes, further 
recombinant viruses, each containing a single gene candidate were attempted. 
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CHAPTER 6 
Characterisation of the FIR1 and FIR2 loci 
 
In Chapter 5, the identification of two recombinant viruses containing different 
fragments of the FP9 genome, both with an increased ability to form plaques in 
ChIFN-treated cells compared to controls, was described. Here, the further 
characterisation of the loci that these two FP9 fragments represent, FIR1 and 
FIR2, in an attempt to identify individual FP9 genes conferring resistance to 
ChIFN, is described. Characterisation of the FIR2 genes is described in Section 
6.1, whilst that of the FIR1 genes is described in subsequent sections. 
 
6.1) Characterisation of the FIR2 locus 
6.1.1) PCR analysis of viruses containing genes from FIR2 
As described in Section 5.5.3, MVA-f6b, with an insertion of five FP9 genes 
collectively called the FIR2 locus, had an increased resistance to ChIFN. A panel 
of viruses was identified that contained fragments overlapping the FIR2 locus, 
described in Section 5.5.3.2. Those that seemed to contain an unstable insertion, 
MVA-f6a and MVA-f7a, were further analysed by PCR in an attempt to map the 
FP9 genes present and so potentially reduce the number of candidate FIR2 genes. 
Each gDNA analysed was not prepared from plaque purified virus, but from cell 
lysates from the third or fourth MXH passage. Primers with binding sites within 
fragments 6 and 7 were paired with a primer that bound outside the homologous 
recombination flanks, Out_F or Out_R. MVA-f6b gDNA template was used as a 
positive control for primer quality and binding. 
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PCR Forward Primer Reverse Primer 
1 Out_F Out_R 
2 Out_F KB2R-v024 
3 Out_F KB2R-5 
4 Out_F KB2R-v022 
5 Out_F KB2R-4 
8 KB2F-7 Out_R 
9 KB2F-v026 Out_R 
 
 
Figure 6.1: PCR analysis of FP9 insertion (fragment 6) into MVA-f6a. A: 
Schematic representation of expected PCR products (numbered) from fragment 
6 internal primers. Blue boxes show ORFs with direction of transcription; dashed 
lines represent limits of fragment 6 within MVA-f6a. B: Table of primers for each 
PCR product in A. C: Actual PCR products from MVA-f6a or MVA-f6b (as a 
positive control). PCR numbers as in A & B. 
A 
B 
C 
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PCR Forward Primer Reverse Primer 
1 Out_F Out_R 
2 Out_F KB2R-v024 
3 Out_F KB2R-5 
6 Out_F KB2R-6 
7 Out_F KB2R-v026 
9 KB2F-v026 Out_R 
10 KB2F-8 Out_R 
 
Figure 6.2: PCR analysis of FP9 insertion (fragment 7) into MVA-f7a. A: 
Schematic representation of expected PCR products (numbered) from primers 
that bound within fragment 7. Blue boxes show ORFs with direction of 
transcription; dashed lines represent limits of fragment 7 within MVA-f7a. B: 
Table of primers for each PCR product in A. Actual PCR products from MVA-f7a 
gDNA. PCR numbers as in A & B. 
A 
B 
C 
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Primers that flanked the insertion site (Out_F  & Out_R; Figs. 6.1 & 6.2, PCR 1) 
amplified products from all gDNA preparations, confirming that the templates 
and these flanking primers were functional. Although all potential products were 
amplified from MVA-f6b, few of the same products were visibly amplified from 
MVA-f6a (Fig. 6.1C). The only PCR in which a product was amplified from 
MVA-f6a used internal primer KB2R-5 (Fig. 6.1, PCR 3). MVA-f6a had lost 
several internal primer binding sites that were not clustered together; no products 
were visible from PCRs with primers that bound either side of KB2R-5. 
Therefore a single deleted region could not be identified within the FP9 fragment 
of MVA-f6a.  
Primers Out_F and Out_R amplified a product from MVA-f7a, but it was 
approximately 2 kbp shorter than expected (Fig. 6.2C, PCR 1). A single PCR, 
with KB2R-v024, failed to amplify a visible product from MVA-f7a (Fig. 6.2, 
PCR 2). Products were amplified with internal primers KB2R-5 (Fig. 6.2, PCR 
3) or KB2F-v026 (Fig. 6.2, PCR 9), which lay 1788 bp apart, on either side of 
the KB2R-v024 binding site. Therefore either the product in PCR 1 (Fig. 6.2C) is 
no more than 1788 bp shorter than expected, or there are further deletions in the 
MVA-f7a insertion that were not detected by these PCRs. 
The region between KB2R-5 and KB2F-v026 binding sites includes the ORF 
FP9.025, and part of FP9.024. Therefore FP9.025 may be missing from MVA-
f7a. As FP9.024 was not complete within fragment 7 this protein was not 
expected to be functional in MVA-f7a anyway. However, as MVA-f7a showed a 
variable resistance to ChIFN (Section 5.5.3.3), the contribution of FP9.025 to the 
ChIFN resistance remained unclear.  
FP9 genes in MVA-f6a and MVA-f7a could have been better characterised by 
sequencing or reverse transcriptase (RT)-PCR but gene expression could only be 
correlated to ChIFN resistance if these viruses had consistent phenotypes.  
To identify which of the FIR2 genes was responsible for the resistant phenotype, 
synthesis of further recombinant viruses was attempted, each containing a single 
gene from the FIR2 locus. 
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6.1.2) Generation of recombinant viruses containing single genes from the 
FIR2 locus 
As described in Section 5.5.3, MVA-f6b, with an insertion of five FP9 genes 
collectively called the FIR2 locus, had an increased resistance to ChIFN. To 
identify which of these five genes were responsible for the resistant phenotype, 
synthesis of further recombinant viruses was attempted, each containing a single 
gene from the FIR2 locus. 
 
6.1.2.1) Primer design for FIR2 single gene recombinant viruses 
Pairs of primers flanking each of the genes FP9.022 to FP9.026 were designed to 
amplify products v022, v023, v024, v025 and v026 respectively. These included 
intergenic regions in case any promoter elements were present. Consistent with 
the original library, native gene orientations were maintained. Because FP9.022 
to FP9.026 are transcribed in a leftward direction, the start codon for each ORF 
was closest to the reverse primer. 
The forward primer for fragment 6 was retained for v022 amplification and only 
a new reverse primer was designed. Continuous FP9 genomic sequence from the 
KB2F-6 binding site extending 195 bp into FP9.023 was used as input sequence 
for reverse primer design. Of the first 15 reverse primers suggested by Primer3, 
the one that had the lowest predicted likelihood to form primer dimers, and 
formed the largest PCR product was selected. The intergenic region between 
FP9.022 and FP9.023 is only 80 bp long, and the reverse primer chosen included 
50 bp of the end of FP9.023 within v022. As described in Section 5.5.3.1, the last 
208 bp of FP9.021 were also included in v022 due to the position of KB2F-6. 
Genomic sequence including the entire intergenic region between FP9.022 and 
FP9.023, extending 66 bp into FP9.024, was used as input sequence for v023 
primer design. From suggested Primer3 output, primers that formed the largest 
PCR product but that did not impinge on FP9.024 or FP9.022 were chosen for 
v023. The forward primer annealed immediately after FP9.022, including the 
entire intergenic region downstream of FP9.023 within v023. The reverse primer 
annealed 59 bp upstream of the FP9.023 start codon, omitting the first 6 bp of 
this short (65 bp) intergenic region.  
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For the design of v024, all the intergenic regions on either side of FP9.024 were 
included in the input sequence, together with 93 bp of FP9.025. Primers that had 
the lowest predicted likelihood to form primer dimers and formed the largest 
PCR product were chosen. The forward primer annealed at a position to include 
33 bases of the intergenic region downstream of FP9.024, but omitting the final 
32 bp. The v024 reverse primer annealed within FP9.025, including the last 93 
bp of this gene within v024. 
For v025 design, all the intergenic regions on either side of FP9.025 were 
included in the input sequence, together with 64 bp of FP9.026. Primers were 
selected on the same basis as those for v024. The chosen forward primer 
annealed 74 bp downstream of FP9.025, omitting the final 28 bp. The entire 
upstream intergenic region was included within v025, as was 31 bp of FP9.026 
due to the position of the chosen reverse primer.  
The input sequence for v026 design consisted of the entire intergenic region 
downstream of FP9.026 until the right-hand limit of the original fragment 6, 
formed by the binding site of KB2R-6. This extended 729 bp into the beginning 
of FP9.027. The primers recommended by Primer3 were accepted for this 
fragment. These had a balance of low complementarity, large product size and 
high Tm. The reverse primer lay 88 bp downstream of the FP9.027 start codon, 
including the first 29 codons of this GPCR family protein. The original fragment 
6 included 243 codons of the 331 aa of FP9.027. Because FP9.026 and FP9.027 
transcribe away from each other, inclusion of this complete intergenic region 
could have included any promoter elements for both of these ORFs. Assembly of 
v026 into the linear recombination cassette and insertion into MVA-LZ would 
result in the addition of 12 aa, derived from the GPT cassette, to the C-terminus 
of FP9.027. 
The positions of these primers and the fragments produced from them relative to 
the ORFs are depicted in Fig. 6.3. 
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Figure 6.3: Diagram showing positions of primers flanking FP9 ORFs FP9.022 
to FP9.026, to amplify fragments v022 to v026 prior to recombinant virus 
generation. Forward primer annealing sites are indicated on the upper grey bar, 
reverse primers on the lower grey bar. ORFs are shown as blue boxes with 
genes transcribed rightwards shown above the grey bars and genes transcribed 
leftwards shown below the grey bars. 
 
The same 5’ tails, with complementarity to FLL (for forward primers) or RHSb 
(for reverse primers), as described in Section 3.6 were incorporated into each 
oligonucleotide for use in SOE-PCR. Resulting oligonucleotides were named 
KB2F or KB2R with a suffix indicating the relevant fragment e.g. KB2F-v022, 
KB2R-v022 etc. Sequences are listed in Appendix 1. Some of these primers were 
used for analysis of viruses described in Section 6.1.1. 
 
6.1.2.2) PCR amplification of FIR2 gene candidate fragments 
The primers described above were used to amplify FIR2 candidate fragments 
from FP9 gDNA in a single batch. The lowest Tm (without the 5’ tail) among 
these primers was 42.6 oC, therefore annealing was carried out at 41 oC. The 
predicted product sizes ranged from 1136 to 2136 bp, so the extension time used 
was 2 min. 
All PCRs were loaded onto a 0.8% agarose gel stained with crystal violet, but 
only v022 and v026 products were visible. These were excised, extracted with 
the QIAquick gel extraction kit and eluted into elution buffer (37 µl). 
PCRs for v023, v024 and v025 were repeated, with the annealing temperature 
reduced to 40 oC, and 12.5% of each reaction was loaded onto a 0.8% agarose 
gel stained with ethidium bromide (Fig. 6.4). 
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Figure 6.4: PCR amplification of three FP9 FIR2 fragments, v023 (1486 bp), 
v024 (2061 bp) and v025 (1136 bp). Amplification from 100 ng FP9 gDNA, with 
30 cycles at 94 oC (30 sec), 40 oC (30 sec) and 68 oC (2 min). 
 
Visualisation on an ethidium bromide gel, which is more sensitive than crystal 
violet, confirmed amplification of these fragments although v024 and v025 were 
at very low levels. These yields were unlikely to be sufficient for visualisation 
with crystal violet, or successful SOE-PCR. 
To increase yields, optimisation of v024 and v025 was attempted in two ways. 
The Tm of the full-length primers, including the 5’ extensions, ranged from 58.7 
oC to 64.8 oC. After the first 10 cycles, the annealing temperature was raised 
from 40 oC to 57 oC, to encourage specific annealing along the full length of the 
oligonucleotides for a further 25 cycles. In parallel, PCRs were repeated under 
conditions described in Fig. 6.4, with all annealing at 40 oC, but the number of 
cycles was increased to 40.  
A sample (5%) of each reaction was loaded onto a 0.8% agarose gel stained with 
ethidium bromide, but no products were visible from any PCR. 
Given this failure to amplify v024 or v025 sufficiently for extraction from a 
crystal violet-stained gel for SOE-PCR, attempts to make recombinant viruses 
expressing single genes from the FIR2 locus were postponed indefinitely. 
Instead, each of the FIR2 candidate genes were cloned into an expression 
- 154 - 
plasmid, as described in the following sections, for studies into ChIFN resistance 
using transient transfection. 
 
6.1.3) Cloning of FIR2 candidate genes 
The vector pEFplink2FLAG containing the EF1α promoter was known to drive 
effective expression in transient transfections of avian cells (S. Laidlaw, 
unpublished data). Primers were designed to clone each of the FIR2 candidate 
genes into pEFplink2FLAG. BamHI and XbaI restriction endonuclease 
recognition sites were present in the multiple cloning site of pEFplink2FLAG but 
not in any of the FIR2 ORFs. Ligation at the BamHI site would place an inserted 
gene in-frame with the N-terminal FLAG tag and upstream initiation codon 
within the vector. 
 
6.1.3.1) Primer design for cloning FIR2 candidate genes 
Primers were designed to bind to each end of the coding sequence of each of 
FP9.022, FP9.023, FP9.024, FP9.025 and FP9.026. Forward primers bound at 
the second codon of the ORFs, immediately after the initiation ATG. These 
primers also incorporated 4 thymidine bases followed by a BamHI recognition 
site at the 5’ end. 
The reverse primers incorporated 4 guanine bases and an XbaI recognition site at 
the 5’ end, followed by the sequence complementary to the end of the ORFs. No 
intergenic regions were included in these predicted products. 
All primers were predicted to have very weak to moderate secondary structure 
(Sigma-Genosys) except the forward primer for FP9.026 which was predicted to 
have strong secondary structure. Forward primers were named F_Bam and 
reverse primers were named R_Xba. A prefix indicated the amplified gene e.g. 
022_F_Bam, 022_R_Xba etc. Sequences are given in Appendix 1. 
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6.1.3.2) Amplification and digestion of FIR2 candidate genes 
Primers described in Section 6.1.3.1 were used to amplify PCR products i.022, 
i.023, i.024, i.025 and i.026. These were purified with the QIAquick PCR 
purification kit and eluted into water (30 µl). Each purified PCR product (1 µg) 
was then digested with XbaI (10 U) at 37 oC for 3 hours, and enzymes were 
removed with the QIAquick PCR purification kit. The entirety of the XbaI 
digested products were then digested with BamHI (10 U) at 37 oC for 3 hours, 
followed by treatment with the PCR purification kit and elution into elution 
buffer (50 µl).  
The digested products were visualised on an ethidium bromide gel to confirm 
that they were of the expected sizes and had not been degraded. 
 
Figure 6.5: FIR2 genes after PCR amplification and digestion. PCR products 
i.022, i.023, i.024, i.025 and i.026 were amplified from 100 ng FP9 gDNA, 
treated with the QIAquick PCR purification kit and eluted into water. Products 
were then sequentially digested with XbaI followed by BamHI. 10% of the 
digested products were electrophoresed in a 0.8% agarose gel. 
 
A single band was visible for each product, confirming that PCR amplification 
had been successful and that restriction digestion had not caused degradation. 
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6.1.3.3) Digestion of pEFplink2FLAG 
To compare sequential digestions of the vector, pEFplink2FLAG (10 µg) was 
digested with XbaI (50 U) followed by BamHI (50 U), the same order as the 
inserts, or with BamHI followed by XbaI. All digestions were for 3 h at 37 oC 
followed by column purification with the QIAquick PCR purification kit. After 
the first digestion, DNA was eluted into water (30 µl). After the final digestions, 
DNA was eluted into elution buffer (50 µl). 
A sample (approximately 200 ng) of each digestion was visualised on a 0.8% 
agarose gel (Fig. 6.6). 
 
Figure 6.6: Digestion of pEFplink2FLAG plasmid. Lane 1: Undigested 
pEFplink2FLAG. Lane 2: Plasmid after XbaI digestion. Lane 3: Plasmid after 
XbaI and BamHI digestion. Lane 4: Plasmid after BamHI digestion. Lane 5: 
Plasmid after BamHI and XbaI digestion. 200 ng each lane. 
 
After each digestion only one plasmid isoform was visible, with no supercoiled 
plasmid.  
To confirm linearisation, double-digested plasmids (50 ng) were incubated with 
or without T4 DNA ligase (400 U) at 15 oC for 18 h in the absence of an insert, 
prior to transformation into XL1-Blue competent cells and spread onto LB 
plates. 
No colonies were visible after transformation with DNA without ligase, 
confirming that all plasmid was linearised. However, many colonies were visible 
after transformation with double-digested DNA that had been incubated with 
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ligase. The numbers of colonies with plasmid digested in either sequence were 
comparable to the number after transformation with control undigested pUC18 
(100 ng).  
Double-digested plasmid may have re-ligated either because digestion with one 
of the restriction enzymes was inefficient, or because the excised (32 bp) 
fragment between the XbaI and BamHI restriction sites was still present in the 
mixture. To examine the latter possibility, pEFplink2FLAG (2.9 to 4 µg), 
digested with both enzymes in either order, was electrophoresed in a 0.6% 
agarose gel stained with ethidium bromide, extracted with the QIAquick gel 
extraction kit and eluted into 50 µl elution buffer. These gel-extracted plasmids 
were incubated with or without T4 DNA ligase as above and transformed into 
XL1-Blue competent cells. 
Again, no colonies were visible after transformation with DNA without ligase, 
and more than 100 colonies were visible with the control pUC18 transformation. 
However only 2 (BamHI then XbaI) or 9 (XbaI then BamHI) colonies were 
visible after transformation with digested, gel-extracted pEFplink2FLAG. This 
suggested that the colonies seen when doubly-digested plasmid was religated 
were due to the continued presence of excised fragment, which had not been 
removed by the column purification, and were not due to inefficient digestion. 
 
6.1.3.4) Ligation and transformation of FIR2 plasmids 
pEFplink2FLAG (50 ng) that had been digested with BamHI followed by XbaI 
and gel-extracted was ligated with a 3-fold molar excess of each of the digested 
inserts from Section 6.1.3.2 at 15 oC for 20 hours. DNA (7 to 11 ng) was then 
transfected into XL1-Blue cells.  
Approximately 100 colonies formed on each plate transformed with the resulting 
pFLAG.022, pFLAG.023, pFLAG.024, pFLAG.025 or pFLAG.026.  
For each plasmid, Wan Fan (Imperial College) picked and amplified colonies 
and confirmed by sequencing that the correct insertion was present. These 
plasmids could then be used in transient transfection assays to identify whether 
any of the FIR2 plasmids were able to inhibit induction of IFN-β by the synthetic 
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dsRNA, poly(I:C). However, due to time constraints these experiments were not 
carried out. 
 
6.2) Generation of recombinant viruses containing single genes from the 
FIR1 locus 
To identify which gene or genes were causing the increased ChIFN resistance of 
virus MVA-f3La, synthesis of recombinant viruses each expressing one of the 
three genes from the FIR1 locus was attempted. 
 
6.2.1) Primer design for FIR1 single gene recombinant viruses 
Primers were designed to flank each of genes FP9.012, FP9.013 and FP9.014, to 
amplify fragments named v012, v013 and v014 respectively. During primer 
design, the entire intergenic regions were included in the sequence input to 
Primer3. 
Due to the short (25 bp) intergenic sequence between FP9.013 and FP9.014, the 
input sequence for the FP9.013 primer design included the last 49 bp of FP9.014, 
whilst the input sequence for the FP9.014 template included the first 27 bp of 
FP9.013. The template sequence used for v012 primer design did not include any 
coding sequence other than FP9.012.  
Primer pairs that gave a large product, but with low predicted self-
complementarity were selected. To increase the choice of potential primers, the 
maximum permitted difference between primers for v014 was increased from 2 
to 10 oC. 
Fragment v012 included 450 to 500 bp of intergenic sequence on either side of 
FP9.012. The forward primer for v012 was closer to FP9.012 than the forward 
primer for fragment 3L, losing 320 bp of the intergenic region between FP9.011 
and FP9.012 (downstream of FP9.012). 
Fragment v013 included 346 bp of sequence between FP9.013 and FP9.012, all 
of the intergenic sequence upstream of FP9.013, and 25 bp of the end of 
FP9.014. 
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The reverse primer used for v014 was the same as that for fragment 3L, KB2R-2. 
Fragment v014 included the first 18 bp of FP9.013, all of the FP9.013-FP9.014 
intergenic sequence and 179 bp of intergenic sequence upstream of the FP9.014 
N-terminus.  
Some of the intergenic regions were common to overlapping fragments, as 
shown in Fig. 6.7. 
 
Figure 6.7: Diagram showing positions of primers flanking FP9 ORFs FP9.012 
to FP9.014, to amplify fragments v012 to v014 prior to recombinant virus 
generation. Blue boxes show ORFs with direction of transcription. Forward 
primer binding sites are shown as white rectangles on the upper grey bar. 
Reverse primers are shown on the lower grey bar. 
 
DNannotator was used to confirm that each selected primer did not bind to the 
FP9 genomic sequence more than once. A 5’ tail with complementarity to FLL 
(for forward primers) or RHSb (for reverse primers) was incorporated into each 
oligonucleotide, for use in SOE-PCR. These overlaps increased the final sizes of 
the amplicons to 1991 (v012), 621 (v013) and 1578 (v014) bp. Resulting 
oligonucleotides were named KB2F or KB2R with a suffix indicating the 
relevant fragment e.g. KB2F-v012, KB2R-v012 etc. Sequences are listed in 
Appendix 1. 
 
6.2.2) Amplification of FIR1 single gene fragments 
The v012, v013 and v014 fragments were initially amplified from 100 ng FP9 
gDNA in a single batch, for 30 cycles with annealing at 39 oC and extension for 
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2 mins. Products were visualised on a 0.6% agarose gel stained with ethidium 
bromide.  
 
Figure 6.8: Amplification of fragments v012, v013 and v014 for generation of 
recombinant viruses containing single genes from the FIR1 locus. 100% of a 40 
µl PCR per lane. 
 
Although single products were visible for v013 and v014, bands ranging from 2 
to 3.5 kbp were seen for v012, requiring further optimisation.  
The first 5 cycles of v012 amplification annealed at 38 oC, with extension for 2 
mins. Annealing temperature was then increased to 57 oC for a further 30 cycles, 
for annealing along the full length of the primer including the 5’ tails. The PCR 
product was visible as a single 2 kbp product on a 0.6% agarose gel stained with 
crystal violet, from where it was extracted with a Recochip and eluted into 
elution buffer (37 µl). 
The v013 and v014 fragments were amplified successfully using common 
conditions, with annealing at 39 oC and 90 sec extension for 30 cycles. PCRs 
were treated with the QIAquick PCR purification kit and eluted into 37 µl TE 
(v013) or elution buffer (v014). 
 
6.2.3) Assembly of FIR1 recombinant virus insertion cassettes 
Molar equivalents of FLL and RHSb, from batches that had been successfully 
used in previous SOE-PCRs, were assembled with an excess of v012 to form 
a012, or v014 to form a014. Templates were added stepwise as described in 
Section 3.12. 
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Because FIR1 assembly reactions were carried out at the same time as another 4 
kbp fragment, conditions were optimised for the largest product. SOE-PCR 
conditions used the same format as described in Section 3.12. FLL and v012 or 
v014 were initially assembled together in the absence of primers for 9 cycles 
with 43 oC annealing and 30 sec extension, for the polymerase to extend from 
FLL along to the far terminus. RHSb was then added, for 3 cycles with 45 oC 
annealing and 90 sec extension, for RHSb to become incorporated. Finally 
primers KB1F-seq and KB4Rb were added, for a final 28 cycles with annealing 
at 39 oC and extension for 6.5 mins (a012) or 4 mins (a014). 
Either 20% (a012) or 4% (a014) of the assembly reactions were visualised on 
0.6% agarose gels stained with ethidium bromide (Fig. 6.9). 
 
Figure 6.9: Assembly of transfection cassettes containing FP9.012 or FP9.014 
by SOE-PCR. Lane 1: 20% of a012 SOE-PCR, using v012 (364 ng) as a 
component template. Lane 2: unassembled v012 (62 ng), for comparison. Lane 
3: 3% of a012 yield, after 80% of SOE-PCR was extracted from a crystal violet 
gel with a Recochip. Lane 4: 4% of a014 SOE-PCR, using v014 (743 ng) as a 
component template. Lane 5: unassembled v014 (44 ng), for comparison. Lane 
6: 3% of a014 yield, after 96% of SOE-PCR was extracted from a crystal violet 
gel with a Recochip. Expected product sizes were 3828 bp (a012), 1991 bp 
(v012), 3415 bp (a014) and 1576 bp (v014). 
 
After electrophoresis of a012, a major 3.8 kbp product was visible as expected 
(Fig. 6.9, lane 1). After electrophoresis of a014, several products were visible, 
ranging from 1.5 kbp to 10 kbp, but a major product was the 3.5 kbp expected 
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assemblicon (Fig. 6.9, lane 4). For comparison, the unassembled v012 and v014 
component templates are shown in lanes 2 & 5 (Fig. 6.9), respectively. 
The remainder of the SOE-PCRs (80% of a012, 96% of a014) were 
electrophoresed on 0.6% agarose gels stained with crystal violet. The bands of 
the desired sizes were extracted with Recochips and eluted into TE (37 µl). The 
extracted DNA products were confirmed to be single bands of the correct size on 
ethidium bromide agarose gels (0.6%) (Fig. 6.9, lanes 3 & 6). Final yields were 
1.32 µg (a012) and 2.80 µg (a014). 
Fragment v013 was assembled with FLL and RHSb into a013 under conditions 
adapted for the sizes of templates involved. FLL and v013 were similar sizes, 
490 and 663 bp respectively. These components were spliced together, in the 
absence of primers for 2 cycles with extension for 30 sec., to form a 1131 bp 
product. RHSb (1390 bp) was then added, for a further 2 cycles with extension 
for 90 sec. Primers KB1F-seq and KB4Rb were present for a final 30 cycles with 
3 min extension, to amplify the 2.5 kbp assemblicon. 
When 10% of the SOE-PCR was visualised on an ethidium bromide agarose gel, 
a major product of the expected size was visible. 
 
Figure 6.10: Assembly of transfection cassette a013, containing FP9.013, by 
SOE-PCR. 10% of a SOE-PCR, using v013 (25 ng) as a component template, 
was electrophoresed in a 0.6% agarose gel. 
 
A faint product of approximately 2 kbp was also visible, which may represent 
v013 annealed to RHSb, without FLL. All of the SOE-PCR was extracted from 
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the ethidium bromide gel with the QIAquick gel extraction kit and eluted into TE 
(90 µl). The final yield was 2.79 µg. 
 
6.2.4) Transfection of FIR1 single gene cassettes and MXH passage 
DF-1 cells (12.5 cm2) at 80% confluency were infected with MVA-LZ at 3 
pfu/cell. After 90 mins adsorption, DMEM 2% FBS to a total volume of 3.5 ml 
was added. Cells were then transfected with a012 (1 µg), a013 (2.7 µg) or a014 
(1µg), complexed with carrier DNA (2.5 µg) and Polyfect (12%) in Optimem. 
After 3 days, when cpe were visible, cells were scraped into the culture medium, 
centrifuged at 500 g for 5 mins, and resuspended in supernatant (1 ml). 
Harvested cells were freeze-thawed three times before 1.4 µl was diluted in 
DMEM 2% FBS with MXH. This inoculum was adsorbed onto confluent CEF 
(25 cm2) for 90 mins prior to addition of a further 6 ml DMEM 2% FBS with 
MXH. After 6 days, foci of infection were visible, and cells were harvested into 
1 ml supernatant as before and freeze-thawed three times. 
MXH passage of each virus was repeated for a total of three times, to create 
MVA-F.012b, MVA-F.013 and MVA-F.014. 
 
6.2.5) PCR analysis of FIR1 single gene recombinant viruses 
The third MXH passage harvest of each recombinant virus was titrated with and 
without MXH in the overlay, to identify any major differences between total titre 
and GPT-positive virus titre.  
The MXH titre of MVA-F.012b was 81% of the titre obtained without MXH and 
the presence of parental virus was confirmed by PCR (Fig. 6.11). The titre of 
MVA-F.013 was similar with and without MXH, but PCR analysis identified a 
potential complex of viruses, requiring plaque purification (Fig. 6.11). 
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Figure 6.11: PCR analysis of recombinant viruses MVA-F.012b (lanes 1 to 3) 
and MVA-F.013 (lanes 4 to 6) gDNA prior to plaque purification. The upper and 
lower panels of lanes 1 to 3 show the same gel, with a longer exposure for the 
lower panel. Primers used were: Out_F & Out_R (lanes 1 & 4), BridgeF & 
KB4Rb (lanes 3 & 6), KB2F-v012 & KB2R-v012 (lane 2) and KB2F-v013 & 
KB2R-v013 (lane 5). 20% of PCRs were electrophoresed on a 0.6% agarose gel 
with ethidium bromide for visualisation. 
 
Primers flanking the insertion site of MVA-F.012b (Fig. 6.11, lane 1) amplified a 
major product (4.1 kbp) representing insertion of the expected cassette, but a 
longer exposure also indicated presence of a product from non-recombinant virus 
(1311 bp; lower panel). Primers specific to v012 (Fig. 6.11, lane 2) amplified a 
major product of the expected size (1991 bp), but also a larger product, 
approximately 3 kbp. A product specific to MVA-LZ amplified a faint product, 
visible at higher exposure (Fig. 6.11, lane 3). 
Primers flanking the insertion site of MVA-F.013 amplified a range of products 
(Fig. 6.11, lane 4), including those expected from a non-recombinant virus (1311 
bp), an insertion of FP9.013 and GPT (2805 bp) and others. Primers specific to 
the desired insertion (Fig. 6.11, lane 5) or parental virus (Fig. 6.11, lane 6) 
produced single products of the expected sizes, confirming that a mixture of 
recombinant and parental viruses was present. 
MVA-F.014 was not PCR analysed at this stage, but titres with and without 
MXH were similar.  
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For each virus, a plaque was picked from under an MXH overlay and amplified 
on CEF without selection medium, as described in Section 2.19. The gDNA 
extracted from the amplified plaques was PCR analysed as before. 
Two plaques were amplified from each of MVA-F.012b and MVA-F.013, and all 
plaques were pure recombinant virus, without any parental MVA-LZ, according 
to PCR analysis. Five plaques from MVA-F.014 were amplified, but only 2 were 
PCR analysed. Again, both were pure recombinant virus (Fig. 6.12). 
 
Figure 6.12: PCR analysis of recombinant viruses MVA-F.012b (lanes 1 to 6), 
MVA-F.013 (lanes 7 to 12) and MVA-F.014 (lanes 13 to 18) gDNA after plaque 
purification. The upper and lower panels of lanes 7 to 12 show the same gel, 
with a longer exposure for the lower panel. gDNA templates were: MVA-F.012b 
plaque 13 (lanes 1 to 3), MVA-F.012b plaque 15 (lanes 4 to 6), MVA-F.013 
plaque 1 (lanes 7 to 9), MVA-F.013 plaque 4 (lanes 10 to 12), MVA-F.014 
plaque 1 (lanes 13, 15 & 17) and MVA-F.014 plaque 2 (lanes 14, 16 & 18). 
Primers used were: Out_F & Out_R (lanes 1, 4, 7, 10, 13 & 14), KB2F-v012 & 
KB2R-v012 (lanes 2 & 5), KB2F-v013 & KB2R-v013 (lanes 8 & 11), KB2F-v014 
& KB2R-v014 (lanes 15 & 16) and BridgeF & KB4Rb (lanes 3, 6, 9, 12, 17 & 18). 
 
All plaques analysed showed PCR products that were specific to recombinant 
virus, and no MVA-LZ or spurious products. 
Stocks of both MVA-F.012b plaques (pp13 and pp15) were grown up in the 
absence of MXH. A further stock of MVA-F.012b virus derived from pp15 
(stock pp15g2) was grown up for a second round in the absence of MXH. Stocks 
from one plaque each of MVA-F.013 (plaque 4) and MVA-F.014 (plaque 1) 
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were also grown in the absence of MXH, and were used for all future 
experiments. All virus stocks were titrated for future use. 
 
6.2.6) Sequencing analysis of FIR1 recombinant viruses 
The Deletion II insertion sites of plaque purified MVA-F.012b, MVA-F.013 and 
MVA-F.014 were amplified using primers Out_F and Out_R, and the PCR 
products were sequenced. For comparison, the Deletion II insertion site for 
plaque purified MVA-f3La was also amplified and sequenced in the same way. 
Results were compared to the FP9 genomic sequence (Accession no. AJ581527) 
and all positions quoted refer to this genome. 
Continuous sequence for the complete FP9 fragment in MVA-f3La was obtained. 
This identified three thymine to cytosine mutations, at positions 14302, 14586 
and 15316 of the FP9 genome. The first occurred in an intergenic region between 
FP9.012 and FP9.013, 134 bp upstream of the FP9.012 initiation codon. Position 
14586 resulted in a coding change from glutamic acid to glycine at codon 427 of 
FP9.014. The third mutation occurred at codon 184 of FP9.014, but was silent, 
leaving the amino acid residue unchanged from leucine. 
In MVA-F.012b, the complete FP9.012 ORF and downstream intergenic region 
of the FP9 fragment was sequenced, but 435 bp of the intergenic region upstream 
of FP9.012 could not be interpreted due to poor quality data.  Sequence analysis 
revealed an adenine to cytosine mutation at position 12218 in the intergenic 
region 456 bp downstream of FP9.012. At position 13586, a cytosine to thymine 
mutation at codon 28 had a silent effect on the valine residue. 
Sequence was obtained for the complete FP9 fragment in MVA-F.013, and 
revealed two mutations. At position 14463, a thymine to cytosine resulted in a 
coding change from asparagine to aspartic acid at codon 22 of FP9.013. A further 
coding mutation occurred at position 14471, changing isoleucine to threonine at 
codon 19. 
Only codons 161 to 438 of FP9.014 and the entire subsequent downstream 
intergenic region were sequenced within the FP9 fragment of MVA-F.014. A 
silent mutation (thymine to cytosine at position 15086) did not affect the serine 
residue at codon 260 of FP9.014. Poor quality data prevented sequence analysis 
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of the complete FP9 fragment from this virus, and it was not established whether 
any mutations occurred within the first 160 codons of FP9.014 or in the upstream 
intergenic region of MVA-F.014. 
 
6.3) Screening of FIR1 recombinant viruses for increased ChIFN resistance 
Viruses recombinant for a single FP9 gene from the FIR1 locus were screened 
for increased ability to form plaques in CEF that had been pre-treated with 
ChIFN, in the same way as described in Chapter 5.  
 
A 
B 
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Figure 6.13 (previous page): FIR1 virus resistance to 27 U/ml or 6 U/ml S.G. 
ChIFN. CEF (in 9 cm2 wells) were incubated with 1 ml DMEM 2% FBS in 
triplicate, or 1 ml ChIFN in DMEM 2% FBS, for 18 h. Cells were aspirated and 
infected with MVA-LZ at 90 pfu/well, MVA-fC2a at 180 pfu/well, MVA-f3La at 
135 pfu/well, MVA-F.012b (pp13) at 90 pfu/well, MVA-F.013 at 90 pfu/well, or 
MVA-F.014 at 180 pfu/well. All viruses except MVA-fC2a were plaque-purified. 
After adsorption for 90 mins, virus was aspirated and 2 ml/well solid overlay was 
added to cells. After 3 days incubation, a second overlay containing X-gal was 
added and plaques were counted the following day. The numbers of plaques 
formed in the ChIFN-treated wells (single well per virus) were expressed as a 
percentage of the mean (n=3) number of plaques formed in mock-treated wells. 
A: ChIFN was diluted to 27 U/ml. B: ChIFN was diluted to 6 U/ml ChIFN. 
 
MVA-F.013 did not form any plaques in cells treated with 27 U/ml ChIFN, 
which may have been due to insufficient virus inoculated; the mean (n=3) was 56 
pfu/ml MVA-F.013 in mock-treated wells. In the same experiment, when cells 
were pre-treated with 6 U/ml S.G. ChIFN, MVA-F.013 was not more efficient at 
plaquing than control viruses. 
MVA-F.014 efficiency of plaque formation was higher than control viruses at 
both concentrations of ChIFN, but not as high as MVA-f3La, where the FIR1 
locus was originally identified. 
MVA-F.012b plaquing efficiency was similar to MVA-F.014 at the lower 
concentration (6 U/ml) used, but when cells had been treated for 18 h with 27 
U/ml, MVA-F.012b plaqued at a similar efficiency to MVA-fC2a. 
These results were from a single ChIFN-treated well, so the experiment was 
repeated with treatments in triplicate. 
In two independent experiments, also shown in Fig. 5.11, when cells were treated 
for 18 h with 2 U/ml S.G. ChIFN in triplicate, MVA-fC2a was less efficient at 
plaquing than MVA-LZ, consistent with previous results. 
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Figure 6.14: FIR1 virus resistance to 2 U/ml S.G. ChIFN. In two independent 
experiments, CEF (9 cm2) were incubated in triplicate for 18 h with 1 ml DMEM 
2% FBS or 1 ml ChIFN in DMEM 2% FBS. Cells were aspirated and infected at 
100 pfu/well with MVA-LZ, MVA-fC2a, MVA-f3La, MVA-F.012b (pp15), MVA-
F.013 or MVA-F.014. All viruses were plaque-purified. After adsorption for 90 
mins, virus was aspirated and 2 ml/well solid overlay was added to cells. A 
second overlay containing X-gal was added 3 days PI and plaques were 
counted the following day. Plaques formed in ChIFN-treated wells were 
expressed as a percentage of the mean (n=3) number of plaques formed in 
mock-treated wells for each virus. Mean of triplicate wells ± SEM. 
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In the first experiment (Fig. 6.14, upper graph), MVA-F.012b and MVA-F.013 
were similar to controls, whilst MVA-F.014 had a similar efficiency to MVA-
f3La. A one-way ANOVA with Bonferroni’s post-test identified that the only 
statistically significant differences were between MVA-F.014 and both MVA-
fC2a and MVA-F.012b. 
When the experiment was repeated (Fig. 6.14, lower graph), the pattern of 
resistance across the panel of viruses was the same, but a one-way ANOVA 
found no significant difference between any groups. The poor reproducibility of 
these results may be due to the low concentration of ChIFN used. 
The trend across these experiments was that the ChIFN resistance of MVA-F.014 
was the most similar to MVA-f3La. Therefore FP9.014 was the most likely gene 
at the FIR1 locus to be causing or contributing to the ChIFN-resistant phenotype. 
Because MVA-F.013 was consistently similar to the control viruses, it was not 
included in further studies, whereas MVA-F.014 and MVA-F.012b were 
characterised further.  
 
6.4) Resistance of MVA-F.012 and MVA-F.014 across a range of ChIFN 
concentrations 
Resistance of MVA-F.014 was compared to MVA-F.012b and control viruses 
across a range of ChIFN concentrations to calculate the IC50 for each virus. 
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Figure 6.15: Titrations of ChIFN inhibition for FIR1 viruses. CEF were incubated 
in triplicate for 18 h with S.G. ChIFN in DMEM 2% FBS at 0, 0.3, 0.6, 3, 6 or 13 
U/ml. Cells were aspirated and infected at 100 pfu/well with MVA-LZ, MVA-fC2a, 
MVA-f3La, MVA-F.012b (pp15) or MVA-F.014. All viruses were plaque-purified. 
After adsorption for 90 mins, virus was aspirated and 2 ml/well solid overlay was 
added to cells. A second overlay containing X-gal was added 3 days PI and 
plaques were counted the following day. Plaques formed in ChIFN-treated wells 
were expressed as a percentage of the mean number of plaques formed in 
mock-treated wells for each virus. Mean of triplicate wells ± SEM. 
 
At very low ChIFN concentrations, the closely overlapping steep curves could 
not be clearly distinguished. At concentrations above 1 U/ml, MVA-fC2a, MVA-
LZ and MVA-F.012b followed similar curves. At some points MVA-fC2a was 
slightly below MVA-LZ, consistent with the results of the screening assays using 
a single concentration of ChIFN. MVA-f3La was more resistant than other 
viruses at all concentrations above 1 U/ml, whilst MVA-F.014 was intermediate 
between MVA-f3La and the others. 
A one-way ANOVA found a highly significant difference between groups 
(p<0.0001), and Bonferroni’s post-test found individual significant differences 
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only between MVA-f3La and all other viruses except MVA-F.014. Non-linear 
regressions calculated the IC50 for each virus as 5 (MVA-f3La), 3 (MVA-F.014) 
and 2 (MVA-F.012b, MVA-fC2a & MVA-LZ) U/ml. The IC50 for MVA-LZ in 
this experiment was lower than that calculated in Section 5.4 , where it was 8 
U/ml, but the relationship between MVA-f3La and MVA-LZ was representative 
of 3 other experiments, where MVA-f3La was consistently more resistant than 
MVA-LZ. 
The variation seen between experiments may be due to the use of primary cells. 
Although embryos of the same age were used throughout as a source of CEF, 
they may vary in the exact development of the innate immune system. This could 
also explain differences seen between experiments using a single ChIFN 
concentration, such as those in Fig. 6.14. 
 
6.5) Multi-step growth curves of MVA-F.014 and MVA-F.012b 
To examine any growth advantage conferred by FP9.014, multi-step growth 
curves of MVA-F.014 and MVA-F.012b were compared with control viruses 
MVA-LZ and MVA-fC2a. In a multi-step growth curve, cells are infected at a 
low MOI, to allow more than one round of viral replication. Typically these 
assays are used to examine any differences in cell egress or inter-cellular spread 
of virus. They would also reflect the summative effect of IFN release from a 
virus-infected cell on viral replication in neighbouring cells and thus the 
resistance of the virus to the antiviral effects of IFN. 
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Figure 6.16 (previous page): Multi-step growth curves for viruses recombinant 
for FIR1 candidate genes. CEF (12.5 cm2) were infected at 0.01 pfu/cell with 
MVA-LZ, MVA-fC2a, MVA-F.012b (pp15) or MVA-F.014 in 18 replicates. All 
viruses were plaque-purified. After adsorption for 90 mins, virus was aspirated 
and DMEM 2% FBS (3.5 ml) was added to cells. At 4, 10, 24, 48 and 72 h PI 
culture medium from triplicate flasks for each virus was removed and freeze-
thawed 3 times, whilst cells were washed with PBS, aspirated and stored in PBS 
(3 ml). Cells were freeze-thawed 3 times and shaken vigorously to disrupt and 
homogenise the monolayers. Cell-associated virus in the cellular fraction (A), 
and extracellular virus in the culture media (B) were titrated by plaque assay. 
Total virus (C) was the sum of cell-associated and extracellular virus titres. For 
each fraction and time point, the product of the virus titre (pfu/ml) and the 
harvest volume (3.5 ml for culture medium, 3 ml for cells) is plotted. Mean ± 
SEM. 
 
Until 24 h PI, the cellular titre of MVA-F.012b was slightly higher than other 
viruses, although closest to MVA-F.014. At 48 h PI, MVA-F.014 had the highest 
titre of cell-associated virus although this was not maintained to 72 h PI when all 
virus cellular titres were similar. 
When extracellular virus was examined, MVA-F.012b again had a higher titre 
than other viruses for early time points, until 48 h PI After this, MVA-F.014 had 
the highest titre of extracellular virus. 
Total virus, calculated by the addition of cell-associated with extracellular virus, 
showed the same pattern as cell-associated virus as the latter fraction comprised 
at least 70% of the total from 10 h PI onwards. The total titre of MVA-F.012b 
was highest until approximately 30 h PI, after which MVA-F.014 was highest.  
However, statistical comparison of the exponential growth curves found no 
significant difference between total titres of the viruses (p=0.12), and a single 
curve could fit all data sets. 
Induction of ChIFN by infected cells would have the effect of putting uninfected 
cells in the same culture into an antiviral state. When infected at a low MOI, 
there are a greater number of uninfected cells that could potentially respond in 
this way. Increased titres of MVA-F.014 at late time points, after induction of 
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ChIFN, is consistent with the screening results that showed MVA-F.014 was 
better able to replicate in cells pre-treated with ChIFN. 
In an attempt to imitate replication at late time points when cells are in an 
antiviral state, single step growth curves in cells pre-treated with ChIFN were 
analysed. 
 
6.6) Single-step growth curves of MVA-F.014 and MVA-F.012b 
Single-step growth curves use a high MOI to compare replication rates but do not 
take account of viral cell-cell spread. CEF were pre-treated with 0.6 U/ml ChIFN 
for 18 h prior to infection at 5 pfu/cell.  
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Figure 6.17 (previous page): Single-step growth curves for viruses recombinant 
for FIR1 candidate genes, in cells pre-treated with 0.6 U/ml ChIFN. CEF (12.5 
cm2) were incubated with 0.6 U/ml S.G. ChIFN in DMEM 2% FBS for 18 h. Cells 
were aspirated and infected at 5 pfu/cell with MVA-LZ, MVA-fC2a, MVA-F.012b 
(pp15g2) or MVA-F.014 in 9 replicates. MVA-fC2a virus stock used had been 
grown for a second round in the absence of MXH after plaque purification. All 
viruses were plaque-purified. After virus adsorption for 90 mins, cells were 
aspirated, washed twice with PBS and incubated in DMEM 2% FBS (3 ml). At 6, 
21 and 32 h PI culture medium from triplicate flasks for each virus was removed 
and freeze-thawed 3 times, whilst cells were washed with PBS, aspirated and 
stored in PBS (3 ml). Cells were freeze-thawed 3 times and shaken vigorously 
to disrupt and homogenise the monolayers. Cell-associated virus in the cellular 
fraction (A), and extracellular virus in the culture media (B) were titrated by 
plaque assay. Total virus (C) was the sum of cell-associated and extracellular 
virus titres. For each fraction and time point, the product of the virus titre (pfu/ml) 
and the harvest volume (3 ml) is plotted. Mean ± SEM. 
 
Statistical comparison of the exponential growth curves identified a difference 
between MVA-LZ and MVA-fC2a. At 32 h PI MVA-LZ had a higher titre than 
MVA-fC2a, which may contribute to the difference in plaque formation seen 
between these control viruses in screening assays. Because of this difference 
between the controls, MVA-LZ was excluded from subsequent analyses. 
An extra sum-of-squares F test was used to ask whether a single curve could fit 
the total virus data from a pair of viruses. This was found to be the case between 
MVA-fC2a and MVA-F.012b i.e. they were not significantly different. However 
MVA-F.014 was significantly different to both MVA-fC2a and MVA-F.012b. 
Figures 6.17A and 6.17C indicate that MVA-F.014 produced less cell-associated 
and total virus than MVA-F.012b or MVA-fC2a under these conditions. 
Although MVA-F.014 extracellular virus titre was higher at some time points, 
there was no significant overall difference between MVA-fC2a, MVA-F.012b or 
MVA-F.014 in this fraction. Whether MVA-F.014 was replicating at a lower 
level, or more slowly, could not be distinguished, as the growth curves were not 
continued until a final plateau was reached. 
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The concentration of ChIFN used to pretreat the cells in the single step growth 
curve was very low and may not have been high enough to have an effect on 
titres of MVA viruses lacking an FP9 IFN-resistance gene. If this was the case, 
and the expression of FP9.014 had a detrimental effect on virus fitness, this may 
explain why the titre of MVA-F.014 was lower in this experiment. 
 
6.7) Bioinformatic analysis of FIR1 and FIR2 genes 
PFAM analysis of the FIR1 and FIR2 proteins confirmed that most of them were 
ankyrin repeat proteins, and also contained a C-terminal PRANC (Pox protein 
Repeats of ANkyrin C-terminal) domain. 
 
Figure 6.18: Domain architecture for FIR1 and FIR2 proteins predicted by 
PFAM. Each green box represents an ankyrin repeat (ANK). Red boxes 
represent PRANC domains. No protein family domains were predicted from the 
amino acid sequences of FP9.013 or FP9.025.  
 
The number of ANKs in the FIR1 and FIR2 ankyrin proteins ranged from 4, (in 
FP9.012) to 12 (in FP9.024). A PRANC domain was predicted in all the FIR 
ankyrin proteins except FP9.023. 
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A BLASTN search of the FP9.014 nucleotide sequence showed strongest identity 
with itself (FP9 genome, 100%) and with the genomic sequence of the virulent 
HP-1 strain of FWPV. There was a maximum of 63% identity along 71% of the 
FP9.014 sequence with the Canarypox virus orthologue, CNPV019. All other 
similarities were for very short regions, less than 4%, of the FP9.014 sequence. 
A BLASTP search of FP9.014 again identified itself and CNPV019, but also 
showed a very high similarity (alignment >200) with CNPV229. Other 
avipoxvirus proteins with alignment scores of 80 to 200 were FPV219, 
CNPV296, CNPV017 and CNPV294. Gallus gallus proteins identified were 
ankyrin 3 and ankyrin B (Gene ID 422689 ANK2). 
A BLASTN search with the FP9.012 nucleotide sequence also showed strongest 
identity with itself and HP-1. The third highest hit was with the CNPV 
orthologue, CNPV030, which showed a maximum identity of 66% along 23% of 
the FP9.012 sequence. All other hits were for no more than 6% of the FP9.012 
length. 
A BLASTP search of the amino acid sequence of FP9.012 identified several 
strong similarities, almost all with other ankyrin repeat proteins. Avipoxvirus 
proteins identified were CNPV030, CNPV151, FPV240, CNPV028 and 
CNPV308. Ankyrin repeat proteins from several other organisms were listed, 
including ankyrin B from Gallus gallus. 
A BLASTN search with FP9.013 produced hits as long as 33% of the nucleotide 
sequence, although this increase is probably aided by the short nature of this 
hypothetical protein. The third highest hit was for a human gene on chromosome 
11 (Accession number AC023080.6). No proteins were identified with a 
BLASTP search of FP9.013. 
BLASTP analyses of the FIR2 ankyrin repeat protein sequences identified 
similarities with many ankyrin repeat proteins, mostly from Canarypox virus and 
the parasite Trichomonas vaginalis. FP9.025, which does not have any predicted 
protein family domains, did not have any hits that scored above 40 bits with 
proteins other than itself and the Canarypox virus orthologue. 
The amino acid sequences of all FP9 genes were analysed with the SignalP 3.0 
software to predict a signal peptide or signal anchor, which could indicate protein 
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secretion or membrane association. Both neural networks and hidden Markov 
models predicted that all 3 FIR1 genes and all 5 FIR2 genes were not secreted. 
 
6.8) Summary 
To identify the gene or genes causing ChIFN resistance at the FIR2 locus, 
recombinant viruses containing single candidate genes were attempted. However, 
these were unsuccessful at an early stage and were aborted due to time 
constraints. 
In order to reduce the number of candidate genes at the FIR2 locus, a panel of 
viruses were PCR analysed in an attempt to correlate FP9 gene expression with 
ChIFN resistance. However, MVA-f6a had lost several internal primer binding 
sites that were not clustered together and so the extent of the instability could not 
be clearly delimited. MVA-f7a may have lost FP9.025, but the variable 
phenotype by this virus limited interpretation of the contribution of this gene to 
ChIFN resistance.  
The FIR2 candidate genes were cloned into the expression vector 
pEFplink2FLAG, for transient transfections to investigate any inhibition of 
ChIFN induction, although due to time constraints these experiments were not 
completed. 
Recombinant viruses containing single genes from the FIR1 locus were 
constructed, plaque-purified and screened in ChIFN resistance assays. MVA-
F.014, containing FP9.014, was identified as having the most similar phenotype 
to MVA-f3La, containing the whole FIR1 locus, although FP9.012 also showed 
some resistance at lower ChIFN concentrations. Titrations of ChIFN resistance 
confirmed the positive result of MVA-F.014, but also indicated that resistance 
was not as high as that by MVA-f3La. The mutation identified in FP9.014 within 
the single recombinant virus, or any further unidentified mutations in this 
protein, could have partially impaired the function of FP9.014 in MVA-F.014. It 
was not possible to eliminate the possibility of IFN resistance by FP9.013, as 
coding mutations were identified within this gene in MVA-F.013.  
Expression studies with faithful protein sequences are required to confirm that 
FP9.012 and FP9.013 do not play a role in isolation. Alternatively, there may be 
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synergy between any of the FIR1 candidates to achieve the resistance level of 
MVA-f3La. Another possible explanation for the discrepancy between MVA-
F.014 and MVA-f3La may be due to different expression levels of FP9.014 by 
these viruses. The same intergenic region upstream of FP9.014 was used in the 
construction of both viruses, but the absence of mutations in this region of MVA-
F.014 has not been confirmed and quantitative expression studies are required to 
investigate this possibility. 
The effects of FP9.014 and FP9.012 on virus growth were also investigated. In a 
multi-step growth curve, FP9.012 may have slightly increased virus replication at 
early time points, whereas FP9.014 increased yields at later time points. 
However, none of these effects were significant.  
When a higher MOI was used, in cells that had been pre-treated with a very low 
dose of ChIFN, the virus expressing FP9.014 replicated at lower levels, or more 
slowly. This indicated a ‘cost’ of FP9.014 expression, which was not outweighed 
by a benefit of ChIFN resistance in this situation, possibly because the 
concentration of ChIFN used might have been ineffective at inducing an antiviral 
state. 
Bioinformatic analysis of FP9.012 and FP9.014 indicated that these proteins 
were not secreted, and had significant similarity to other ankyrin repeat proteins, 
including some from the host species, Gallus gallus. However, sequence 
similarity searches did not identify any other proteins with known anti-IFN 
functions. Therefore FP9.014 may function using a previously unknown 
mechanism. 
In this work, a large library of recombinant viruses was constructed and screened 
to identify molecular determinants that contribute to FP9 resistance to ChIFN. 
Two loci, FIR1 and FIR2 were identified with this approach. The major 
contributor to the FIR1 phenotype was identified as FP9.014. However, none of 
the recombinant viruses made showed a level of resistance comparable to native 
FP9. Therefore either a major locus was not included in the library, or molecular 
determinants operate in synergy to produce the remarkable resistance of FP9. 
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CHAPTER 7 
Discussion 
 
FWPV is more resistant to a ChIFN-induced antiviral state than VACV (Asch & 
Gifford, 1970; Pollitt, 1997). In Section 5.3 this resistance was confirmed where 
FP9 was shown to be greater than 300 times more resistant than MVA to ChIFN. 
The aim of the project was to identify one (or more) genes that contribute to FP9 
resistance to ChIFN. Due to the paucity of information and reagents for the 
innate immune system of the natural FWPV host, the chicken, a genetic approach 
was chosen as most likely to succeed. Fragments of the FP9 genome were 
recombined into MVA viruses, which were screened for increased resistance to 
ChIFN. 
 
7.1) Design of the FP9 library 
Construction of a recombinant MVA library expressing FP9 proteins that could 
be generated using techniques suitable for high-throughput production required 
careful design and optimisation of various parameters for the multiple stages of 
the process. Stages that required careful consideration included:  
 (i) Choice of insertion site (see 7.1.1 below) 
 (ii) Choice of selection marker (see 7.1.1 below) 
 (iii) Choice of technique to generate FP9 genomic fragments (see 7.1.2) 
 (iv) The size of FP9 genomic fragments and their overlaps (see 7.1.3) 
 (v) Choice of assembly method (see 7.1.4 below) 
 
7.1.1) Choice of insertion site and selection marker  
Deletion II was chosen as the insertion site, due to the large region between 
functional genes. Deletion III was a viable alternative (Sutter & Moss, 1992), 
although it is located within a fusion product. Wyatt et al. have recently 
suggested that a position between converging transcriptional units is less likely to 
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result in unstable insertions (Wyatt et al., 2008). Such a site could have been an 
alternative, but none of the major deletion sites I to VI lie between converging 
ORFs. Undisclosed intergenic regions have been used for stable integration in 
the Bavarian-Nordic proprietary strain MVA-BN (Timm et al., 2005). 
Notwithstanding that both of these reports were published after the work 
described here was begun, alternative, intergenic sites not commonly used could 
have been investigated but these would have required validation before 
generation of the recombinant library. 
Some of the FP9 insertions contained genes transcribing in the opposite direction 
to the adjacent MVA genes and GPT. If this rightward transcription was under 
the control of a powerful promoter, read-through could have inhibited MVA023L 
due to transcription machinery clashing. Formation of dsRNA from 
complementary transcription products could also be a complication, potentially 
obscuring some IFN modulating effects. 
GPT was chosen as the selection marker for recombinant viruses, although 
several alternatives were available, as discussed in Section 1.9.2. Because of the 
large number of viruses involved, the GPT cassette was retained in the 
recombinant viruses, rather than being removed by TDS. This was controlled for 
with a virus that contained just the GPT cassette and 340 bp of intergenic FP9 
DNA. In view of the fact that insertion of GPT results in an apparent increase in 
sensitivity to interferon, the inclusion of this control was invaluable. 
This control virus was less resistant to ChIFN than MVA-LZ (Fig. 4.11), 
indicating that either the GPT cassette or the intergenic FP9 sequence had an 
effect on virus growth. The GPT cassette was oriented towards the FP9 fragment 
but did not include a stop signal for transcription. Continuous transcriptional 
read-through from the powerful p7.5 promoter may have affected the MVA 
genes to the left of the insertion site. Such an effect would be more likely with 
the short control FP9 fragment than the longer insertions. This could have been 
assessed by monitoring expression of MVA021L, the gene downstream of the 
insertion site, for instance by quantitative PCR. 
The MVA-LZGPT-KB virus contained the GPT cassette without the FP9 
sequence, so this virus could have been used to address the effect of GPT 
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expression. However, the GPT cassette in this virus was slightly different to that 
used for the FP9 library itself, and may have had altered transcription signals, 
making this virus an imperfect control. 
 
7.1.2) Generation of FP9 fragments 
The method chosen for the production of FP9 gDNA fragments was 
amplification by PCR, but alternatives were available. Physical shearing methods 
such as sonication or passage through a needle generate random fragments of 
varying sizes (Skinner & Laidlaw, 1999) but rarely generate fragments larger 
than about 3 kbp (S. Laidlaw, Imperial College; personal communication). Such 
small fragments would require several genomes-worth in the library to increase 
the probability of an intact version of all ORFs. Any ORFs still missing, 
including those larger than 3 kbp, would need to be identified and synthesised 
individually. 
Digestion of FP9 gDNA with a cocktail of rarely cutting endonucleases is 
reproducible and predictable. It would be difficult to avoid disruption of ORFs 
larger than 5 kbp and there would be no overlaps between fragments unless DNA 
was partially digested, which carries the same complications as randomly 
produced fragments. With any of these alternative approaches, at least partial 
sequencing would be required to identify each fragment. A disadvantage of these 
techniques is that they may require large quantities of gDNA but a major 
advantage is that they do not run the risk of introducing artificial mutations, such 
as in PCR. 
The manufacturer of the polymerase used (AccuPrime Taq High Fidelity; 
Invitrogen) claimed that this enzyme had a 9-fold higher fidelity than Taq DNA 
polymerase. Alternative polymerases with even higher fidelity are available and 
these could have been investigated for suitability with FP9 genomic template 
DNA. 
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7.1.3) Size of FP9 fragments and overlaps 
Preliminary PCR confirmed that 10 kbp could be amplified (Fig. 3.4), allowing 8 
kbp for the FP9 fragments. Approximately 32 fragments of this size would be 
required to span the FP9 genome and one of the ITRs. To provide redundancy in 
the library, and to accommodate ORFs spanning the fragment boundaries, each 8 
kbp fragment overlapped those adjacent by 4 kbp, effectively providing a second 
pass through the genome and increasing the total number of fragments to 61. 
This second tiling path could have been omitted, relying on duplication or 
triplication of each fragment as the only source of redundancy. This would have 
reduced the number of intended viruses (32 x 3 = 96, compared to 61 x 2 = 122), 
but the additional advantages of the large overlaps would have been lost. The 
overlaps provided shorter alternative fragments that in some cases were required, 
not least for the production of a virus containing the FIR1 locus. The overlaps 
also provided primer binding sites within each fragment that were used to 
confirm PCR assembly during optimisation, to confirm incorporation of 
fragments into recombinant viruses and to assess stability of recombinant virus 
insertions. 
The fragments were designed without respect to ORFs. With retrospect, it may 
have been preferable to force each FP9 primer to lie in an intergenic region, 
avoiding any confounding effects of truncated proteins. The potential loss of any 
promoter sequences with such a method would have been compensated for by 
the overlapping fragments. 
 
7.1.4) Assembly method 
SOE-PCR was used to assemble the GPT cassette and FLRb into RHSb, and 
subsequently RHSb with FLL and the FP9 fragments. As an alternative to using 
SOE-PCR assembly, RHSb and FLL could have been cloned into a plasmid, 
ready to accept each FP9 fragment. As discussed in Section 1.9.4, it was 
preferable to transfect linear rather than circular DNA. PCR amplification of the 
FLL-FP9-RHSb portion of each plasmid could have been used to generate a 
linear product for transfection after assembly by cloning. 
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Considering the number of PCRs undertaken, even with the high fidelity 
polymerase used, the probability of a mutation being introduced into the library 
was extremely high.  
In any PCR where a mutation occurs, unless it occurs in one of the initial cycles, 
the resulting PCR product will be a heterogeneous mix of correct and mutated 
products. Transfecting such a mixture maintains a chance of a ‘correct’ product 
undergoing recombination. In contrast, cloning requires picking a single colony 
that may contain only one kind of plasmid: either ‘correct’ or mutated. A PCR 
product from a cloned plasmid should therefore be more homogeneous prior to 
transfection and if it happens to be mutated, then recombination can only occur 
with a mutated insertion. To avoid this, plasmid insertions could be sequenced, 
but the number of fragments involved was prohibitive. 
 
7.1.5) Alternatives to the recombinant MVA library approach 
Rather than making a library of recombinant viruses, FP9 genes could have been 
individually cloned into plasmids and screened for inhibition of IFN-β, IFN-α or 
Mx induction using reporter plasmids in transient transfections (Schwarz et al., 
2004). In these assays, cells are transfected with a plasmid containing a reporter 
gene (such as luciferase) downstream of a ChIFN-β, ChIFN-α or chicken Mx 
promoter. Cells are simultaneously transfected with the plasmid containing the 
gene to be screened and another plasmid to control for transfection efficiency. 
After stimulation with poly(I:C), ChIFN or viral infection, the amount of reporter 
protein produced is measured for any inhibition by the plasmid being screened 
(Andrejeva et al., 2002).  
A library of FP9 viruses with targeted deletions of non-essential genes had 
already been partially constructed by K. Hughes (Institute for Animal Health). 
Once completed, this library could have been screened for loss of ChIFN 
resistance. The main difficulty with this approach is the high resistance of FP9. A 
large amount of ChIFN would have been required to assay FP9 and the lack of 
complete inhibition at the highest doses may have meant that this screen would 
not be sensitive enough to identify mutant viruses with a partial loss of 
resistance. However, S. Laidlaw (Imperial College, unpublished results) has 
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since successfully screened this library, using luciferase reporter assays, for a 
loss of ability to block ChIFN induction. 
As opposed to these broad-scale screens, which have the added benefit of 
producing a library with multiple potential applications, bottom-up, targeted 
approaches could have been used to identify proteins with particular properties. 
For example, FP9 genome fragments could have been inserted into recombinant 
MVA-ΔE3L, and screened for complementation of E3 function that allowed 
growth in CEF (Hornemann et al., 2003). The MVA-ΔE3L mutant would first 
have to be obtained, either through negotiation or construction in-house. 
Identification of a candidate protein could be clouded by complex issues of host 
range restriction, which is not completely understood for MVA-ΔE3L or for 
FWPV.  
Identification of any dsRNA binding proteins could also have been attempted 
biochemically, such as by Northwestern blot, where viral proteins are 
electrophoresed and then probed with labelled dsRNA, or by gel filtration 
through agarose conjugated to dsRNA (Jacobs et al., 1998). Any protein bound 
to dsRNA would then have to be identified, possibly by mass spectrometry 
analysis.  
This sort of approach, using immobilised ChIFN-γ to capture the FWPV viral 
protein, followed by 2-dimensional gel electrophoresis and mass spectrometry, 
identified the FWPV IFN-γ binding protein, FPV016. This approach revealed 
that the FWPV IFN-γ binding protein contains a novel structure (an 
immunoglobulin domain) not previously seen in any other viral or cellular IFN-γ 
receptor, which all contain fibronectin type III domains (Puehler et al., 2003). 
Although there is no significant sequence homology to VACV interferon-
modulatory proteins, there may be structural homology. The VACV N1 protein 
structure closely resembles the cellular anti-apoptotic protein Bcl-x(L), despite 
having no sequence similarity (Cooray et al., 2007). IL-28A (IFN-λ2) and IL-29 
(IFN-λ1) were initially identified in silico as putative helical cytokine family 
members through their conserved cysteine patterns and expected amphipathic 
profile (Sheppard et al., 2003). Therefore the FP9 genome could be scanned for 
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predicted structural similarity to immunomodulatory proteins from other DNA 
viruses. 
 
7.2) Establishing a SOE-PCR protocol 
In order to prepare linear DNA cassettes for construction of the recombinant 
library, a SOE-PCR protocol suitable for assembly of multiple, large templates of 
varying sizes was established. Stages that required optimisation included: 
 (i) Development of electrophoresis with crystal violet agarose to reduce 
degradation of large templates (see 7.2.1 below) 
 (ii) Stepwise addition of templates for assembly of multiple components 
in a single reaction (see 7.2.2 below) 
 (iii) Rationalised PCR conditions for assembly of asymmetrically sized 
templates (see 7.2.2 below). 
 
7.2.1) Crystal violet agarose enabled assembly of large templates 
SOE-PCR was initially only successful with relatively short components. The 
GPT cassette and FLRb were assembled into RHSb and three components were 
simultaneously assembled into LINK2. Throughout this work, agarose gels 
stained with ethidium bromide were visualised with UV light at 302 nm. Most 
researchers acknowledge that short wavelength (254, 302 or 312 nm) UV light is 
more damaging to DNA than long wavelength (360 nm). However, few 
transilluminators use 360 nm UV light, and the “UV preparation” option on the 
transilluminator used only decreases the intensity of light, without altering the 
wavelength. 
Problems with assembling 8 kbp fragments were solved by replacing ethidium 
bromide in agarose gels with crystal violet, which eliminated exposure to UV 
light. This allowed subsequent reamplification of extracted PCR products and 
increased transfection efficiency (Sections 3.11 and 4.3). It has also been 
associated with increased cloning efficiency (Turgut-Balik et al., 2005). 
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Excluding ethidium bromide and UV from the protocol reduces the risk of 
exposure to these hazards, making this method suitable for use in schools. 
Crystal violet is much cheaper than some safe, proprietary stains, and so this 
method may also have applications in secondary and tertiary education teaching 
laboratories and laboratories with low budgets. 
The reduced sensitivity of DNA detection is one disadvantage of crystal violet 
compared to ethidium bromide in this application. Another is that during DNA 
extraction from crystal violet gels, dissolved agarose appears violet. Therefore 
any colorimetric pH assessment (such as in the QIAquick kits) must be replaced 
by an alternative method. 
 
7.2.2) Assembly of multiple, large, asymmetrically-sized templates 
Assembly of DNA fragments of such unequal size as 0.5, 1.5 and 8 kbp together 
in a single reaction has not been previously described, and nor has assembly of 
fragments greater than 6 kbp. Crystal violet agarose enabled large template 
reamplification, and sequential template addition improved the yield of multiple 
template assembly even though primers were present for fewer cycles (Fig. 3.9). 
Combination of these improvements with rationalised extension steps enabled 
simultaneous assembly of three components, where not only was one template 
particularly long and susceptible to UV-induced damage, but it had a large size 
differential with the others.  
The rationalised extension steps of the SOE-PCR were not directly compared for 
increased yield, but there is no report in the literature where templates with a 16-
fold size difference have been successfully annealed, so the rationalised 
conditions may be a requirement. 
SOE-PCR has been used to synthesise scFv antibodies and to design fusion 
proteins, although usually with 2 small fragments of similar sizes (Zuo et al., 
1995; Liu et al., 2005). Weisbart assembled three components into a single 
template, but did this by 2 separate successive SOE-PCRs (Weisbart et al., 
1998). Similarly, 2 successive SOE-PCRs were required to assemble 3 Hepatitis 
C virus amplicons (2.5, 3.2 and 5.2 kbp) into a single product  (9.3 kbp)(Sheehy 
et al., 2005). 
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An et al. (2005) described a method where 6 DNA fragments were 
simultaneously spliced together in order to introduce multiple point mutations, 
but all the components were similar sizes and relatively small (approximately 
100 to 500 bp), assembling into a final construct of less than 2 kbp. After initial 
amplification and purification of the components, An’s assembly technique 
consisted of 4 stages:  
1) assembly of pairs of adjacent fragments, for 15 cycles without primers 
2) combination of all 5 paired fragments, for 20 cycles of denaturing and 
annealing only without primers 
3) 30 standard cycles with primers 
4) 10 cycles of denaturing and extension only (An et al., 2005).  
Interestingly, An also initially assembled only pairs of templates in the absence 
of primers, similar to my technique. The subsequent simultaneous assembly of 5 
paired components was achieved by uncoupling the annealing and extension 
steps. 
After successful assembly of a 10 kbp cassette had been verified, the SOE-PCR 
protocol was scaled-up for high throughput assembly with various FP9 
fragments. There were four 8 kbp fragments that could not be initially amplified; 
all were located towards the right end of the FP9 genome. There was no obvious 
reason why fragments 57 and 60 failed to amplify, as the primers successfully 
amplified 4 kbp alternative products.  
Of the 57 amplified 8 kbp fragments, 18 would not properly assemble. These had 
a wider spread across the genome, and there was no correlation between failure 
to assemble and number of ORFs within a fragment. The likelihood of successful 
assembly did seem to correlate with the mass of 8 kbp fragment present in the 
reaction, rather than with quantities calculated to give equimolar amounts of 
templates. Failure may therefore have been due to stochastic effects in the 
reaction. 
Using the improved SOE-PCR method, 90% of all FP9 ORFs were amplified 
and assembled into 56 different fragments, ready to be transfected into cells and 
used to make recombinant MVA viruses. These improvements made this process 
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suitable for high-throughput production of multiple constructs and could be 
applied to genome analysis or complex plasmid construction. 
 
7.3) Establishing a protocol for recombinant MVA generation 
There is a large literature regarding generation of recombinant MVA viruses, but 
most use plasmids as shuttle vectors, and many insert into the deletion III site. 
Further, K1L selection is more commonly reported than GPT for MVA 
recombination. Therefore a protocol using transfection of linear cassettes and 
GPT selection in avian cells was developed for producing large numbers of 
recombinant MVA viruses. 
This could assist research that uses MVA as a recombinant vaccine vector (Sutter 
et al., 1994; McConkey et al., 2003; Gherardi & Esteban, 2005). Development of 
the individual steps in this protocol could also have applications: permissivity of 
the DF-1 cell line for poxvirus infections provides another option for MVA and 
avipoxvirus research. The high transfection rate of DF-1 can also be applied to 
research into avian cell signalling or avian viruses such as influenza. 
 
7.3.1) An avian cell line permissive for MVA 
The DF-1 chicken fibroblast cell line was confirmed as permissive for MVA, 
although not suitable for plaque formation (Section 4.1). This was nevertheless 
advantageous because DF-1 cells are more easily prepared and were more 
effectively transfected than CEF. This expands the number of cell lines generally 
available for manipulating MVA. The hamster fibroblast cell line BHK-21 
(ATCC number CCL-10), a popular choice for generating recombinant MVA 
(Carroll & Moss, 1997; Sanchez-Puig & Blasco, 2005), was an available 
alternative. However, BHK-21 cells do not offer the advantage of limiting the 
cell species involved in the library to avian.  
 
7.3.2) Transfection of avian cells 
Presumably because of the relatively low prevalence of research using avian 
cells, no commercially available transfection reagent was advertised at the time 
- 192 - 
as being suitable for avian cells. Therefore an optimal reagent and protocol had 
to be identified. DF-1 cells were much more readily transfected than CEF, and 
both Lipofectamine and Polyfect gave good results. Optimisation could have 
improved the efficiencies of the other transfection reagents tried, but this was not 
deemed worthwhile. Polyfect, the reagent of choice, is a polyamidoamine 
dendrimer with a net positive charge to assist receptor binding and pH inhibition 
of lysosomal nucleases. The other reagents used are lipid based, with the 
exception of GeneJuice, which is a proprietary formulation of a polyamine and a 
cellular protein. 
Other workers have successfully transfected CEF for MVA recombination (M. 
Cottingham, Oxford University; personal communication), and if this had been 
pursued it would not have been necessary to establish DF-1 as an alternative. 
However, even with conditions optimised for CEF, transfection efficiencies may 
not have been sufficient for the relatively low masses of PCR products that were 
synthesised. 
DNA extracted from a crystal violet gel had a higher transfection efficiency than 
that from an ethidium bromide gel, consistent with the damage caused by UV 
exposure discussed above. 
A recombination experiment with FP9 further optimised transfection conditions. 
This indicated similar transfection efficiencies of linear and supercoiled DNA, 
supporting the finding of Boulanger et al. (2002a). Although there was no 
difference in virus recovery when 35 to 170 ng of specific DNA had been 
transfected (Fig. 4.7), there was a positive correlation between the mass of total 
DNA transfected (between 1.5 to 2.5 µg) and the titre of recovered virus (Fig. 
4.5C). To increase the likelihood of recombination, most transfections were done 
with the entire SOE-PCR yield. 
 
7.3.3) MPA selection 
CEF were found to tolerate MXH selection better than DF-1, and 3 passages of 
0.1% total cell lysate volume in 25 µg/ml eliminated non-recombinant MVA 
whilst allowing recovery of GPT+ virus. This is the concentration of MPA used 
to select GPT-positive cells (Mulligan & Berg, 1981) and virulent strains of 
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VACV (Boyle & Coupar, 1988), but is higher than a previous report of GPT 
selection of MVA that used 1 µg/ml MPA (Scheiflinger et al., 1998). 
Passage of MVA-LZ spiked with GPT-positive virus recovered 11 pfu of MVA-
LZgpt4 (Section 4.6). Persistence of GPT-negative virus could have been tested 
for in this experiment by comparison of final titres in the presence or absence of 
MXH. Although virus was passaged at a low MOI, GPT-positive virus may have 
synthesised sufficient XMP and hence GMP to support replication of co-
infecting GPT-negative virus. This could explain the persistence of parental 
MVA-LZ in several of the recombinant virus preparations. 
PCR analysis of the intermediate passages of MVA-LZGPT-KB partially 
characterised the kinetics of recombinant virus enrichment by MPA. Titration 
after each passage of MVA-LZGPT-KB or the mixtures of the spiked virus could 
have further supplemented this information.  
 
7.4) Generation of the recombinant virus library 
Having established protocols to produce linear DNA cassettes and recombinant 
MVA, the next aim was to use them to generate a library of recombinant MVA 
viruses expressing FP9 proteins. The relatively high-throughput saw a peak of 6 
to 8 recombinant viruses produced each week. Initial transfections/infections 
were done in 35 mm tissue culture dishes or 6-well tissue culture plates, but this 
was associated with a high rate of fungal contamination, possibly confounded by 
transfection with non-sterile DNA. These early losses were almost completely 
reduced by the elution of DNA assemblicons into sterile filtered TE, and 
transfection of cells cultured in small tissue culture flasks (12.5 cm2) with close-
fitting caps. 
A total of 65 viruses were produced, that together contained 84% of all FP9 
ORFs; 65% of ORFs were present in a stable insertion and 43% were duplicated 
at least once. 
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7.4.1) Characterisation of recombinant viruses 
PCRs were developed to distinguish between parental and recombinant viruses. 
Primers that annealed outside the recombination sites were used to identify 
insertions, an approach that has been previously used for identification of 
recombinant viruses (Boulanger et al., 1998; Bartlett et al., 2005). In addition, a 
primer that annealed between the recombination flanks (BridgeF) was specific 
for parental virus DNA. The primers initially designed for amplification of the 
overlapping fragments were also routinely used to test each recombinant virus 
for stability of the insert. 
 
7.4.2) Purity of recombinant viruses 
Nearly half of the viruses produced contained parental MVA-LZ as detected by 
PCR, but this did not prevent identification of the MVA-f3La phenotype, which 
initially contained persisting MVA-LZ. Removal of this parental virus by an 
additional selection passage or by plaque purification yielded viruses that had 
similar levels of ChIFN resistance to each other (Fig. 5.8). The absolute plaquing 
efficiencies of these purified viruses were lower than the initial result obtained 
with ‘mixed’ virus, but the purified and mixed viruses were not compared in the 
same experiment. When the relative increase in ChIFN resistance was compared 
to control MVA-fC2a, virus that still contained MVA-LZ was similar to that 
which did not (Section 5.5.2). Plaquing efficiency of MVA-fC2a was also not 
affected by plaque purification. 
As discussed above (Section 7.3.3), it is conceivable that GPT-negative virus 
could have persisted in cells co-infected with GPT-positive virus. PCR analysis 
of MVA-LZGPT-KB derivation (Fig. 4.10) detected parental virus after two 
MXH passages. It seems that low amounts of non-recombinant virus can persist 
after a third passage.  
This persistent parental virus is distinguishable from virus that has undergone 
recombination followed by loss of the entire insertion, with the parent-specific 
PCR that used a primer binding to the parental sequence between FLL and 
FLRb. In the absence of true parental virus, a virus that had gained and lost an 
insertion would give a short product with the flanking primers but no product 
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with the parent specific PCR, although this could also be explained by failure of 
the parent-specific PCR. Such a result was obtained with 15 viruses. 
 
7.4.3) Stability of recombinant viruses 
Over 40% of recombinant viruses that were PCR analysed with an insert-specific 
PCR showed an unstable insertion. The major deletions in the MVA genome 
occurred at sites that already contained genes fragmented in CVA (Meisinger-
Henschel et al., 2007). Deletion II included the loss of the fragmented gene 
CVA035/036, originally encoding an ankyrin repeat protein. Whatever drives 
this mechanism may have also contributed to the instability of the FP9 gDNA 
insertions, as these were adjacent to the truncated MVA022L (Fig. 1.10). 
Another possible explanation for insert instability is that promoters within the 
FP9 fragment may have affected the expression of MVA genes adjacent to the 
insertion site. If a strong FP9 promoter was in the same orientation as MVA021L 
and MVA023L, expression of these genes could be increased. If a promoter was 
in the opposite orientation, conflicting transcription machinery could affect gene 
transcription levels. 
Improvement of recombinant virus stability could have been pursued by 
reversing the orientation of the insertion, or by using recombination flanks that 
matched the sequences immediately surrounding the Deletion II site, rather than 
those used which placed the insertion equidistant between the neighbouring 
functional genes (Fig. 1.10B). 
It has been suggested that insertions between converging transcription units of 
essential MVA genes and interruption of long GC runs with silent codon changes 
increases the stability of insertions into recombinant MVA viruses (Wyatt et al., 
2008). The unstable FP9 fragments were not characterised sufficiently to identify 
whether deletions were occurring at particular loci, such as GC-rich sequences. 
The FP9 genome is 30.8% GC, so has relatively few GC-rich areas, but it could 
be argued that any that do occur may have a greater impact on the surrounding 
DNA topology. 
Stability could also have been improved by investigating an alternative insertion 
site, as discussed in Section 7.1.1. 
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7.4.4) Library validation 
Each virus recovered after MXH passage was crudely analysed by PCR, which 
would be expected to identify deletions greater than at least 1 kbp between the 
recombination flanks. Smaller deletions that included loss of an internal primer 
binding site could also be identified. However, the PCR analysis used could not 
identify more subtle mutations that may have inactivated any gene product. 
The FP9 insertions from recombinant MVA viruses were not sequenced, as the 
cost would have been prohibitive. The total length of FP9 gDNA inserted into 
the MVA library was between 287 and 445 kbp, depending on the length of 
inserts remaining in unstable viruses.  
In addition to PCR, recombinant virus DNA could have been analysed by 
restriction digestion to identify any major genomic changes elsewhere in the 
genome. An alternative to this is to make revertant viruses, where the inserted 
fragment is again excised, to confirm that phenotypic changes are due to the 
intended genetic change. However, in this broad screen, a positive phenotype 
was being sought and this would be unlikely to occur from the loss of an 
alternative host gene, as presumably there would be selection pressure for this to 
occur during normal MVA culture. 
Recombinant viruses could have been tested for expression of FP9 genes by RT-
PCR or Northern blot analysis, which test for RNA transcription. This would 
have been especially useful for unstable viruses, where RNA analysis could have 
indicated which genes were still present and would provide a stronger argument 
for screening these unstable viruses for increased IFN resistance. This would also 
have been useful with viruses containing genes from the FIR1 and FIR2 loci, to 
try and correlate FP9 gene expression with IFN resistance. 
Quantitative RT-PCR could have been used to confirm stable levels of native 
MVA genes, especially those neighbouring the insertion site, where varying 
expression levels may have contributed to instability as discussed above. 
Ultimately, it is not the presence of FP9 DNA or RNA that confers an IFN 
resistance phenotype, but correctly folded protein. Functional assays could have 
been used to confirm expression of correctly folded recombinant protein by a 
- 197 - 
representative virus, such as expression of FP9.016, the IFN-γ binding protein, 
by MVA-f4La.  
Unfortunately a lack of antibodies prevented confirmation of protein expression 
(irrespective of conformation) by Western blot analysis for all but one FP9 
protein, FP9.191 that occurred in fragment 50. Expression of FP9.191 was 
confirmed in two viruses containing stable versions of this fragment, but not in 
an unstable virus. 
Antibodies for two other structural FP9 proteins are available and react by 
Western blotting (Boulanger et al., 2002b): a 35 kDa protein (FPV140; 
orthologue of VACV IMV envelope protein H3) and a 39 kDa protein (FPV168; 
distantly related orthologue of VACV IMV core protein A4; (Boulanger et al., 
1998)). FP9.140 occurred in fragment 38, which was recovered from 2 
recombinant viruses, the stable MVA-f38a and the unstable MVA-f38b.  
FP9.168 occurred in fragments 44 and 45, but fragment 45 could not be 
assembled into a transfection cassette. A single transfection with fragment 44 
was attempted, which resulted in recovery of the unstable virus MVA-f44a. 
Analysis of these viruses by Western blotting would have indicated whether they 
expressed FP9.140 or FP9.168, but these proteins constitute a very small 
proportion of the overall library. To circumvent the risk of introduced mutations, 
13 fragments, representing 43% of ORFs, were duplicated into independent 
recombinant viruses. Five of these duplications provided a stable insertion as an 
alternative to an unstable one. 
 
7.4.5) Alternative applications of the recombinant library 
All the stable recombinant viruses have been screened, but the unstable viruses 
could also be screened for an increase in IFN resistance. Any with a positive 
phenotype should be characterised by RT-PCR to identify true candidates before 
attempting single gene recombinant viruses. 
Rather than screening viruses individually, a selection process could have been 
used, such as infection of a single culture with all recombinant viruses in the 
presence of an inhibitory ChIFN concentration. Stimulation with poly(I:C) could 
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be an alternative to ChIFN stimulation, although virus replication of non-
recombinant viruses would first have to be investigated in cells stimulated in this 
way. Any surviving and proliferating virus could then be plaque purified and 
identified by partial sequencing of the insertion.  
The gradual nature in which recombinant viruses were obtained lent itself to 
screening viruses individually rather than this selection method. Retrospectively, 
this selection method could be verified by testing whether it could successfully 
be used to identify MVA-f3La. 
It is possible that some FP9 proteins may cooperate with each other to contribute 
to IFN resistance. If such cofactors were not present within the same recombined 
fragment, then they would not be identified when screened individually. They 
may, however, be identified under IFN selection using mixed infections. If such 
cooperation were occurring, pooling viruses in ever smaller groups, until the 
synergistic effect was lost could identify the relevant partners. 
The whole library could be screened for an increased block to IFN induction, 
such as using luciferase-based assays. In these assays, cells (DF-1 which have a 
higher rate of transfection than CEF) are transfected with a reporter plasmid 
expressing firefly luciferase under the control of the ChIFN-β promoter, and a 
control plasmid to correct for transfection efficiencies. Transfected cells are then 
infected with virus (recombinant MVA, MVA-LZ or FP9) and induction of 
ChIFN-β is accompanied by an increased production of firefly luciferase, which 
can be quantitated. Induction of ChIFN-β with poly(I:C) acts as a positive 
control. Similarly, the library could also be screened for induction of ChIFN-α or 
chicken Mx, as reporter plasmids containing luciferase under the control of these 
chicken promoters are also available. The luciferase gene under control of an 
ISRE promoter can be expressed in the quail cell line CEC-32 (Schwarz et al., 
2004). If this promoter is also active in chick cells, it could indicate a block in 
ChIFN signalling. These non-IFN-β luciferase assays would require exogenous 
ChIFN for positive controls. 
Pollitt found that SFV replication in CEF treated with 4 U/ml IFN was rescued 
when cells were co-infected with FWPV (Pollitt, 1997). This was similar to the 
rescue of VSV by VACV in murine L cells (Whitaker-Dowling & Youngner, 
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1983). The rescue of SFV replication by MVA in ChIFN-treated cells has not 
been established, but could theoretically be investigated and used for screening 
the recombinant MVA library to identify FP9 genes that contribute to this 
phenomenon, which may be different to those identified in the direct plaque 
assay used. The rescue assays have a number of operational drawbacks, 
including requirement for ACDP category 2 containment and their laborious and 
time-consuming nature (approximately 3 weeks are required for the final read-
out of each experiment). 
The recombinant MVA library could also be screened for more diverse 
functions, such as increased immunogenicity or improved growth, which could 
be beneficial to applications using MVA as a vaccine vector. It is also a useful 
tool with which to study the basic virology of FWPV, to analyse features such as 
morphogenesis that distinguish avipoxviruses from orthopoxviruses. 
 
7.5) Establishing a screening assay for IFN resistance 
A plaque assay was developed to screen the recombinant MVA library for 
increased ChIFN resistance. This successfully identified two recombinant 
viruses, containing two different FP9 fragments, which were named Fowlpox 
Interferon Resistance loci (FIR). However, these did not increase resistance of 
the recombinant viruses to the level observed for FP9, indicating that further loci 
also contribute. 
 
7.5.1) ChIFN used 
Two batches of recombinant type I ChIFN were available, IFN-α2 supplied by S. 
Goodbourn (S.G. ChIFN) and an unknown subtype supplied by P. Staeheli (P.S. 
ChIFN). World Health Organisation International Standard ChIFN is available 
from the U.K. National Institute of Biological Standards and Control (NIBSC; 
Potters Bar, U.K.) but this is virally induced rather than recombinant, prepared 
from “chick embryo tissue cultures infected with influenza B virus” and semi-
purified (NIBSC data sheet, product code 67/018). This preparation is a 
- 200 - 
relatively low titre, at 80 IU/ml, and probably heterogeneous (Mire-Sluis et al., 
1996).  
The recombinant ChIFNs used here were functionally quantitated using an SFV 
plaque reduction assay, as recommended by Pestka and Meager (1997). Ideally, 
they should have also been compared to the international standard in order to 
calibrate the laboratory units with international units. 
Some functional differences between mammalian IFN subtypes have been 
described, for example IFN-α2 was able to augment NK cell cytotoxicity more 
than IFN-α4 or IFN-α1 (Verhagen et al., 1990). However, as mentioned in 
Section 1.2.1, how closely ChIFN subtypes reflect mammalian subtypes is not 
understood. 
 
7.5.2) Screening assay used 
In all IFN resistance assays, exogenous ChIFN was added to homologous cells 
for up to 18 h prior to infection. This restricted the resistance mechanisms to 
those that were acting downstream of IFN signalling and ISGF3 activation (if 
avian cells use an equivalent to mammalian ISGF3). As described above, 
luciferase assays could have been used to characterise induction of IFN or the 
Mx effector. 
Calculation of an IC50 curve for all recombinant viruses could have identified 
subtle alterations in IFN resistance, but this would have been labour-intensive 
and required substantial quantities of CEF and ChIFN. Instead, viruses were 
screened for an increased ability to plaque in cells treated with a single dose of 
ChIFN. The single dose used needed to be sufficient to significantly but not 
completely inhibit MVA-LZ plaque formation, in order to observe slight 
increases in plaquing efficiency by the recombinants. An initial dose of 10 U/ml 
ChIFN was selected, as this inhibited MVA-LZ by approximately 75% (Fig. 
5.4).  
However, errors during measurement of S.G. ChIFN concentration led to 
miscalculations of stock ChIFN concentration. When these had been corrected, it 
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was found that actually 2, 6 or 27 U/ml S.G. ChIFN had been used. The 
corrected concentrations are provided throughout Chapters 5 & 6. 
The absolute plaquing efficiency varied between experiments, so in each 
experiment viruses were compared to a control recombinant, MVA-fC2a or 
MVA-fC2b. Between experiments, the plaquing efficiency in cells treated with 
10 U/ml ChIFN ranged from 3% to 5.5% for MVA-fC2a, compared to 10 to 24 
% for MVA-f3La. At 27 U/ml, the plaquing efficiency of MVA-fC2a was always 
less than 1%, compared to between 5% and 12% for MVA-f3La, and 2% to 10% 
for MVA-f6b. Despite the inter-experimental variation, the comparative 
difference between the control viruses and those containing putative FIR loci was 
reproducible. 
The variation in plaquing efficiency between experiments may have been due to 
slight variations between CEF batches. These were always prepared fresh from 
10-day old chick embryos but there may have been slight variations in the 
maturity of the IFN system or cell subtypes present between batches. 
PCR analysis showed that MVA-fC2b contained persisting MVA-LZ whilst 
MVA-fC2a did not. It may have been appropriate to correlate the control virus 
used with the purity of the viruses screened. For example, to compare pure 
recombinants with MVA-fC2a and to compare recombinants mixed with 
persisting MVA-LZ with MVA-fC2b. However, plaque purification of MVA-
fC2a, MVA-f3La or MVA-f6b did not significantly alter resistance to ChIFN. 
 
7.6) Identification of genes within FIR loci contributing to the phenotype 
7.6.1) Construction of FIR1 single gene recombinant viruses 
To identify individual genes causing the FIR1 phenotype, recombinant viruses 
containing a single gene candidate from the FIR1 locus were generated using the 
same techniques as used for the initial library. In order not to exclude adjacent 
promoter sequences, each transfected fragment included a maximal amount of 
intergenic sequence upstream of the desired gene. For these second-iteration 
viruses, an alternative could have been to limit the FP9 sequences to the relevant 
ORF and place it under the control of an exogenous promoter. This may be 
especially appropriate for FP9.013, which has only 25 bp separating its start 
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codon from the termination codon of FP9.014. Because of this short intergenic 
sequence, the single gene fragments v013 and v014 actually overlapped slightly. 
MVA-F.014 actually included 9 N-terminal aa of FP9.013, and MVA-F.013 
included 49 bp of FP9.014. 
The MVA-F.012b and MVA-F.013 recombinant viruses yielded unexpected 
PCR products at the insertion site prior to plaque purification (Section 6.2.5). 
The cause of these is unclear, but they disappeared after plaque purification. 
 
7.6.2) Screening of FIR1 single gene recombinant viruses 
The FIR1 recombinant viruses were screened for plaquing efficiency in cells 
treated with ChIFN. At all concentrations of ChIFN used (2, 6 or 27 U/ml), 
MVA-F.014 had a higher rate of plaquing than MVA-fC2a, whereas MVA-F.013 
had a similar or lower rate of plaquing than the control (Figs. 6.13 & 6.14). At an 
intermediate ChIFN concentration (6 U/ml), MVA-F.012b was similar to MVA-
F.014. But at lower (2 U/ml) or higher (27 U/ml) concentrations, this virus was 
more similar to the negative controls. This was consistent with ChIFN titrations 
(Fig. 6.15), where MVA-F.012b had a higher rate of plaque formation than 
MVA-fC2a in cells treated with 3 to 13 U/ml ChIFN. 
It may be that FP9.012 does play a role in IFN-modulation that is different to that 
of FP9.014, but cannot overcome high doses of ChIFN and does not show an 
effect with low doses.  
The ChIFN titrations showed that although MVA-F.014 was more resistant than 
MVA-F.012b or MVA-F.013, it was not as resistant as MVA-f3La. The mutation 
identified in FP9.014 within MVA-F.014, or any further unidentified mutations 
in this virus, could have partially impaired the function of FP9.014 in the single 
gene recombinant virus. Alternatively, FP9.014 may not be the only gene 
contributing to ChIFN resistance at the FIR1 locus.  
Without viruses recombinant for unmutated versions of the FIR1 candidate genes 
and quantitative expression studies such as RT-PCR, the possibility that FP9.012 
and/or FP9.013 are playing a role in isolation has not been eliminated. The 
limited sequencing data did not exclude the possibility of a mutation in the 
intergenic region upstream of FP9.012 in MVA-F.012b (Section 6.2.6), 
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potentially affecting the expression levels of the recombinant protein by this 
virus. Similarly, it is possible that the lack of IFN resistance shown by MVA-
F.013 was due to inactivation of FP9.013 by the mutations identified by 
sequencing. Therefore the difference between the ChIFN resistance levels of 
MVA-F.014 and MVA-f3La could be explained by ‘missing’ activity of FP9.012 
or FP9.013 by the single recombinant viruses.  
Alternatively, there may be synergy between the FIR1 proteins; FP9.014 may 
require the presence of FP9.012 or FP9.013 to reach the same level of activity as 
that shown by MVA-f3La. FP9.012 or FP9.013 may possess IFN-modulatory 
activity, but only in the presence of another protein from the FIR1 locus. 
In a multi-step growth curve, FP9.012 may have slightly increased virus 
replication at early time points, whereas FP9.014 increased yields at later time 
points. None of these effects were significant, but in a model where ChIFN is 
induced by virus infection, with a positive correlation between quantity produced 
and time post-infection, this is consistent with the observation that FP9.012 
provides an advantage at low to intermediate concentrations of ChIFN, and 
FP9.014 provides an advantage post-induction. 
In a single-step growth curve in cells that had been pre-treated with a very low 
dose of ChIFN, MVA-F.014 replicated at lower levels, or more slowly. This 
indicated a ‘cost’ of FP9.014 expression, which was not outweighed by a benefit 
of ChIFN resistance in this situation, possibly because the concentration of 
ChIFN used might have been ineffective at inducing an antiviral state. 
 
7.6.3) Characterisation of the FIR2 locus 
To identify the gene or genes causing ChIFN resistance at the FIR2 locus, 
construction of recombinant viruses containing single candidate genes was 
attempted. However, these attempts were unsuccessful at an early stage and were 
aborted due to time constraints. Had these been successfully pursued, then in 
parallel with the FIR1 viruses, expression studies would have been required to 
confirm that each recombinant virus was transcribing its intended FP9 gene 
product, to validate any negative results from screening. 
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The original unstable viruses containing insertions across the FIR2 locus gave 
inconsistent results when screened for ChIFN resistance. MVA-f6a had lost 
several internal primer binding sites that were not clustered together and so the 
extent of the instability could not be clearly delimited. It is possible that MVA-
f6a actually consisted of a complex of viruses with a variety of internal deletions 
in the FP9 fragment. MVA-f7a appeared to have lost FP9.025, but the variable 
phenotype of this virus limited interpretation of the contribution of that gene to 
ChIFN resistance. Plaque purification might have reduced the heterogeneity and 
improved the reproducibility of the screening results for MVA-f6a and MVA-
f7a. The genotypes of these viruses could also have been better characterised 
with more internal primers or by sequencing of their insertions. 
The FIR2 candidate genes were cloned into the expression vector 
pEFplink2FLAG, for transient transfections to investigate any inhibition of 
ChIFN induction in luciferase-based assays, although due to time constraints 
these experiments were not completed. As the FIR2 locus was identified in a 
screen where cells were pre-treated with ChIFN, it is possible that none of the 
candidate genes affect IFN induction.  
To use the FIR2 plasmids in a screen where cells are pre-treated with ChIFN 
prior to virus infection, infection and transfection must occur in the same cell. 
CEF have a low rate of transfection so would not be suitable for this type of 
plaque assay. DF-1 are readily transfected but do not support plaque formation. 
A 2-step assay could be investigated, such as transfection and infection in DF-1 
followed by plaque assays in CEF, but the amplification step in CEF may 
obscure small or qualitative differences.  There is no avian cell line that supports 
MVA plaque formation that could be engineered to stably express the FIR2 
candidate proteins. 
Alternatively, DF-1 or CEF transfected with the FIR2 expression plasmids could 
be screened for rescue of SFV replication in ChIFN-treated cells. A similar 
approach has been successful at rescuing NDV replication in CEF, with plasmids 
expressing influenza virus NS1 or other RNA virus IFN modulators (Park et al., 
2003b). 
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FP9 viruses with interrupted ORFs in FP9.022, FP9.023, FP9.024 or FP9.026 are 
available, and these could be screened for a reduced resistance to ChIFN 
compared to native FP9. However, if it is not possible to completely inhibit FP9 
plaque formation, then it may not be possible to observe a small reduction in 
resistance. 
 
7.7) Ankyrin repeat proteins 
Bioinformatic analysis of FP9.012 and FP9.014 indicated that these proteins 
were not secreted, and had significant similarity to other ankyrin repeat proteins, 
including some from the host species, Gallus gallus.  
A 33 amino acid repeat was first identified in yeast, Drosophila melanogaster 
and Caenorhabditis elegans (Breeden & Nasmyth, 1987) but it was not until 
1990, when 24 copies of this repeat were identified in the human cytoskeletal 
protein ankyrin, that this motif was named the ankyrin repeat (ANK) (Lux et al., 
1990). There are now 11690 protein sequences containing ANK domains stored 
in the PFAM database (www.pfam.sanger.ac.uk), found in 798 species. These 
species include bacteria (54%), eukaryotes (36%), viruses (8%) and archaea 
(1%). Within viruses, ankyrin repeats are almost exclusively found in dsDNA 
viruses that lack an RNA stage, with a single additional protein reported in the 
retrovirus Feline leukemia virus. Sixty percent of the viral ankyrin proteins are 
found within Poxviridae. It has been proposed that the wide evolutionary 
distribution of ankyrin-like repeats was partially caused by horizontal gene 
transfer (Bork, 1993).  
The ANK secondary structure consists of pairs of antiparallel alpha-helices 
stacked side by side and connected by a series of intervening beta-hairpin motifs. 
The extended beta-sheet projects away from the helical pairs almost at a right 
angle, resulting in a characteristic L-shaped cross-section, also referred to as a 
‘cupped hand’ (Jacobs & Harrison, 1998; Sedgwick & Smerdon, 1999). No 
single position within the 33 aa of the ANK motif contains an invariant residue, 
and insertions have been reported within and between the ANK motifs which 
vary the curvature and twist of the stacked domains (Bork, 1993). ANK domains 
can constitute a whole protein, or can occur with other domains.  
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In eukaryotic cells, ANK proteins have a wide variety of cellular localisations 
and functions, although involvement in protein-protein interactions is a common 
theme (Bork, 1993). These interactions are involved in regulation of several 
cellular pathways, including cell cycling, apoptosis, transcription regulation and 
ubiquitin-mediated degradation (Li et al., 2006). The diversity of the ANK 
proteins is paralleled by the diversity of targets with which they interact 
(Sedgwick & Smerdon, 1999). According to the PFAM database, ANK proteins 
interact with 8 protein motif families, notably including 4 different domains 
found in transcription factors. Other interactions are with other ANKs, protein 
kinase domains, small GTPase activating proteins and SH3 domains, which are 
involved in signal transduction. 
Several crystal structures of ANK proteins have been resolved, including NF-κB 
complexed with its inhibitor IκBα, which showed that the most conserved ANK 
residues are internal to the structure (Jacobs & Harrison, 1998).  
Intermolecular interactions are not restricted to any particular secondary 
structural element within the ANK motif (Sedgwick & Smerdon, 1999) but target 
specificity is determined by exposed residues at the base or tip of the beta-hairpin 
‘fingers’ (Batchelor et al., 1998; Jacobs & Harrison, 1998). Jacobs and Harrison 
propose that the ankyrin repeat proteins have evolved as scaffolds to display a set 
of variable contact residues for protein recognition, analogous to antibody 
recognition (Jacobs & Harrison, 1998). 
 
7.7.1) F-box domains 
The F-box domain was first described as a sequence motif that interacts with 
Skp1, which is involved in ubiquitin mediated proteolysis (Bai et al., 1996). 
Skp1 was then described as part of the SCF (Skp1 - Cdc53 - F-box protein) 
complex (Skowyra et al., 1997). Cdc53 is also known as Cullin. The SCF 
complex was shown to act as an E3 ubiquitin ligase, according to the model 
previously proposed by Hershko and colleagues (Hershko et al., 1983). These 
workers identified three components of a complex required for conjugation of 
ubiquitin to proteins. These were an ubiquitin activating enzyme (E1), an 
ubiquitin conjugating enzyme (E2), and an ubiquitin protein ligase (E3). 
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Together, these polyubiquitinate lysine residues on target proteins, which can be 
subsequently recognised and degraded by the proteosome.  
Specific targets are recruited to the SCF complex through different F-box 
proteins (Skowyra et al., 1997). The F-box domain is approximately 50 aa long, 
and usually found towards the N-termini of proteins, often associated with 
leucine rich repeats or WD repeats. Leucine rich repeats (LRRs) are short (20 to 
30 aa) sequence motifs present in a diverse range of proteins and involved in 
protein-protein interactions (Kobe & Deisenhofer, 1994). WD repeats are short 
(40 aa) motifs that often terminate in a W-D (tryptophan-aspartic acid) dipeptide. 
They serve as a rigid scaffold for protein interactions, to coordinate multi-protein 
complex assemblies (Neer et al., 1994). It is these LRR or WD domains that 
recruit specific targets to the SCF complex (Patton et al., 1998). Regulation of 
cell cycling is a well studied function of ubiquitin mediated proteolysis, but it is 
also active in other processes including IFN receptor turnover (Kumar et al., 
2003) and apoptotic signalling (Nateri et al., 2004).  
 
7.7.2) PRANC domains 
ANK proteins can constitute significant proportions of chordopoxvirus genomes. 
Canarypoxvirus encodes 51 predicted ANK proteins, representing 21% of the 
genome (Tulman et al., 2004). The USDA strain of FWPV encodes 31 ANK 
proteins, (Afonso et al., 2000), and FP9 encodes 23 (Laidlaw & Skinner, 2004). 
In contrast, MVA encodes only a single ANK protein (Antoine et al., 1998), 
compared to 10 in the ancestral CVA strain (Meisinger-Henschel et al., 2007). 
Mercer et al. (2005) observed that the majority of poxviral ANK proteins contain 
a C-terminal F-box-like domain. Significant differences from cellular F-boxes 
led to their separate classification as PRANCs (Mercer et al., 2005; Sperling et 
al., 2008). PRANCs are shorter than cellular F-boxes (the consensus sequence is 
26 aa long), and are located at the C-terminus rather than the N-terminus. 
Whereas cellular F-boxes occur in proteins also containing LRRs or WD motifs, 
PRANCs occur with ANK domains. No cellular protein has been identified that 
contains both an ANK domain and an F-box. 
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Some members of the SOCS protein family contain an N-terminal ANK domain 
with a C-terminal SOCS box domain. The SOCS box has a similar role to the F-
box, participating in an alternative E3 ubiquitin ligase complex: elonginC - 
cullin2 - SOCS box (Kile et al., 2002). Despite this architectural similarity, the 
PRANC consensus sequence is closer to that of the F-box domain than to the 
SOCS box domain (Mercer et al., 2005). 
Mercer et al. proposed a model where the poxviral PRANC proteins associate in 
a SCF-like complex to act as an E3 ubiquitin ligase. The ANK domain at the N-
terminus of the protein provides specificity for an unidentified substrate to be 
ubiquitinated, analogous to the role provided by the LRR or WD domains of the 
cellular F-box proteins (Mercer et al., 2005).  
This model has been supported by findings concerning the M-T5 protein of 
myxoma virus (a leporipoxvirus), which has 7 ANK motifs. M-T5 binds cullin-1 
via Skp1 to prevent cell cycle arrest by promoting degradation of the cyclin 
dependent kinase inhibitor p27/Kip-1 (Johnston et al., 2005) (Fig. 7.1B). The M-
T5 protein plays an analogous role to the host F-box protein Skp2, to recruit 
p27/Kip-1 for ubiquitination (Tsvetkov et al., 1999) (Fig. 7.1A). M-T5 can also 
activate Akt (Wang et al., 2006a), the serine/threonine kinase responsible for 
phosphorylating p27/Kip-1 at the Thr187 residue that is required for its 
recognition by Skp2 (Fujita et al., 2002).  
 
Figure 7.1: Ubiquitination of phosphorylated p27/Kip-1 by A: cellular SCFSkp2 or 
B: viral SCFM-T5. The E3 ubiquitin ligase complex is shown in orange in both 
diagrams. E1 and E2 represent respective components of the ubiquitin-protein 
ligase system. Ub: ubiquitin. P: phosphorylated Thr187 residue. 
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MVA produces only one ANK protein, encoded by MVA186R. This ANK 
protein directly interacts with human and mouse Skp1a through its PRANC 
domain, and thereby complexes with cullin-1 (Sperling et al., 2008). Ectromelia 
virus, the causative agent of mousepox, encodes seven ANK proteins. At least 
one of these proteins, ECMV005, interacts with cullin-1 and Skp1 through its 
PRANC domain (van Buuren et al., 2008). To date, p27/Kip-1 remains the only 
documented ligand for a viral protein ANK domain. 
 
7.7.3) FIR ankyrin repeat proteins 
Of the 31 ANK proteins in the USDA strain of FWPV, Mercer identified 
PRANC domains in 19 of them (Mercer et al., 2005). Some of the proteins that 
lacked this C-terminal domain could be fragmented, but this did not explain 
every absence of the PRANC in avipoxvirus ANK proteins. Both of the ANK 
proteins in the FIR1 locus, FP9.012 and FP9.014, possess PRANC domains. 
There are 4 N-terminal ANK motifs in FP9.012 predicted by PFAM, and 8 in 
FP9.014 (Fig. 6.18). 
Mercer identified a PRANC domain in two of the four ANK proteins at the FIR2 
locus, FPV022 and FPV026 (Mercer et al., 2005). A PRANC domain was also 
predicted in FP9.024 by the PFAM software (Fig. 6.18). The absence of a 
PRANC in FP9.023 could not be explained by likely gene fragmentation and so 
has no obvious explanation for its absence. 
Comparison of the intergenic sequence between FP9.013 and FP9.014 in FP9 
with the equivalent sequence in the USDA strain of FWPV reveals an interesting 
difference. In the USDA strain, there are 18 bases between FPV013 and FPV014. 
The equivalent intergenic sequence in FP9 contains a 7 base insertion, which is a 
repeat of the first 7 bases of FP9.013. In the USDA strain, FPV013 and FPV014 
are transcribed in the same frame, but FP9.013 is in a different frame in FP9 
(Fig. 7.2). 
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Figure 7.2: Intergenic sequence between FPV013 and FPV014 in USDA strain 
of FWPV (upper panel), and between FP9.013 and FP9.014 in FP9 (lower 
panel). The 7 bp insertion in FP9 is underlined in red. These ORFs transcribe in 
a right-to-left direction, and the complementary strand sequences are shown 
above the reverse frame lines. 
 
This insertion also occurs in HP-1, the virulent ancestor of FP9, indicating that 
the insertion did not occur during tissue culture for the derivation of FP9, but 
reflects a difference between USDA and European FWPV lineages (Laidlaw & 
Skinner, 2004). The authors of this paper pointed out that this insertion affects 
the Kozak consensus sequence (Kozak, 2002), potentially upregulating 
translation of this ORF. In the USDA strain, where FPV013 and FPV014 are in 
the same frame, there is only one termination codon between the two ORFs. It is 
possible that FPV014 was previously continuous with FPV013, although the 
presence of the PRANC in FPV014 counts against this. 
It is possible that FP9.014 functions through the mechanism proposed by Mercer, 
to recruit a component of the ChIFN system to be polyubiquitinated. The 
PRANC domain would interact with the E3 ubiquitin ligase complex, whilst the 
ANK domain recruits the target for ubiquitination. Considering the bias for 
cellular ANK proteins to interact with transcription factors, it is tempting to 
suggest one of these. However, as FP9.014 was identified with a screening assay 
that used pre-treatment with ChIFN, signalling and upregulation of ISGs would 
have occurred prior to infection. Therefore a target of FP9.014 is more likely to 
be an IFN effector. 
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7.8) Follow-on work 
Further work can clarify the findings identified here, and further characterise 
both the general nature of FP9 resistance to ChIFN and the specific mechanism 
employed by FP9.014. The recombinant virus library could also be used in 
alternative screening assays to identify additional FIR loci. 
 
7.8.1) Clarification of identified FIR loci 
As highlighted in Section 7.6.2, any IFN-modulatory role of FP9.012 and 
FP9.013 in isolation needs to be clarified. This requires unmutated versions of 
each of the FIR1 candidate genes together with quantitative expression studies 
such as RT-PCR. The difference in IFN resistance between MVA-F.014 and 
MVA-f3La must be explained, whether it is due to independent action of 
FP9.012 or FP9.013, or synergy between the FIR1 proteins.  
Plaque purification may reduce the heterogeneous screening results for MVA-f6a 
and MVA-f7a. If MVA-f7a reproducibly failed to show increased IFN resistance, 
FP9.025 and FP9.026 could be eliminated as FIR2 candidate genes. The 
expression plasmids containing individual current FIR2 candidate genes are 
ready to be screened for reduced induction of ChIFN-β, ChIFN-α or chicken Mx 
using luciferase assays, described in Section 7.4.5.  
 
7.8.2) Characterising the FP9.014 mechanism of action 
The mode of action of FP9.014 can now be further characterised. The FP9 
mutant that has an inactivated FP9.014 gene, FP9Δ014, must be characterised for 
ChIFN resistance to confirm the role of this protein. 
If a monoclonal antibody to FP9.014 was generated, this could be used for 
biochemical analysis of the protein, to investigate post-translational 
modifications and sub-cellular localisation. 
It would be very interesting to establish whether FP9.014 is also active against 
any other species of type I ChIFN, such as duck or human. Activity against 
mammalian IFN would be relevant in the application of FP9 as a vaccine vector. 
To use the existing MVA-F.014 in a mammalian IFN assay would require 
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obtaining a species of type I IFN that is active in hamster cells. Alternatively, 
FP9.014 could be cloned into a plasmid for expression in mammalian cells. This 
plasmid could then be tested for inhibition of IFN in homologous cells. The 
wider availability of luciferase reporter plasmids for mammalian IFN system 
promoters enables a variety of potential promoters to be tested. 
It would also be interesting to test MVA-F.014 for any difference in 
immunogenicity in vivo compared with standard MVA. An increased resistance 
to type I IFN could lead to increased antigen presentation and hence increased 
immunogenicity. Alternatively, increased resistance to type I IFN leading to 
increased viral replication could trigger greater adaptive immunity, preventing 
prolonged antigen presentation. Even if FP9.014 has no effect on mammalian 
type I IFN, FP9Δ014 can be characterised for any improvement in 
immunogenicity in poultry, which would be relevant for avian vaccines. 
Removing this gene from the virus could increase exposure to the avian immune 
system, increasing its immunogenicity, or it could reduce the time for virus 
clearance, reducing the immunogenicity. 
 
7.8.3) Characterising the nature of FP9 resistance to ChIFN 
This work has shown that FP9 is able to counter post-signalling effects of ChIFN 
after cells have entered the antiviral state, and the rescue of SFV (described in 
Section 7.4.5) shows that this effect is not a ‘native’ property of FWPV, but is 
active in trans to a co-infecting virus (Pollitt, 1997). The nature of FP9 resistance 
to ChIFN can be further characterised. Rescue of SFV in the presence of cytosine 
arabinoside, which inhibits DNA replication, will indicate whether this ability is 
an early or late gene function. Similarly, rescue of SFV by FP9 conditioned 
supernatant would indicate whether the responsible protein(s) is secreted. If this 
were the case, it would indicate a function in addition to that of FP9.014, where a 
signal peptide has not been predicted. Incubation of FP9 conditioned supernatant 
with ChIFN will indicate whether a ChIFN-binding protein, analogous to VACV 
B18R, is secreted. 
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However, careful consideration must be given to the preparation of FP9 
conditioned supernatant. Filtration may remove active protein by adsorption 
whereas ultracentrifugation may not completely remove viable virus.  
Long wavelength UV light and cross-linking by psoralen inactivates both RNA 
and DNA viruses (Hanson et al., 1978) although this has not been demonstrated 
for FWPV. However, this treatment does not necessarily abolish and can even 
enhance early gene expression (Tsung et al., 1996). Additionally, FWPV 
encodes a photolyase, FPV158, that restores the infectivity of UV exposed virus 
(Srinivasan et al., 2001). This gene is truncated in FP9 and may no longer 
function (Laidlaw & Skinner, 2004). 
 
7.8.4) Identification of additional FIR loci 
Additional FIR loci may be identified by screening the unstable viruses with the 
same assay that identified FIR1 and FIR2. The entire library can also be screened 
in alternative assays that would highlight interference at different points of the 
IFN pathway. For example, luciferase assays using a ChIFN-β promoter reporter 
plasmid could identify loci that block ChIFN induction. Reporter plasmids to 
screen for increased blocks in ChIFN-α and chicken Mx induction are also 
available.  
As outlined in Section 7.4.5, SFV rescue assays or culturing pools of viruses in 
growth medium containing ChIFN could also identify additional FIR. As neither 
FIR1 nor FIR2 showed a level of resistance comparable to native FP9, the 
presence of additional FIR loci is highly likely. 
 
7.9) Concluding remarks 
The aim of this project, to identify a molecular determinant of FP9 resistance to 
avian type I IFN has been achieved, with the identification of not one but two 
Fowlpox Interferon Resistance loci. This was done by the construction and 
screening of a large library of recombinant viruses, which also provides a useful 
resource for other investigations. It is likely that other FIR loci still await 
identification to produce the overall resistance of FP9 to type I ChIFN. 
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One of these loci has been resolved to the level of an individual gene, FP9.014, 
which encodes an ankyrin repeat protein. Although ANK proteins have been 
associated with host range functions, this is the first example of an ANK protein 
that directly enables viral resistance to an IFN-induced antiviral state, potentially 
utilising a previously unknown mechanism of IFN-modulation and justifying the 
approach taken. 
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APPENDIX 1 
Primers Used in this Study 
 
Primers for amplification and assembly of FLL, FLRb and GPT cassettes: 
Primer 
Name 
Sequence (5’→3’) 
KB1F tggtcaatcgccatttgttcg 
KB1R ggacatagtgccttgtattatg 
KB4F-3’ atctttgctagagagaaagc 
KB4F gctattcgacatcgagaacaatctttgctagagagaaagc 
KB4Rb gagggatattaagtcgatag 
KB3F ggatgcagcctccagaatac 
KB3R-3’ tgttctcgatgtcgaatagc 
KB3R gctttctctctagcaaagattgttctcgatgtcgaatagc 
KB1F-seq ttagttcatccttgttcatc 
 
Primers used in initial analysis of recombinant viruses: 
Primer 
Name 
Sequence (5’→3’) 
Out_F aatggtgtgatgttgattagg 
Out_R atatgacatggtacgccttc 
BridgeF atggacatccgccttaaatg 
KB4R-seq ggaatttaatacaccatttg 
KB3Rc-3’ tagttgcgatatacataaactg 
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Primers for amplification of FP9 fragments: 
Primer 
Name 
Sequence (5’→3’) 
KB2F-1 cataatacaaggcactatgtccgagaagttaaatcgagacg 
KB2F-2 cataatacaaggcactatgtccagagggttttgtaatagcag 
KB2F-3 cataatacaaggcactatgtccaatctccaataactgagtcg 
KB2F-4 cataatacaaggcactatgtccgattcgatagcctcaaatac 
KB2F-5 cataatacaaggcactatgtccatagtttcaccattttaggg 
KB2F-6 cataatacaaggcactatgtcccgcagatacgataatagatg 
KB2F-7 cataatacaaggcactatgtccttgcataaacgtaataatgg 
KB2F-8 cataatacaaggcactatgtccggtttataggattcaaatgg 
KB2F-9 cataatacaaggcactatgtcctatccatttttaaccacctc 
KB2F-10 cataatacaaggcactatgtcctaatgcatacatgctttttc 
KB2F-11 cataatacaaggcactatgtccccccaattaattttatcttc 
KB2F-12 cataatacaaggcactatgtcctgatttaacaaacaaactgg 
KB2F-13 cataatacaaggcactatgtccgtatcttgggttttgtaagg 
KB2F-14 cataatacaaggcactatgtccatccacgattctgtagaaag 
KB2F-15 cataatacaaggcactatgtccaatccaacatttccaatatc 
KB2F-16 cataatacaaggcactatgtccgattttccagtagctgtttc 
KB2F-17 cataatacaaggcactatgtcccgcgtatacattttgtaatc 
KB2F-18 cataatacaaggcactatgtcctcatttcttgatattcttgc 
KB2F-19 cataatacaaggcactatgtccccgaaggtaataatcttgac 
KB2F-20 cataatacaaggcactatgtccaataccatctgggtattctg 
KB2F-21 cataatacaaggcactatgtccttaagagtttctccggttag 
KB2F-22 cataatacaaggcactatgtcctacagcgtccagtaacatag 
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Primer 
Name 
Sequence (5’→3’) 
KB2F-23 cataatacaaggcactatgtcctgctgctattgtgaataaac 
KB2F-24 cataatacaaggcactatgtccaatctgctaacggataaaac 
KB2F-25 cataatacaaggcactatgtccttgttcatcttgtgttcatc 
KB2F-26 cataatacaaggcactatgtcccaactcgtagctgataatcc 
KB2F-27 cataatacaaggcactatgtccatctgacgaagaacctactg 
KB2F-28 cataatacaaggcactatgtccattggaagatgatatggaag 
KB2F-29 cataatacaaggcactatgtccagatcacaaacgttagaagg 
KB2F-30 cataatacaaggcactatgtccgagtgctattaggattttgg 
KB2F-31 cataatacaaggcactatgtcccaatagggatttttaccatc 
KB2F-32 cataatacaaggcactatgtccacggactcttatcacgtaac 
KB2F-33 cataatacaaggcactatgtccttttgtaccgatgatagatg 
KB2F-34 cataatacaaggcactatgtcccatcctctgaagtttctctc 
KB2F-35 cataatacaaggcactatgtccataactggttccgctaatac 
KB2F-36 cataatacaaggcactatgtcccccaaagaacaagatacttc 
KB2F-37 cataatacaaggcactatgtccgtaaggatttccgattgtag 
KB2F-38 cataatacaaggcactatgtccacgagatcttagctgcttac 
KB2F-39 cataatacaaggcactatgtcctataatttccttaccgcttc 
KB2F-40 cataatacaaggcactatgtccatgttccgaatcaaatactc 
KB2F-41 cataatacaaggcactatgtccaagctttagaagaatgcaac 
KB2F-42 cataatacaaggcactatgtcctgaaaatgtctgcatatcac 
KB2F-43 cataatacaaggcactatgtcctatccggtcttaaagaagtc 
KB2F-44 cataatacaaggcactatgtccattagacgcgtttagatttc 
KB2F-45 cataatacaaggcactatgtccagaacacagagcgataaaag 
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Primer 
Name 
Sequence (5’→3’) 
KB2F-46 cataatacaaggcactatgtccactactcaatcacctcatcc 
KB2F-47 cataatacaaggcactatgtcccgtatgtacgtatgcagttc 
KB2F-48 cataatacaaggcactatgtcccagactccttctttatcagc 
KB2F-49 cataatacaaggcactatgtccggaattatatcccatacagc 
KB2F-50 cataatacaaggcactatgtccccgtggattaaatctatctc 
KB2F-51 cataatacaaggcactatgtccccgtggtaagaaaactaaac 
KB2F-52 cataatacaaggcactatgtccatgttggtgtatctttttcc 
KB2F-53 cataatacaaggcactatgtcctacgcgtgtaatagatcaag 
KB2F-54 cataatacaaggcactatgtccgagattagaattacggatgc 
KB2F-55 cataatacaaggcactatgtccaccataggtaggtattgtgg 
KB2F-56 cataatacaaggcactatgtccaatattccatttcctttgtc 
KB2F-57 cataatacaaggcactatgtccgtatccttctcttttgcatc 
KB2F-58 cataatacaaggcactatgtcctttaaccatgaaagacacag 
KB2F-59 cataatacaaggcactatgtccagcatttcccatgttaatac 
KB2F-60 cataatacaaggcactatgtccaaatggtgcttctattaacg 
KB2F-61 cataatacaaggcactatgtccataataatacttccgcatgg 
KB2R-1 gtattctggaggctgcatcctaggttcggaagaaaataag 
KB2R-2 gtattctggaggctgcatcccatcagcagttttatttttg 
KB2R-3 gtattctggaggctgcatcccaaattctatgggaagaaac 
KB2R-4 gtattctggaggctgcatccgaatcatccaaaattaaagg 
KB2R-5 gtattctggaggctgcatccttacattacgctgtatcgag 
KB2R-6 gtattctggaggctgcatcctacaaatatagatgccgttg 
KB2R-7 gtattctggaggctgcatcctagggggttgtatatcattc 
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Primer 
Name 
Sequence (5’→3’) 
KB2R-8 gtattctggaggctgcatccggaaacttattgattcgttc 
KB2R-9 gtattctggaggctgcatccttcatgtagcgaaactgtag 
KB2R-10 gtattctggaggctgcatcctccgtacataattacgagtg 
KB2R-11 gtattctggaggctgcatccatcacgtatggtaagagacc 
KB2R-12 gtattctggaggctgcatcctgtagagtaacgaatgaacg 
KB2R-13 gtattctggaggctgcatccagagtagatatgtcggatgg 
KB2R-14 gtattctggaggctgcatccaccgatttgttactatgtcc 
KB2R-15 gtattctggaggctgcatccccttggaaagttttaaattg 
KB2R-16 gtattctggaggctgcatccaacctaaaatcaaggaattg 
KB2R-17 gtattctggaggctgcatccagctttagtcacatctggag 
KB2R-18 gtattctggaggctgcatcccccaatttccattttattag 
KB2R-19 gtattctggaggctgcatccaaaaccgattaaaagcatag 
KB2R-20 gtattctggaggctgcatcctaaggcctatcgttattagc 
KB2R-21 gtattctggaggctgcatcccatcgggatacttctttatc 
KB2R-22 gtattctggaggctgcatccttactgaatcccattaaacc 
KB2R-23 gtattctggaggctgcatcccaacacattatcagacgaag 
KB2R-24 gtattctggaggctgcatccttatatgcaggaacatatcg 
KB2R-25 gtattctggaggctgcatccagaatttagctattggcttg 
KB2R-26 gtattctggaggctgcatccgaatccgtgactaagaaaag 
KB2R-27 gtattctggaggctgcatccggattattccttgactatcg 
KB2R-28 gtattctggaggctgcatccatggtgattaaaatgagacc 
KB2R-29 gtattctggaggctgcatcccagacattaaactcatcgtg 
KB2R-30 gtattctggaggctgcatccttaacatggatgtgtgtttc 
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Primer 
Name 
Sequence (5’→3’) 
KB2R-31 gtattctggaggctgcatccgtttttcttctgatggattg 
KB2R-32 gtattctggaggctgcatccgtaaatacgaaggactttgc 
KB2R-33 gtattctggaggctgcatccaagggttagaagaattgatg 
KB2R-34 gtattctggaggctgcatcccatccattcgttacacatag 
KB2R-35 gtattctggaggctgcatccagcaaaatccgaagtataac 
KB2R-36 gtattctggaggctgcatccggaaagaatagaatcgacag 
KB2R-37 gtattctggaggctgcatccgggtattaaaaatggatacg 
KB2R-38 gtattctggaggctgcatccgaaaataatacggaatctgg 
KB2R-39 gtattctggaggctgcatcctcctgttatatttcccagtc 
KB2R-40 gtattctggaggctgcatccgtcaatacataagcagcaac 
KB2R-41 gtattctggaggctgcatccgccatatatcaatgaaaacc 
KB2R-42 gtattctggaggctgcatcctgtgtagcatttatgtagcc 
KB2R-43 gtattctggaggctgcatccaacggattgataacagaatc 
KB2R-44 gtattctggaggctgcatcctaactttcggataaaattcc 
KB2R-45 gtattctggaggctgcatcccaaatagttcaggatcttcc 
KB2R-46 gtattctggaggctgcatccgttaacggtggtagaaaaac 
KB2R-47 gtattctggaggctgcatccgcgttctttttatgagtacc 
KB2R-48 gtattctggaggctgcatccaaattatttcaatcgtctgc 
KB2R-49 gtattctggaggctgcatccagatgtatacaggcctcatc 
KB2R-50 gtattctggaggctgcatccgaattagccgcttttagtag 
KB2R-51 gtattctggaggctgcatccttagagattcccacgagtag 
KB2R-52 gtattctggaggctgcatccgaagaaatgtatgggttctg 
KB2R-53 gtattctggaggctgcatcctatcaatgtaaaccgatgg 
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Primer 
Name 
Sequence (5’→3’) 
KB2R-54 gtattctggaggctgcatccaggttatcttcttcggtatg 
KB2R-55 gtattctggaggctgcatccattagcagctggagtatttc 
KB2R-56 gtattctggaggctgcatcccctatttctacaatcggttc 
KB2R-57 gtattctggaggctgcatccgggttgtaacctttgtttag 
KB2R-58 gtattctggaggctgcatccagtactacggacgttaaagg 
KB2R-59 gtattctggaggctgcatccaaaattcggattgatgtaag 
KB2R-60 gtattctggaggctgcatccttgcctgatattacctatcc 
 
Primers used for FIR2 single gene recombinant viruses: 
Primer 
Name 
Sequence (5’→3’) 
KB2F-v022 cataatacaaggcactatgtcccgcagatacgataatagatg 
KB2F-v023 cataatacaaggcactatgtcctatgtgtggtataattagcctatgca
c 
KB2F-v024 cataatacaaggcactatgtcccgtaattgaataagatataaaaatt
gg 
KB2F-v025 cataatacaaggcactatgtccaatatgtggtcgtatgaacg 
KB2F-v026 cataatacaaggcactatgtcctcgatatcgtatgagaacatcagg 
KB2R-v022 gtattctggaggctgcatccaagaatacgatttagatgggtggag 
KB2R-v023 gtattctggaggctgcatccccaatttttatatcttattcaattacg 
KB2R-v024 gtattctggaggctgcatccagcgcggatgatgaagac 
KB2R-v025 gtattctggaggctgcatccgactaataaagaattatgcgaaataag 
KB2R-v026 gtattctggaggctgcatccgcgacacacgtgtaaaatcg 
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Primers used for FIR2 candidate gene cloning. Restriction endonuclease sites are 
in bold: 
Primer 
Name 
Sequence (5’→3’) 
022_F_Bam ttttggatccgcctatagaagaaaaagcgcg 
023_F_Bam ttttggatccgactatactaaaataactagatatac 
024_F_Bam ttttggatccggcaatgaaaaacttagaaaagatttac 
025_F_Bam ttttggatccgctactactatacagaaggagttag 
026_F_Bam ttttggatcctggctatttccagaacggg 
022_R_Xba ggggtctagatcataatttttctagttcattatttg 
023_R_Xba ggggtctagatcaactaatagaacaagatgtggatc 
024_R_Xba ggggtctagattatttgttaactgaatcaattatag 
025_R_Xba ggggtctagatcactcgtaccaaccagttac 
026_R_Xba ggggtctagattatcttatttcgcataattctttattag 
 
Primers used for FIR1 single gene recombinant viruses: 
Primer 
Name 
Sequence (5’→3’) 
KB2F-v012 cataatacaaggcactatgtccttattttcttccgaacctacc 
KB2F-v013 cataatacaaggcactatgtccaacgcatttttaccgtattg 
KB2F-v014 cataatacaaggcactatgtcccgtaactcttgttttcatttttc 
KB2R-v012 gtattctggaggctgcatccttattaaacccggaaatgtg 
KB2R-v013 gtattctggaggctgcatcctgaagaagatctcccttattg 
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APPENDIX 2 
MVA-FP9 Chimaeric Viruses Recovered 
 
As described in Section 4.10, viruses that received 4 MXH passages were 
passaged twice with 1% harvest volume followed by 2 standard (0.1% harvest 
volume) MXH passages. Plaque purified viruses underwent a single round of 
plaque purification after 3 standard MXH passages. Presence of MVA-LZ and 
insertion stability were characterised by PCR analysis. 
FP9 
Fragment 
Virus 
Name 
Preparation 
MVA-LZ 
Presence 
Insertion 
Control MVA-fC2a plaque purified no 339 bp 
Control MVA-fC2b 3 MXH passages yes 339 bp 
1 MVA-f1a 3 MXH passages no 8 kbp stable 
1 MVA-f1b 3 MXH passages yes 8 kbp stable 
3L MVA-f3La 3 MXH passages yes 4 kbp 
4L MVA-f4La 3 MXH passages yes 4 kbp 
4R MVA-f4Ra plaque purified no 4 kbp 
5 MVA-f5b 3 MXH passages no 8 kbp stable 
6 MVA-f6a 3 MXH passages no 8 kbp unstable 
6 MVA-f6b 4 MXH passages yes 8 kbp stable 
7 MVA-f7a 4 MXH passages yes 8 kbp unstable 
8 MVA-f8a plaque purified no 8 kbp stable 
8 MVA-f8b 3 MXH passages no 8 kbp stable 
9 MVA-f9a 4 MXH passages yes 8 kbp stable 
9L MVA-f9La 3 MXH passages no 4 kbp 
9R MVA-f9Ra 3 MXH passages yes 4 kbp 
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FP9 
Fragment 
Virus 
Name 
Preparation 
MVA-LZ 
Presence 
Insertion 
11 MVA-f11a 3 MXH passages yes 8 kbp unstable 
11 MVA-f11b 4 MXH passages yes 8 kbp stable 
12 MVA-f12a 3 MXH passages yes 8 kbp stable 
13 MVA-f13a 3 MXH passages no 8 kbp unstable 
14 MVA-f14a plaque purified no 8 kbp stable 
14 MVA-f14b 3 MXH passages no 8 kbp unstable 
15 MVA-f15a 3 MXH passages no 8 kbp unstable 
17L MVA-f17La 3 MXH passages yes 4 kbp 
17R MVA-f17Ra 3 MXH passages yes 4 kbp 
19 MVA-f19a 3 MXH passages yes 8 kbp stable 
20L MVA-f20La 3 MXH passages yes 4 kbp 
20L MVA-f20Lb 3 MXH passages yes 4 kbp 
20R MVA-f20Ra 3 MXH passages no 4 kbp 
20R MVA-f20Rb 3 MXH passages yes 4 kbp 
21 MVA-f21a 4 MXH passages no 8 kbp stable 
22R MVA-f22Ra 3 MXH passages no 4 kbp 
23 MVA-f23a plaque purified no 8 kbp stable 
23 MVA-f23b 3 MXH passages no 8 kbp unstable 
24 MVA-f24a plaque purified no 8 kbp stable 
24 MVA-f24b 3 MXH passages yes 8 kbp stable 
25 MVA-f25a plaque purified no 8 kbp stable 
25 MVA-f25b 4 MXH passages yes 8 kbp stable 
27 MVA-f27a 3 MXH passages no 8 kbp unstable 
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FP9 
Fragment 
Virus 
Name 
Preparation 
MVA-LZ 
Presence 
Insertion 
28 MVA-f28a 3 MXH passages no 8 kbp unstable 
30 MVA-f30a 3 MXH passages no 8 kbp unstable 
31 MVA-f31a plaque purified no 8 kbp stable 
32 MVA-f32a plaque purified no 8 kbp stable 
32 MVA-f32b 3 MXH passages yes 8 kbp stable 
33 MVA-f33a plaque purified no 8 kbp stable 
34R MVA-f34Ra 3 MXH passages no 4 kbp 
35 MVA-f35a 3 MXH passages no 8 kbp unstable 
38 MVA-f38a plaque purified no 8 kbp stable 
38 MVA-f38b 3 MXH passages yes 8 kbp unstable 
40 MVA-f40a 3 MXH passages no 8 kbp unstable 
40R MVA-f40Ra 3 MXH passages no 4 kbp 
44 MVA-f44a 3 MXH passages no 8 kbp unstable 
48L MVA-f48La 3 MXH passages no 4 kbp 
48R MVA-f48Ra 3 MXH passages yes 4 kbp 
50 MVA-f50a 3 MXH passages yes 8 kbp stable 
50 MVA-f50b 3 MXH passages yes 8 kbp unstable 
50 MVA-f50c 4 MXH passages yes 8 kbp stable 
52 MVA-f52a 3 MXH passages no 8 kbp unstable 
54L MVA-f54La 3 MXH passages yes 4 kbp 
57L MVA-f57La 3 MXH passages yes 4 kbp 
57R MVA-f57Ra 3 MXH passages yes 4 kbp 
58 MVA-f58a 3 MXH passages no 8 kbp unstable 
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FP9 
Fragment 
Virus 
Name 
Preparation 
MVA-LZ 
Presence 
Insertion 
59 MVA-f59a 3 MXH passages yes 8 kbp stable 
60L MVA-f60La 3 MXH passages yes 4 kbp 
61 MVA-f61a 3 MXH passages no 8 kbp unstable 
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